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Abstract 
The mammalian adult heart appears devoid of endogenous reparative processes 
capable of compensating a massive loss of functional tissue. Hence, the discovery of 
heart resident cells with typical progenitor features and allegedly primed to originate 
cardiac lineages, hereby designated adult cardiac progenitor cells (CPCs), raised 
expectation in the cardiovascular area. However, a decade after their original 
identification, the elusive developmental origin and role of CPCs, in addition to the lack 
of robustness in generating cardiomyocytes are troubling the field. Conversely, the 
notion that a deeper knowledge on the signaling milieu and master regulators 
determining cardiac specification and differentiation during embryogenesis, will 
significantly reshape the clinical options currently available, has been strengthened. 
In this doctoral dissertation original work is reported and discussed within the context 
of main findings and pending questions in cardiogenesis. In addition, strategies for 
cardiac regeneration and signaling pathways in heart formation and pathological stress 
are briefly reviewed, with emphasis placed on the Notch pathway, for which the role in 
cardiogenesis was further explored. Our research plan was primarily devoted to the 
generation and validation of in vitro model systems in which initiation and 
differentiation of the cardiac molecular program could be investigated. 
To this end, we specifically immortalized adult Lin-Sca-1+ CPCs via overexpression of 
the murine telomerase catalytic subunit (mTERT), aiming to establish an in vitro tool to 
study this subset of CPCs. Extensive in vitro and in vivo characterization of an 
immortalized cell-clone enabled its validation as a cell line representative of CPCs 
expressing Sca-1, and therefore designated iCPCSca-1. This cell line retained the 
phenotypic features of primary CPCSca-1 but had the advantage of constituting an 
unlimited source of cells endowed with a stable phenotype in long-term culture. These 
cells engrafted the infarcted myocardium and directed improvement in cardiac 
performance contributing for increased neovascularization as they differentiated, 
although to variable extents, into cardiomyocyte-, endothelial- and smooth muscle-like 
cells. Importantly, this work provided the scientific community with a benchmark that 
can be used for functional and mechanistic studies targeting adult CPCs. 
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A second aim of this Thesis was the identification of early regulators involved in 
cardiogenesis using the robustness of embryonic stem cells (ESCs) for cardiac 
differentiation. Due to the role demonstrated for Notch signaling in directing cardiac 
fate from ESCs-derived mesodermal progenitors and hemangioblasts, we envisaged 
the identification of downstream effectors of Notch in the onset of cardiogenesis. For 
this purpose, a mES cell line expressing the Notch1 intracellular domain (NICD1) under 
the control of a Doxycycline (Dox)-inducible promoter was chosen. By using this 
inducible expression system a candidate, i.e. Hes5, was selected for validation in loss 
and gain-of-function studies. Our data fit into a model where Hes5 acts as a regulator 
of Isl1 and Scl levels in mesodermal progenitors, thus determining cardiac over 
hematopoietic cell-fate choice. Moreover, after induction of cardiac fate, Hes5 
withdrawal is required to allow continued progression of the cardiomyocytic program. 
This work has provided mechanistic insight into how the Notch pathway specifies 
cardiac fate and reported for the first time the participation of Hes5 in cardiogenesis. 
Finally, the role of Hes5 as a putative key factor for the regulation of cardiogenic 
processes in adult CPCs was investigated in a proof of concept study. The iCPCSca-1 cell 
line was used as a model system to examine the role of Hes5 in the regulation of 
proliferation and differentiation in adult CPCs. Hes5 had no effect in cell proliferation, 
yet Hes5-transfected iCPCSca-1 were able to upregulate structural cardiac genes in basal 
culture conditions. Interestingly, Hes5 negatively regulated Isl1 expression, suggesting 
Isl1 as a putative Hes5 target also in the adult context. Moreover these results suggest 
that the activation of structural cardiomyocytic genes in Hes5-transfected iCPCSca-1 may 
be triggered by the decreased levels of Isl1, thereby identifying Hes5 as a candidate 
factor for enhancing cardiomyocytic differentiation in adult CPCs. 
Overall, the work performed in the frame of this Thesis contributed (i) a cell line model 
system that will facilitate mechanistic and functional studies in need to resolve 
conflicting data on adult CPCs biology, (ii) the identification of a novel early regulator in 
the onset of cardiogenesis, i.e. Hes5, and (iii) the indication that Hes5 may take part, at 
a later time point, to reinforce a cardiogenic program in adult CPCs. 
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Resumo 
O coração de mamíferos adultos é aparentemente desprovido de processos de 
reparação endógenos capazes de compensar uma perda dramática de tecido 
funcional. Deste modo, a descoberta de células presentes no coração com o típico 
fenótipo de células progenitoras e alegadamente pré-condicionadas para originar 
linhagens cardíacas, daí a designação de células progenitoras cardíacas (CPCs) adultas, 
criou expectativa na área cardiovascular. Contudo, uma década após a primeira 
identificação, a origem ontogénica e função imprecisas, bem como a falta de robustez 
na diferenciação em cardiomiócitos, têm sido alvo de controvérsia. Por outro lado, 
fortaleceu a noção de que um conhecimento mais aprofundado das vias de sinalização 
e dos reguladores fundamentais na especificação e diferenciação cardíaca durante a 
embriogénese contribuirá para uma reformulação das opções clínicas disponíveis. 
Nesta dissertação de Doutoramento é documentado e discutido um trabalho original 
no contexto dos principais avanços e questões pendentes na cardiogénese. 
Adicionalmente, são brevemente revisitadas estratégias para regeneração cardíaca e 
vias de sinalização envolvidas na formação do coração e condição patológica, 
enfatizando a via de sinalização Notch, para a qual o papel na cardiogénese foi 
aprofundado. O plano de trabalhos foi essencialmente dedicado à génese e validação 
de sistemas modelo que permitissem o estudo da iniciação e diferenciação do 
programa molecular cardíaco in vitro. 
Deste modo, foi realizada a imortalização específica de CPCs Lin-Sca-1+ adultos, através 
da sobreexpressão da subunidade catalítica da telomerase de murganho (mTERT), com 
o intuito de estabelecer uma ferramenta in vitro para o estudo desta população de 
CPCs. A extensiva caracterização in vitro e in vivo de um clone imortalizado, permitiu a 
sua validação como um linha celular representativa de CPCs que expressam Sca-1 e, 
por isso, designada iCPCSca-1. Esta linha celular mantém as características fenotípicas 
das CPCSca-1 primárias, com a vantagem de constituir uma fonte ilimitada de células 
providas de um fenótipo estável em culturas de longo termo. Após lesão do miocárdio, 
as iCPCSca-1 integraram o tecido e promoveram a melhoria da função cardíaca, 
contribuindo para o aumento da neovascularização e simultaneamente expressando, 
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ainda que em proporções variáveis, proteínas típicas de cardiomiócitos, de células 
endoteliais e de células do músculo liso. Fundamentalmente, este trabalho resultou na 
disponibilização de uma ferramenta acessível à comunidade cientifica para estudos 
mecanísticos e funcionais relativos às CPCs adultas.  
Um segundo objetivo da Tese prendeu-se com a identificação de reguladores 
participantes nas fases iniciais da cardiogénese, usando a robustez do sistema de 
diferenciação de células estaminais embrionárias (CEEs) em células cardíacas. Dado o 
papel, previamente demonstrado, da via de sinalização Notch no direcionamento de 
progenitores mesodérmicos e hemangioblastos derivados de CEEs para linhagens 
cardíacas, foi antecipada a identificação de efetores da via Notch na iniciação da 
cardiogénese. Assim, foi escolhida uma linha de CEEs que expressa o domínio 
intracelular do Notch1 sob o controlo de um promotor induzido por doxiciclina. O uso 
deste sistema de expressão induzida permitiu a seleção de um candidato, i.e. o Hes5, 
para validação em estudos de perda e ganho de função. Os resultados enquadram-se 
num modelo em que o Hes5 regula os níveis de Isl1 e Scl, em progenitores 
mesodérmicos, determinando deste modo uma decisão preferencial pela 
diferenciação em linhagens cardíacas em detrimento de hematopoiéticas. Além disso, 
uma vez instruída a iniciação da cardiogénese, a remoção de Hes5 é obrigatória de 
forma a permitir a contínua progressão do programa molecular cardiomiocítico. Este 
trabalho contribuiu com informação mecanística sobre o controlo mediado pela via de 
sinalização Notch na especificação cardíaca e demonstrou, pela primeira vez, a 
participação do Hes5 na cardiogénese. 
Por último foi investigado, como prova de conceito, o papel do Hes5 como possível 
fator chave na regulação de processos cardiogénicos em CPCs adultas. A linha celular 
iCPCSca-1 foi utilizada como sistema modelo para avaliar o efeito do Hes5 na regulação 
da proliferação e diferenciação de CPCs adultas. A indução do Hes5 não se repercutiu 
na proliferação celular, no entanto, a expressão de genes cardíacos estruturais foi 
ativada em iCPCSca-1 transfectadas com Hes5, mantidas em condições de cultura basais. 
De notar que o Hes5 regulou de forma negativa a expressão de Isl1, o que sugere o Isl1 
como provável gene alvo do Hes5 também no contexto adulto. Adicionalmente, estes 
resultados sugerem que a expressão dos genes cardíacos estruturais possa ser ativada 
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como consequência dos níveis diminuídos de Isl1, identificando assim o Hes5 como 
possível potenciador da diferenciação cardiomiocítica em CPCs adultos. 
Em resumo, o trabalho realizado no âmbito da presente Tese contribuiu com: (i) a 
implementação de uma linha celular, que constitui um sistema modelo para estudos 
mecanísticos e funcionais, necessários para o esclarecimento da informação 
contraditória respeitante à biologia das CPCs adultas; (ii) a identificação de um novo 
regulador na iniciação da cardiogénese, i.e. o Hes5; (iii) a indicação de que o Hes5 
poderá estar envolvido, em fases mais tardias, como potenciador do programa 
cardíaco em CPCs adultos. 
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Brief overview of strategies for cardiac regeneration  
Cardiovascular diseases are a major cause of morbidity and mortality worldwide [1, 2]. 
Ischemic and non-ischemic cardiomyopathies eventually lead to left ventricular 
dysfunction and heart failure [5]. The latter is currently the most common cardiac 
disorder, mainly due to the increase in the average human lifespan and the progressive 
aging of the population in all developed countries [1, 5, 6]. Heart failure hampers 
quality of life, decreases life expectancy and increases medical costs considerably and, 
therefore, constitutes a major public health problem [5]. Heart transplantation 
remains as the only therapy currently available for end-stage heart failure.  
Evidence reporting some capacity of the mammalian heart to generate new 
cardiomyocytes throughout life, although at different turnover rates, has accumulated 
in the past years [7-11], challenging the pre-existing dogma of the mammalian heart as 
a postmitotic organ [12]. It is still debatable, however, whether this newly formed 
cardiomyocytes result from pre-existing cardiomyocytes or from resident progenitors. 
While the issue of cardiomyocytic turnover remains controversial, it is widely accepted 
that the regenerative capacity of the mammalian myocardium is on the whole 
inadequate to compensate for the severe loss of heart muscle in an extensive 
myocardial infarction condition [13].  
Ideally, restoring heart function would involve activation of endogenous regenerative 
processes, including recruitment of endogenous progenitors; or transplantation of pre-
differentiated cardiac cells or progenitor cells capable of producing new and functional 
myocardium in situ. Alternatively, cardiogenic factors such as transcription factors, 
chromatin regulators or microRNAs (miRNAs) might be used for direct lineage 
conversion into cardiomyocytes (Figure 1). 
Stem and Progenitor cell-based therapies  
Stem and progenitor cell-based therapies have been explored in the last decade with 
variable success, and ongoing clinical trials will certainly disclose the therapeutic value 
of cell-based regenerative medicine for the heart. Pioneering attempts with skeletal 
myoblasts and bone marrow-derived cells showed some beneficial effects in cardiac 
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function, which correlated best with the secretion of paracrine factors opposed to a 
direct contribution to new cardiac cells [13]. This part of the general introduction will 
however focus on the current knowledge and on the uncomprehended aspects 
associated to the potential use of pluripotent stem cells and resident cardiac 
progenitor cells as sources for replacing/repairing damaged cardiac muscle. 
Pluripotent stem cells  
Embryonic stem cells (ESCs) are the prototypical stem cells. ESCs are generally derived 
from the inner cell mass of blastocysts [14, 15] and unambiguously fulfill the defining 
hallmarks of stem cells: clonality, self-renewal and pluri/multi-potency. Under specific 
culture conditions, ESCs differentiate as multicellular embryoid bodies (EBs) [16] and 
give rise to derivatives of the three germ layers of the embryo [17]. Indeed, ESCs are 
capable to initiate lineage-specific differentiation programs of many tissue/cell types in 
Figure 1. Strategies for regenerative cardiac treatment. Current approaches focus on the use of 
cardiomyocytes derived from embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs) for 
direct transplantation in the infarcted area (yellow asterisk) (a). Other strategies include the use of 
cardiac progenitor cells (CPCs), which can be directly injected into the infarcted tissue or guided to 
differentiate in vitro followed by transplantation of the mature cardiac cell types (b). As alternative, 
inductive signals can mobilize resident endogenous progenitors to regenerate/repair injured areas, 
overcoming the need for transplantation (c). Additionaly, transcription factors, chromatin regulators 
and miRNAs might be used for direct lineage conversion into cardiomyocytes (d). Reproduced from [4]. 
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vitro [18]. Based on this property, ESCs provide a unique in vitro differentiation 
culture-system to study the very early stages of development [15]. ESCs-derived 
cardiomyocytes have been used as an in vitro model to study early mouse and human 
cardiac differentiation, functional genomics, pharmacological testing, cell therapy and 
tissue engineering. The development of the cardiomyocytic lineage within the ESCs 
differentiation system progresses through distinct stages following closely the kinetics 
of the developing embryo. Strikingly, this relates not only to the sequence of 
expression of cardiac-affiliated proteins (e.g. early cardiac transcription factors, 
sarcomeric proteins, ion channels, connexins and calcium-handling proteins), but also 
to cell morphology (from round to elongated cells with well-developed myofibrils and 
sarcomeres) and similar mechanisms of excitation–contraction coupling and 
neurohormonal signaling [19]. Moreover, because ESCs are both capable to proliferate 
indefinitely and to differentiate into multiple tissue-cell types, they potentially 
represent an unlimited supply of cells/tissues for human transplantation [18]. Human 
ESCs-derived cardiomyocytes have been established in vitro using the EBs 
differentiation system [20, 21]. In this sense, ESCs-derived cardiomyocytes constitute a 
potential source for replacing tissue at the injured area. ESCs have been genetically 
engineered to enable specific selection of cells representing different stages of 
development within a given lineage. As examples, cell lines where the green 
fluorescent protein (GFP) is expressed under the control of a gene of interest, such as 
the mesodermal marker Brachyury, or cardiac-associated genes Nkx2.5, cardiac-actin 
or myosin light chain-2v (Mlc2v) were made available [19]. This is of particular interest, 
while aiming to isolate purified cardiomyocytic populations from undifferentiated or 
noncardiogenic cells within the ESCs differentiation system, limiting also the eventual 
risk of teratoma formation [22, 23].  
Induced pluripotent stem cells (iPSCs) were firstly generated by retroviral integration 
of four transcription factors that reprogrammed adult fibroblasts into an ESC-like 
pluripotent state [24, 25]. iPSCs are used to derive cardiomyocytes which display a 
similar phenotype to those obtained from ESCs [26]. Furthermore, the induced 
pluripotent cells offer the advantages of allowing autologous cell therapies while not 
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involving the ethical concern of embryo destruction, and advances on safer methods 
for their generation are made by the day [27].  
Cardiomyocytes derived from mouse and human ESCs were shown to contribute for 
the improvement of cardiac function in rodent and swine models [21, 28, 29], although 
the long-term benefits of the engraftments are still uncertain. Nonetheless, 
cardiomyocytes derived from pluripotent stem cells are known to display an immature 
phenotype, lacking the morphology, gene expression profile and functional properties 
characteristic of adult ventricular myocytes [30]. As the knowledge of pathways that 
control differentiation of cardiac lineages in embryonic development and in 
differentiating ESCs increases, differentiation will become more controllable, safer and 
will bring on higher indexes of cellular yield and lineage purity. 
Adult Resident Cardiac Progenitor Cells (CPCs)  
The observation that cardiac chimerism occurs in sex-mismatched transplantations led 
to the first proposal that the heart harbors cells with stem cell-like features [31]. These 
observations inspired the work that ultimately led to the identification and 
characterization of putative resident cardiac stem/progenitor cell (CSCs/CPCs) 
expressing c-Kit [32]. The rationale for the choice of c-Kit, the receptor for stem cell 
factor (SCF), reconciled both the fact c-Kit is expressed by stem cells from the 
hematopoietic system [33] and that bone marrow-derived c-Kit+ cells were allegedly 
shown to ameliorate the deleterious effects after infarction while contributing to the 
formation of new cardiac cells [34]. This finding brought excitement to the field owing 
to that any heart resident CPCs would constitute the ideal source for cell therapy due 
to a purported “primed state” to originate cardiac lineages. 
Following this pioneer study, multiple CPCs populations have been isolated based on 
the expression of c-Kit [32, 35] and Stem cell antigen-1 (Sca-1) surface markers [36-40], 
as a strategy imported from the hematopoietic field; but also based on functional 
properties, such as ability to efflux dyes (e.g. side population (SP) cells expressing the 
ATP-binding cassette transporter Abcg2) [41-43] and/or to migrate out of cardiac 
explants and form multicellular spheroids (e.g. cardiospheres (CS)) [44-46] (Table 1).  
 
Chapter I 
7 
 
Table 1. Representation of distinct CPCs populations identified in the myocardium 
 
(+) indicates the observation of clonogenicity; (*) and (†) indicates that determination of the 
differentiation potential into the particular lineage was only performed in vitro or in vivo, respectively; SP: 
Side population; CS: Cardiosphere; CDCs: Cardiosphere-derived cells; CMs: Cardiomyocytes; ECs: 
Endothelial cells; SMCs: Smooth muscle cells.  
CP cell 
type 
 
Phenotype 
 
Determined 
Differentiation 
Potential 
Clonogenicity Ref. 
Sca-1+ CPCs 
 
Sca-1+ c-Kit- Flt-1- Flk-1- CD31+ 
CD38+CD34- CD45- 
 
 
CMs Not determined [36] 
 
Sca-1+ c-Kit- CD34- CD31- 
CD45- CD90+ CD105+ CD29+ CD44+ 
CD106+ CD73+ CD13+ 
 
CMs, ECs, SMCs + [37] 
 
Sca-1+ Pdgfrα+ CD31- Flk-1- 
CD45-CD90+ CD105+ CD29+  
CD44+ 
 
CMs, ECs, SMCs + [38] 
 
Sca-1+c-KitlowCD34lowCD31low 
CD45low CD29+ 
 
CMs, ECs, SMCs
*
 + [39] 
c-Kit+ CPCs 
 
c-Kit+ CD45- CD34- CD20- CD8-
CD45RO- Ter119- 
 
CMs, ECs, SMCs + [32] 
 
c-Kit+ CD29+ CD44+ CD105+ CD90+ 
 
CMs
*
, ECs
*
, SMCs
*
 Not determined [35] 
SP CPCs 
 
Sca-1+ Abcg2+ c-Kitlow CD45low 
CD34low CD31- 
 
CMs
*
 Not determined [41] 
CD29+ CD45+ CD31+ CMs, ECs
†
, SMCs
†
  Not determined [43] 
 
Sca-1+ c-Kit- CD31- CD45- 
CD44- CD34- 
 
CMs
*
 + [42] 
CS/CDCs 
 
Sca-1+ c-Kit+ CD31+ CD34+ 
Flk-1+ 
 
CMs, ECs, SMCs + [44] 
 
c-Kit+ CD105+ CD90+ CD34+ CD31+ 
CD45- CD133- 
 
CMs, ECs
†
 + [45] 
 
Sca-1+ CD45- c-Kitlow CD31low 
CD34lowFlk-1lowCD133-  
CD90low  
 
CMs
*
, ECs, SMCs + [46] 
Brief overview of strategies for cardiac regeneration  
8 
 
Reportedly, as common ground, the distinct CPCs self-renew, are clonogenic and 
express key cardiac transcription factors (e.g. Nkx2.5, Gata4, Mef2c) while lacking 
mature cardiac structural genes. Moreover CPCs are multipotent, contributing for the 
formation of cardiomyocytes (CMs) and cells of the vasculature (e.g. endothelial cells 
(ECs) and smooth muscle cells (SMCs)) throughout life and after transplanted in the 
injured myocardium [12]. However, these cells do not seem capable to compensate for 
the loss of cardiac tissue in chronic heart failure. In the latter setting CPCs have been 
shown to correlate with increased growth arrest and senescence, as consequence of 
decreased telomerase activity [47]. The presumptive organization in discrete histo-
functional units, i.e. clusters of stem/progenitor and early lineage-committed cells in 
close contact with differentiated cells and extracellular matrix (ECM), transported to 
the heart the “niche” concept [48], in close resemblance to well-known self-renewing 
systems [49]. 
The multiplicity of reports describing new CPCs populations isolated by different 
methodological procedures and displaying distinct molecular profiles and behavior in 
vitro and in vivo, could suggest that the adult heart harbors progenitors of unrelated 
lineages/affiliation. However, there is also the possibility of overlapping among the 
distinct subsets that might represent different developmental stages from an unique 
progenitor [1]. That would explain the identification of populations displaying more 
than one of the initially defined criteria (Table 1 and Figure 2). This suggests that 
defining CPCs based on pre-established markers may not be optimal for fully disclosing 
the identity of these cells. 
Nonetheless, and despite the mentioned ambiguity, a main demand is certainly at 
understanding the function of these cells and their role in cardiac homeostasis and 
pathology. CPCs expressing either c-Kit [50, 51] or Sca-1 [52] were found in higher 
abundance in scenarios of cardiac injury. Moreover, Sca-1 upregulates in response to 
pressure overload and protects heart tissue from fibrosis and cardiac hypertrophy [53]; 
while Sca-1 and c-Kit mutations have been shown to cause cardiac dysfunction [51, 53-
55]. Interestingly, Sca-1 deficiency affects the growth and survival of c-Kit+ CPCs in 
normal and infarcted hearts [54]. A role for Sca-1 and c-Kit in the control of 
proliferation and differentiation of the CPCs reservoir has been proposed [54-56]. 
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Importantly, a human ortholog of the Sca-1 protein was not so far identified [57], 
although CPCs have been isolated from human myocardium using an antibody 
recognizing the rodent protein [58]. 
Surprisingly, although more than a decade has passed since CPCs were firstly isolated, 
it is still not clear to what extent these cells contribute to new myocardial tissue, either 
in cardiac homeostasis or after transplanted into injured hearts [3]. In one hand, there 
are reports of large-scale contribution for new cardiomyocytes and cells of the 
vasculature that integrate functionally the injured heart [32, 36, 45, 52, 59, 60]; and 
inclusively claims that c-Kit+ cells are not only necessary, but also sufficient for cardiac 
regeneration and repair [61]. Conversely, there is also indication that the contribution 
of CPCs, although detectable, is minimal both in physiological aging and after injury 
[62, 63]. In fact, although CPCs are able to display phenotypic features of cardiac 
lineages, the in vitro protocols for differentiation require DNA demethylation by 5-
azacytidine (5-aza) [36] and/or co-culture with cardiomyocytes [36, 42, 45], rather 
unusual requirements for bona fide stem cells. In addition, a genetic lineage-tracing 
study demonstrated that Sca-1+ CPCs display a restricted lineage potential [63], thus 
contributing for the lack of certainty on the presumptive multipotency of CPCs. 
Figure 2. Representation of overlapping marker expression in distinct CPCs populations. Distinct 
CPCs have been characterized on the basis of expression of a particular surface marker (e.g. c-Kit or 
Sca-1) or functional properties (e.g. SP cells and CS/CS-derived cells). The display of overlapping 
marker expression might indicate the derivation from a common precursor. Adapted from [3]. 
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Aside from the yet questionable contribution for new functional tissue, CPCs exert an 
overall beneficial effect on cardiac function and contribute for the attenuation of 
adverse tissue remodeling. These beneficial effects have been attributed to secretion 
of paracrine factors responsible for cardiac cell survival and neovascularization [37, 51, 
52, 64, 65], or increased thickness and mechanical stabilization of the myocardial wall 
[66]. In accordance with a role in promoting neovascularization, Sca-1 depletion in 
CPCs interfered with their capacity to improve capillary density after transplanted in 
the infarcted myocardium [37]. Paracrine effects; however, account for the beneficial 
effects of most cell-based therapies, irrespective of the cell source [67]. Finally, 
evidence for another mechanism has been proposed involving a synergistic effect 
between transplanted cells and the endogenous CPCs, in which the latter are provided 
with factors that stimulate their in situ activation, proliferation and/or mobilization [3]. 
Based on the reported beneficial effects, a clinical trial testing the safety and feasibility 
of autologous transplantation of c-Kit+ CPCs (SCIPIO: NCT00474461) in heart failing 
patients, was conducted. The cardiac magnetic resonance results showed improved 
left ventricle (LV) function, reduction in infarct size, and an increase in viable tissue 
[68]. Sca-1+ cardiosphere-derived cells (CDCs) are also under trial (CADUCEUS: 
NCT00893360), as they were envisioned as a consistent starting material for rapid cell 
expansion for transplantation, obtained from small human heart biopsy specimens. 
Noteworthy, preceding reports proposed that cardiac fibroblasts were the cell source 
of CDCs, being the latter merely a result from cell aggregation rather than clonal 
growth; and that contamination with original cardiac tissue would account for the 
spontaneous contraction observed [69]. 
A main controversial aspect of CPCs relates to their developmental origin, and the 
extent to which they constitute remnants of embryonic cardiovascular progenitors. 
Alternatively, these cells can also be derived from circulating cells from the bone 
marrow, or from the neighboring vasculature [40]. In fact, these cells share phenotypic 
features with circulating cells from the bone marrow, despite lacking the pan-
hematopoietic marker, leukocyte common antigen (CD45). This coincides with claims 
that bone marrow-derived stem cells home to the injured heart and acquire a cardiac 
phenotype contributing to the pool of cardiac progenitors [51, 70, 71]. Furthermore, a 
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majority of Sca-1+ cells in the heart co-expresses the platelet endothelial cell adhesion 
molecule, CD31 (also known as Pecam1) [36, 42, 43]; although there is a claim that 
cardiogenic potential is restricted to Sca+CD31- cells [42].  
In this logic, it is important to track Sca-1- and c-Kit-expressing cells back in embryonic 
life, while the heart is still developing. A bipotential c-Kit+Nkx2.5+ myocardial and 
smooth muscle precursor was identified as early as embryonic day (E) 8.5 of mouse 
development. According to this model, c-Kit is expressed in precardiac mesodermal 
progenitors and subsequently downregulates once these cells commit into smooth 
muscle or myocardial precursors. An ancestral relationship between this progenitor 
and the c-Kit+ CPCs isolated from the adult heart has never been clarified [72]. A 
following study described the presence of c-Kit+ progenitors early in the developing 
heart and excluded an extracardiac source for these cells (e.g. migrating hematopoietic 
stem cells) [73]. Sca-1 expression is not detected in the heart before mid-gestation 
increasing after birth, as shown by our laboratory [40]. Interestingly, Sca-1 is found co-
localizing with platelet-derived growth factor receptor alpha (Pdgfrα, also known as 
CD140a) in cells with mesenchymal phenotype and proepicardial/epicardial origin, 
which persist to the adult life [38]. The embryonic epicardium has been shown to 
contribute significantly to the cardiomyocyte lineage [74, 75]. In addition, a population 
containing 80% of Sca-1+ cells in the adult epicardium has been shown to contribute to 
new cardiomyocytes, after re-activation of the embryonic epicardial gene, Wilm's 
tumour 1 (Wt1), through priming by Thymosin β4 (Tβ4) [76]. Increasing evidence 
indicates that CPCs exhibit a mesenchymal-like phenotype, selected either in the basis 
of Sca-1 [37, 38] or c-Kit [35] expression. The reports demonstrating the epicardial 
origin of Sca-1 progenitor cells, reinforce the aforementioned idea, given that 
epicardial-derived cells (EPDCs) contribute to cells of myocardial stroma, i.e. 
fibroblasts, pericytes, and coronary vasculature cells (SMCs and ECs) [77]. In addition 
to this, the preferential commitment to smooth muscle lineage and ability to produce 
ECM components, have brought the question to what extent Sca-1+ CPCs overlap with 
the tissue-resident fibroblast population, as observed in other organs [40].  
All these interrogations urge to determining the developmental origin of adult CPCs 
and whether these cells are truly capable of a significant and equal contribution to 
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CMs, SMCs and ECs, a requisite for a bona fide cardiac stem/progenitor cell. 
Understanding how these lineages are determined during embryonic development is 
expected to contribute cues that may be translated into the modulation of the adult 
regulatory circuitry. The current knowledge supports that during embryonic 
development CMs, SMCs and ECs diverge from a common progenitor expressing Isl1, 
Nkx2.5 and Flk-1 [78]. This population overlaps with the designated second heart field 
(SHF) progenitors that contribute to the outflow tract, to the majority of the right 
ventricle and atria (left and right), and some regions of the left ventricle [79]. Isl1+ 
cardioblasts were identified in the postnatal heart as developmental remnants of the 
fetal progenitor population [80], which persist, although scarce, into adulthood [81, 
82]. Moreover, Isl1 expression is downregulated once cells differentiate into a more 
mature state, suggesting that Isl1 may be used to drive a cardiac progenitor cell state 
[79]. Interestingly, Sca-1+CD45- cells derived from cardiospheres contain progenitors 
expressing Isl1 [46], and Wt1+ epicardial cells (primed with Tβ4) express Isl1, while 
increasing its expression after myocardial infarction [76].  
In summary, there is an overall lack of knowledge on the molecular signature, 
developmental origin and relationship between the distinct putative CPCs populations 
that have been described. Moreover, conflicting data in the field demand for a 
thorough understanding of the biology and of the role of these cells in cardiac 
homeostasis and repair. 
(Re)programming cardiac cell fate 
Following the revolutionary study of Takahashi and Yamanaka [24], the idea of 
reprogramming into virtually any cell type, by direct lineage conversion using a 
combination of transcription factors, became a hot topic of research. The strategy to 
reprogram into a particular cell type consists in a combinatorial approach whereby 
several factors are withdrawn, one at the time, until the minimum set of factors can be 
defined [83]. 
Direct lineage conversion of mouse fibroblasts into cardiomyocytes was achieved by 
overexpressing three developmental transcription factors (e.g. Gata4, Mef2c and Tbx5, 
in brief GMT) [84]. An exciting achievement, was the in vivo direct conversion of 
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cardiac fibroblasts into cardiomyocytes in the mouse, either by overexpressing a 
combination of transcription factors (GMT with or without Hand2) [85, 86] or using 
muscle-specific miRNAs (miRs-1/133/208/499) [87]. This is particularly important since 
cardiac fibroblasts are significantly abundant in the heart and key determinants in 
fibrosis [88]. Importantly, from a therapeutic point of view, the conversion of human 
fibroblasts into cardiomyocytes was also attained by using a combination of 
transcription factors and miRNAs (e.g. Gata4, Hand2, Tbx5, and Myocardin; and miR-1 
and miR-133) [89]. 
The examples of cell plasticity seem to go beyond one could have ever imagined. 
Mesoderm was directed to heart tissue by a combination of three factors (Gata4, Tbx5 
and the cardiac-specific subunit of BAF chromatin remodeling-complexes, Baf60) [90]; 
and activation of Notch signaling in the hemato/vascular progenitor, so-called 
hemangioblast, redirected differentiation towards a cardiac fate [91]. 
Knowledge on the transcriptional regulators and signaling pathways that determine 
cardiac cell fate will unveil new candidates to drive efficient cardiogenesis. 
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Abstract 
Mammalian heart formation is a complex morphogenetic event that depends on the 
correct temporal and spatial contribution of distinct cell sources. During cardiac 
formation, cellular specification, differentiation, and rearrangement are tightly 
regulated by an intricate signaling network. Over the last years, many aspects of this 
network have been uncovered not only due to advances in cardiac development 
comprehension but also due to the use of embryonic stem cells (ESCs) in vitro model 
system. Additionally, several of these pathways have been shown to be functional or 
reactivated in the setting of cardiac disease. Knowledge withdrawn from studying 
heart development, ESCs differentiation, and cardiac pathophysiology may be helpful 
to envisage new strategies for improved cardiac repair/regeneration. In this review, we 
provide a comparative synopsis of the major signaling pathways required for cardiac 
lineage commitment in the embryo and murine ESCs. The involvement and possible 
reactivation of these pathways following heart injury and their role in tissue recovery 
will also be discussed. 
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Introduction 
Cardiogenesis relies on early specification of cardiac myocytes from mesodermal 
progenitors, incorporation of exogenous sources of precursors and the spatial and 
timely integration of distinct signaling pathways. Genetic-based studies using the 
mouse embryo have uncovered regulatory crosstalks between distinct signaling 
pathways and a set of transcriptional cardiac regulators that control lineage 
commitment and heart morphogenesis. Additionally, embryonic stem cells (ESCs) 
derived from the inner cell mass of the embryo blastocyst, have shown to constitute a 
powerful in vitro model that faithfully recapitulates the events occurring during 
embryo development. Similar to the embryo, mouse ESCs (mESCs) commit into the 
epiblast stage and undergo differentiation as aggregates designated embryoid bodies 
(EBs). These are able to differentiate into derivatives of the three germ layers in a 
sequential set of events that mimic embryo gastrulation (reviewed in [1]). Even though 
there are discrepancies in the timing of lineage progenitor segregation, once the 
cardiac molecular program is initiated, ESCs-derived cardiac progenitors engage in the 
recapitulation of all cardiac cell phenotypes, though no particular spatial organization 
is respected (reviewed in [2]). Thus, embryos and ESCs have been used in parallel to 
achieve increased understanding of the complex developmental process. Knowledge 
withdrawn from developmental studies has been used to promote in vitro cardiac 
differentiation of ESCs and these have also brought valuable mechanistic information 
to embryonic studies (reviewed in [2, 3]). Additionally, several pieces of evidence have 
shown that detailed study of the processes regulating heart specification and 
formation provides important clues to attain a better comprehension of cardiogenic 
mechanisms and to envisage improved strategies towards cardiac regeneration. Over 
the following sections, we will focus on the molecular events regulating cardiac 
specification in both embryo and ESCs. We will also address the signaling pathways 
shown to be reactivated in the mammalian myocardium following injury and how they 
can be modulated/potentiated in order to improve cardiac repair in pathological 
stress. 
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Molecular events in cardiogenesis 
In embryo development, gastrulation is a key event through which the three germ 
layers (endoderm, mesoderm and ectoderm) are formed. Cellular fates are specified 
during gastrulation by both time of recruitment to the primitive streak (PS) and 
perceived morphogenetic information [4, 5]. Mesodermal induction is regulated by the 
interaction of distinct signaling pathways including bone morphogenetic proteins 
(BMPs), Nodal/Activin, and Wnt (reviewed in [6]). Mesodermal cells ingressing through 
the PS express the T-box transcription factor brachyury (Bry, also T), a direct target of 
the Wnt pathway [7]. β-catenin, a central player in Wnt signaling, has been shown to 
be essential for mesoderm formation since in β-catenin deficient mice no mesodermal 
or head structures are formed and Bry is not expressed [8]. These early embryonic 
events are also observed in ESCs, in which mesodermal commitment is defined by the 
upregulation of the Bry gene within 48 hours after the onset of differentiation (Figure 
1) [9]. Mesoderm is then patterned and specified to originate distinct mesodermal 
subsets, characterized by differential expression of fetal liver kinase-1 (Flk-1, also 
Vegfr2) and platelet-derived growth factor receptor-alpha (Pdgfrα, also CD140a) [10]. 
Concomitantly, Bry expression in these cells decreases [11] and other transcription 
factors are activated. One key gene in both mouse embryo and mESCs is mesoderm 
posterior 1 (Mesp1) that has been correlated with definite cardiac commitment by 
activating the cardiogenic transcriptional network in a context-dependent manner 
(reviewed in [12, 13]). The conjunction of knowledge acquired from studying 
embryonic development and ESCs system led to the optimization of chemically defined 
cocktails that efficiently drive ESCs differentiation in the absence of serum (reviewed in 
[1]). Different studies have demonstrated that a tight balance between canonical Wnt 
and members of the transforming growth factor-β (TGF-β) superfamily, including 
Nodal/Activin and BMP signaling pathways, regulates the specification of the anterior 
and posterior regions of PS in mouse [14, 15] and human ESCs (hESCs) [16]. In fact, the 
combination of Activin A and BMP4 has been shown to direct mESCs into a 
mesodermal fate [17] whereas inhibition of the Nodal/Activin pathway drives hESCs 
towards a neuroectoderm path [18]. Balanced levels of Nodal and BMPs determine 
mesoderm patterning: increased levels of Activin A favor Flk-1+Pdgfrα+ cardiogenic 
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progenitors while high doses of BMP4 promote the Flk-1+Pdgfrα- hematopoietic 
reservoir [19]. Importantly, activation of Notch pathway in differentiating mESCs has 
been shown to block the emergence of Flk-1+ mesodermal progenitors [20]. 
Migration and specification of the primitive cardiac progenitors occur during 
gastrulation around mouse embryonic day (E) 6.5, when cells leave the PS and acquire 
an anterior-lateral position forming two groups of cells on both sides of the midline [4]. 
The presumptive cardiac cells, which will contribute to the myocardium and 
endocardium, can then be detected as a crescent in the mesoderm underlying the 
head folds (cardiac crescent, E7.5) (Figure 1). The crescent fuses at midline forming the 
beating primitive cardiac tube (E8), which subsequently folds to the right creating an S-
shaped structure. The folded tube then suffers a series of rearrangements and cell 
expansion, which ultimately lead to the formation of recognizable septated cardiac 
chambers (E14.5). The cellular and morphogenic events underlying mammalian heart 
formation have been extensively reviewed elsewhere [5, 6, 21, 22]. At least two 
populations of mesodermal progenitors, arising from a common origin [23], partake in 
heart formation. The earliest group of progenitors (first heart field, FHF) constitutes 
the cardiac crescent and will contribute to the left ventricle (LV) and atria. FHF 
expansion depends on the second heart field (SHF) and provides a platform for 
subsequent heart growth. Cells of the SHF will form the outflow tract and the right 
ventricular region. Over the last years, transcriptional regulators directing the genetic 
program and morphogenesis of the cardiac progenitors have been uncovered: specific 
markers are still lacking for FHF (although Tbx5 has been associated with this field), 
whereas Isl1 has been considered a marker for SHF (reviewed in [6, 21]).  
Both lineages of progenitors are regulated by a complex signaling network, emanating 
from the adjacent tissues. Similarly to the embryo, evidences from the ESCs system 
suggest the existence of two cardiac fields or lineages with comparable molecular 
interregulatory networks (Figure 1) (reviewed in [2]). In the embryo, precardiac 
mesoderm induction and consequent FHF formation require ectodermal inhibitory 
Wnt signaling, as indicated by the respecification of endoderm into precardiac 
mesoderm in β-catenin depleted mice, resulting in the formation of several heart 
primordia [24]. These authors further observed ectopic expression of Bmp2 following 
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Wnt/β-catenin inhibition, suggesting that BMP signaling activation and Wnt inhibition 
are required to induce cardiac mesoderm specification. A similar regulation was 
observed using a Notch-inducible mES cell line, in which Notch was capable of 
redirecting the hemangioblast into a cardiac fate through activation of BMP and 
inhibition of canonical Wnt pathways [25]. Accordingly in chick, zebrafish and Xenopus, 
it has been shown that heart formation is induced in embryonic regions with high 
Bmp2 and low Wnt activities (reviewed in [26]). The function of BMPs in the mouse 
appears to be more complex: Bmp2, Bmp4, Bmp5 and Bmp7 are expressed in the 
anterior mesoderm, including the heart-forming regions but deletion of BMPs seems 
to have a late effect on cardiogenesis: mutants present cardiac defects and are 
embryonic lethal but cardiac mesoderm specification still occurs [2, 27, 28]. In 
conditional knockouts for Bmpr1a, encoding the BMP type 1 receptor, progenitors fail 
to progress towards specific lineages and form the cardiac tube [29]. Correct tissue 
specification relies not only on protein interconnections but also on the time of the 
signaling. For example, Wnt/β-catenin signaling presents a biphasic function in 
cardiogenesis: it has an inhibitory effect in the FHF but plays an inductive function in 
SHF proliferation. β-catenin inactivation in the SHF leads to defects in development 
and expansion of the SHF derivatives due to decreased cell proliferation, probably 
owing to reduced Fgf10 levels (which promote SHF expansion) and residual Bmp4 
expression (capable of maintaining the antiproliferative effect of BMPs) [30]. β-catenin 
gain-of-function, on the other hand, leads to increased proliferation. This work shows a 
clear crosstalk between signaling pathways and evidentiates the crucial role of Wnt in 
regulating proliferation of cardiac progenitors within the SHF and maintenance of their 
undifferentiated state prior to entering the heart tube. The same activity for Wnt/β-
catenin was described in ESCs since the use of a Wnt3a secreting feeder layer or 
conditioned media promotes expansion of Isl1+ progenitors and beating EBs whereas 
the addition of dickkopf-1 (Dkk1), a canonical Wnt inhibitor, has the opposite effect, 
drastically reducing Isl1+ cells and beating EBs [31, 32]. Similar to β-catenin gain-of-
function, Notch1 deletion in embryos and ESCs leads to augmented proliferation of 
cardiac progenitors through increased Wnt/β-catenin activity [33]. However, the 
mutant embryos failed to populate the developing right ventricle (which derives from  
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Isl1+ cells) and genes associated with cardiomyocyte differentiation were 
downregulated in Notch-depleted ESCs. These observations suggest that Wnt/β-
catenin inhibition is required to instruct progenitors to leave the SHF proliferative state 
and to start differentiating. Moreover, non-canonical Wnt pathway was also implicated 
in regulating SHF progenitors differentiation: loss of Wnt5a and Wnt11 affects SHF 
differentiation by increasing β-catenin nuclear levels [34]. The same authors [34] 
further showed that Wnt5a and Wnt11 are required to promote cardiogenesis and 
induce the expression of cardiac-associated genes in differentiating ESCs, indicating 
that non-canonical Wnt signaling regulates the formation of FHF and SHF associated 
progenitors during EBs differentiation [34]. Additionally, exogenous non-canonical 
Wnt2 was shown to increase cardiomyocytic differentiation from murine ESCs [35]. 
Together, these results indicate that Notch signaling and non-canonical Wnt are 
required to instruct progenitors to leave the SHF proliferative state by interfering with 
Figure 1. Signaling events in murine heart development and cardiac ESCs differentiation. In both 
systems, mesodermal induction from the epiblast is regulated by Wnt/β-catenin, Nodal/Activin, and 
BMP signaling pathways and correlates with Brachyury upregulation. Further commitment of 
mesodermal progenitors to cardiac mesoderm and consequent first heart field (FHF) formation require 
the inhibition of Wnt signaling and expression of BMPs. Similarly, in ESCs system Notch pathway 
inhibits Wnt/β-catenin signaling and activates BMP to specify cardiac fate. Wnt/β-catenin signaling is 
then activated to allow proliferation and maintenance of the SHF, both in embryo and ESCs. Further 
differentiation from the cardiac crescent stage to the following morphogenic phases of embryonic 
heart development and, in parallel, the expression of cardiomyocyte differentiation genes in ESCs 
require inhibition of Wnt/β-catenin. In the embryo and ESCs, this is achieved by Notch and non-
canonical Wnt signaling, which inhibit the effect of Wnt/β-catenin and instruct progenitor cells within 
the SHF to leave the proliferative state and start differentiating.  represents inhibitory effect;  
represents maintenance of a proliferative state. 
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Wnt/β-catenin pathway (Figure 1). Different members of the Notch pathway have 
been shown to be expressed along heart development regulating distinct key events in 
cardiogenesis. Notch proteins in the endocardium are responsible for modulating 
myocardial signals (e.g. BMPs) to regulate trabecular formation, chamber specification, 
and cell proliferation and differentiation (reviewed in [36, 37]). Neural crest cells and 
the proepicardial organ also contribute to the forming heart. Events such as cellular 
contribution from external sources, progenitor expansion, and differentiation towards 
the distinct cardiac cell types are tightly coordinated by the distinct signaling pathways, 
including Wnt, FGF, BMPs, Notch and Hedgehog (Hh) (reviewed in [5]). These 
ultimately regulate a plethora of transcription factors that constitute a combinatorial 
code responsible for orchestrating cardiac development and specification and 
differentiation of myocytes. 
Reactivation of the embryonic program in cardiac pathological stress  
The adult heart presents robust plasticity and it is capable of remodeling in response to 
distinct demands, either physiologic (normal aging or increased effort) or pathologic 
(e.g. hypertension, ischemia/myocardial infarction (MI) associated with coronary 
artery disease, hypertrophy, and dilated cardiomyopathies). In both cases, the first 
response to overcome the increased stress on the left ventricle (LV) is myocardial 
hypertrophic growth, which in the long-term is associated with increased risk of heart 
failure and sudden death (reviewed in [38, 39]). 
Efforts have been made towards identifying efficient new therapies to avoid heart 
failure. To accomplish this, a comprehensive understanding of the biological processes 
and signaling pathways involved in cardiac formation and leading to heart disease is 
required. Distinct diseases impacting the adult myocardium have been correlated with 
perturbation in signaling pathways involved in embryonic heart development. On the 
other hand, when under pathological stress, the heart reactivates pathways 
traditionally associated with the developing heart and whose activity is decreased in 
adult hearts (reviewed in [39, 40]). In this section a general overview on the 
involvement of key pathways in heart disease will be presented (see also Table 1). 
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Notch signaling  
Being such an important signaling network in distinct mechanisms, perturbation of the 
Notch pathway has been associated with several genetic diseases and malformations. 
Regarding cardiac morphogenesis, Notch plays a crucial role in regulating events such 
as cardiomyocytes (CMs) differentiation, atrioventricular canal development, 
regulation of the endocardium endothelial-to-mesenchymal transition required for 
valve formation, and trabeculae development (reviewed in [36, 37]). Notch pathway is 
active in proliferating embryonic CMs but its activity decreases after birth and declines 
with age coinciding with CMs maturation [41, 42]. Furthermore, Notch activation in 
neonatal or mESCs-derived quiescent CMs induces cell cycle reentry [43]. The 
involvement of Notch in mammalian cardiac response to stress has been shown to be 
primarily mediated by Notch1 and its ligand Jagged1, which (together with the Notch 
target Hes1) are upregulated in the hypertrophic heart [44]. The authors also analyzed 
mice lacking Notch1 specifically in the heart, which revealed increased hypertrophy, 
fibrosis, and mortality. Following MI, Notch1 expression is also reactivated and 
detected in border zone CMs and this activation was correlated with repair and pro-
survival processes, including prevention of CMs apoptosis, regulation of resident 
cardiac progenitor cells (CPCs) and immature CMs, and promotion of 
neovascularization ([41, 45, 46]; reviewed in [47]). Accordingly, delivery of the Notch 
intracellular domain (NICD) or of a Notch1 pseudo-ligand following MI leads to 
improved wall thickness and cardiac function, enhanced neovascularization, and 
decreased infarct area [41, 45]. Overexpression of Jagged1 in CMs restrains myocardial 
hypertrophy and fibrosis and promotes CPCs proliferation [48]. Importantly, blockade 
of Notch1 signaling with a γ-secretase inhibitor upon MI impairs the commitment of 
heart resident CPCs into the myocytic lineage [49]. This is of particular interest 
considering that stem/progenitor cells have been shown to contribute to generation of 
new CMs after injury, though they do not seem to actively participate in 
cardiomyocytic renewal during normal aging [50]. Taken together, these studies 
evidentiate Notch as an essential pathway with cardioprotective role in the damaged 
myocardium, being able to favor a pro-cardiogenic process by regulating key events in 
cardiac remodeling as fibrogenesis and cardiogenesis. 
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FGF signaling  
FGFs are potent mitogens expressed from early development in the SHF, where Fgf8 
and Fgf10 have been implicated in regulating progenitors proliferation and 
development together with other signaling pathways (reviewed in [5]). Expression of 
these growth factors is augmented during the onset of myocardial ischemia or 
infarction; their therapeutic potential has been addressed in pigs and dogs and shown 
to improve blood flow and preserved cardiac function in acute MI (reviewed in [51]). In 
rats, a combined treatment with Fgf1 and p38 MAP Kinase inhibitor following MI 
results in preserved wall thickness, reduced scarring, and overall improved cardiac 
function [52]. These effects are associated with increased proliferation and 
angiogenesis. Fgf1 per se is capable of inducing CMs cell cycle reentry and angiogenesis 
but the combined therapy with p38 inhibitor enhances FGF effects and cardiac 
regeneration [52]. The role of Fgf2, another potent angiogenic and mitogenic factor, in 
cardiac injury has also been extensively explored and shown to exert a protective 
effect against myocardial dysfunction following myocardial ischemia or infarction by 
increasing myocyte viability (reviewed in [53]). 
Sonic Hedgehog signaling 
Sonic Hedgehog (Shh) morphogens are involved in several developmental processes 
during embryogenesis. In the heart, Shh is involved in the establishment of the left-
right asymmetry and SHF progenitors regulation (reviewed in [5]). Similar to other 
signaling pathways, there is evidence for Shh reactivation with concomitant 
upregulation of the Hedgehog patched-1 (Ptch1) receptor in the ischemic myocardium 
[54]. In this study, the authors performed intramyocardial gene transfer of naked DNA 
encoding human SHH, which resulted in successful restoration of LV function in acute 
and chronic ischemia, enhanced neovascularization, and reduced fibrosis and 
apoptosis [54]. Interestingly, in a recent study, a strategy for controlled release of Shh 
morphogens was developed, which enables a slow and sustained delivery of Shh-
heparin complexes, maintaining a constant local concentration within the therapeutic 
range [55]. This approach allowed a continued exposure of the myocardium to Shh, 
thus promoting a prolonged beneficial effect, which includes production of survival 
factors  and  attenuation of  cardiomyocytic apoptosis [55]. These studies indicate  that  
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Table 1. Overview of studies targeting different signaling pathways in heart 
pathological stress 
Pathway Affected Member Effect Ref. 
 
 
 
Notch1 ( ) 
Increased hypertrophy, fibrosis, and mortality; 
impaired adult CPCs commitment into 
myocytic lineage 
[44] 
[49] 
Notch Notch1 (→) 
Improved wall thickness and cardiac function; 
enhanced neovascularization; decreased 
infarct area 
[41] 
[45] 
 Jagged1 (→) 
Restraint of myocardial hypertrophy and 
fibrosis; increased CPCs proliferation 
[48] 
 
 
FGF 
 
 
Fgf1 (→)        
Fgf2 (→)        
 
Preserved wall thickness; reduced scarring ; 
improved cardiac function; increased 
proliferation and angiogenesis;  
increased CMs viability 
[52] 
[53] 
 
 
Shh 
Shh (→) 
Restoration of LV function in acute and 
chronic ischemia; enhanced 
neovascularization; reduced fibrosis and 
apoptosis 
[54] 
 
Shh-heparin 
complexes (→) 
Production of survival factors; attenuation of 
CMs apoptosis 
[55] 
Wnt/β-catenin 
Sfrp1 (→) 
Sfrp2 (→) 
Prevented CMs apoptosis; 
antifibrotic effect 
[56] 
[57] 
[58] 
Dishevelled (→) 
Myocardial hypertrophy;  
severe cardiomyopathy 
[59] 
TGF/BMP 
Smad6 ( )  
Noggin ( ) 
Increased cell proliferation;  
hyperplastic cardiac cushions 
[60] 
[61] 
Bambi ( ) 
Hypertrophy; chamber dilation; deterioration 
of systolic function; diastolic dysfunction 
[62] 
Tgfb1(→) 
Cardiac hypertrophy;  
increased interstitial fibrosis 
[63] 
( ) Inhibition or (→) activation of the specific pathway member. 
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Shh treatment offers a putative therapeutic approach in acute and chronic ischemia.  
Wnt signaling 
Different studies have shown that several Wnt factors are induced after experimental 
MI in various animal models, being involved in hypertrophy and cardiac wound healing 
following injury [64, 65]. Overall, blockage of Wnt signaling by targeting distinct 
pathway elements has a beneficial effect on cardiac remodeling (reviewed in [66, 67]). 
For example, the use of secreted frizzled related proteins (SFRPs) that antagonize Wnt 
signaling by competing for Wnt binding and preventing ligation to the frizzled receptor, 
reduces infarct size and improves cardiac function. This was shown either by inducing 
MI in transgenic mice overexpressing Sfrp1 [56] or by Sfrp2 local secretion [57] or 
exogenous administration [58]. Sfrp2 was shown to increase myocardial survival after 
MI by preventing CMs apoptosis and exerting an antifibrotic effect through Bmp1 
inhibition, normally involved in collagen biosynthesis [57, 58]. These and other reports 
(reviewed in [66]) seem to indicate a reactivation of the developmental mechanisms 
observed in FHF, in which Wnt inhibition is required for correct formation of the LV. In 
accordance, mice with cardiac-specific overexpression of dishevelled (Dvl), a protein 
acting downstream of frizzled receptor and activator of the canonical and non-
canonical Wnt pathways, present myocardial hypertrophy and severe cardiomyopathy 
[59]. It is worth mentioning that, although the majority of reports indicate a beneficial 
effect upon inhibition of this pathway, some studies have demonstrated favorable 
outcomes upon its activation [67]. These differences might partially be due to 
variations in animal models, cell type, temporal context (essential for Wnt-mediated 
effects, as observed in embryonic heart development) and activation of Wnt-
independent mechanisms by SFRPs [64, 68]. 
TGF/BMP signaling 
In cardiac embryo development, BMP signaling has been associated with valve 
formation: Bmp2 deletion in the atrioventricular murine myocardium demonstrated 
that this protein is required for cardiac jelly formation and cardiac cushions 
development [69]. Conditional Bmp4 mutants have profound defects in outflow tract 
and ventricle septation and perturbed expansion and remodeling of the endocardial 
cushions, resulting in abnormal valve structure [70]. In accordance with this embryonic 
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role, TGF-β, and BMPs in particular, have been extensively implicated in valvular heart 
diseases in mammals and activated BMP signaling has been detected in diseased 
human aortic valves (reviewed in [71]). Accordingly, perturbing the endogenous 
repression of the BMP signaling cascade by deleting either the inhibitory Smad6 [60] or 
noggin [61] leads to hyperplastic cardiac cushions due to increased cell proliferation. 
Besides the role in valve formation, TGF-β signaling is increased in stressed 
myocardium, being associated with augmented fibrosis and hypertrophic growth of 
CMs. Smad proteins, transcription factors downstream of TGF-β/BMP, positively 
regulate cardiac fibrosis, a major contributor to adult heart disease and functional 
impairment by regulating the expression of distinct extracellular matrix (ECM) proteins 
(reviewed in [39]). This was demonstrated to occur both in normal aging hearts and 
following MI. An increase in Tgfb1, Smad proteins, and collagens was observed in 
infarcted rat hearts [72]. Regarding aging, 24-month-old Tgfb1 heterozygous mice 
exhibited decreased myocardial fibrosis and stiffness when compared to control 
animals [73]. Additionally, Tgfb1 overexpression induces cardiac hypertrophy, 
expression of hypertrophy-associated proteins, and increased connective tissue and 
interstitial fibrosis [63]. More recently, it was shown that inhibition of Bambi (BMP and 
Activin membrane-bound inhibitor), a negative regulator of TGF-β-mediated 
deleterious remodeling signals, leads to exacerbated hypertrophy, chamber dilation, 
deterioration of LV systolic function and diastolic dysfunction [62].  
Conclusions 
Heart failure is a major concern in modern society. The approaches currently taken to 
achieve heart function restoration aim to delay or even reverse maladaptive 
remodeling. Even though several advances have been made, these strategies still face 
challenges like preservation of the contractile function and myocyte viability. We have 
reviewed distinct studies showing that in response to pathologic stress there is partial 
reactivation of genes that promote embryonic and fetal heart development. For 
example, Notch signaling may be modulated to expand the resident cardiopoietic 
progenitor pool and reactivate cell cycle reentry of pre-existing cardiomyocytes in the 
adult mammalian heart in the scenario of pathological insult, limiting the extent of 
ischemic injury [49, 50]. Additionally, Shh holds great promise for repair/regeneration 
Chapter I 
37 
 
of tissues suffering ischemic injury, even though clinical translation has been 
hampered by its short half-life in the body [55]. Conversely, inhibition of Wnt/frizzled 
signaling pathway seems also to have beneficial effect on cardiac remodeling 
(reviewed in [66, 67]). In this sense, learning from the embryonic development can 
provide important clues to understand and modulate the injury scenario. This 
knowledge may be used in the future to implement and adopt new therapeutic 
strategies for adult heart disease. Interestingly, considering that resident CPCs have 
been shown to contribute for the generation of new cardiomyocytes in an injury 
setting [50], it would be valuable to analyze whether these signaling pathways are 
active in adult CPCs. In fact, Notch1 has already been shown to regulate adult CPCs 
proliferation and commitment to myocytes [49]. Furthermore, a strategy combining 
CPCs delivery with FGF controlled release is currently under clinical investigation [74]. 
These studies suggest that important pathways for embryonic cardiac morphogenesis 
can be translated to the adult signaling networks. One might then predict that the 
manipulation of this signaling environment will bring forward insights on how to 
modulate/potentiate CPCs response in a disease setting by creating a more suitable 
environment for repair/regeneration.  
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A closer look into the Notch signaling pathway 
 
Overview of the Notch pathway 
Notch was discovered and named in 1919 due to the phenotype observed in 
heterozygous Drosophila females presenting notched wings [1]. The name of the 
receptor baptized the entire pathway which, in a very simplistic view, includes 
receptors, ligands and nuclear effectors extremely conserved from the fruit fly to 
mammals. As both receptor and ligand are transmembrane proteins, Notch signaling is 
transmitted between neighboring cells and thus, by acting through mainly two 
mechanisms, lateral inhibition and boundary induction, Notch pathway orchestrates a 
multiplicity of biological processes (e.g. cell fate specification, cell differentiation, 
boundary formation, progenitor cell maintenance, apoptosis and cell proliferation). 
Lateral inhibition is a process by which the neighbor cell is inhibited from becoming the 
same cell type, whereas by boundary induction the neighbor cell will become the same 
type as the signaling cell. A third mechanism that controls lineage decision involve 
asymmetrical inheritance of Notch regulators by two daughter cells, such as the Notch 
inhibitor Numb, during cell division [2]. 
Most vertebrate species exhibit four receptors (Notch1 to Notch4), being Notch1 and 
Notch2 the most similar to the Notch receptor described in Drosophila. Notch receptor 
is a heterodimeric molecule composed by two fragments linked by disulfide bonds: the 
extracellular domain and a second composed by the transmembranar and intracellular 
domains. Vertebrate ligands, also transmembranar proteins, belong to two families: 
Delta (Delta or Delta-like (Dll) 1, 3 and 4) orthologues of the Drosophila Delta, and 
Jagged (Jagged 1 and 2) orthologues of the Drosophila Serrate [3]. Binding of the ligand 
triggers the proteolytic cleavage of the receptor, firstly by ADAM/TACE-family of 
metalloproteases, and secondly by the γ-secretase complex (containing presenilin and 
nicastrin subunits) which releases the Notch intracellular domain (NICD) [4]. The 
distinct ligands have equal ability to interact with the receptor and trigger proteolytic 
cleavage. However differences are found in their expression pattern and some 
context-specificity is observed, as deletion/inhibition of specific ligands results in 
different effects. In the canonical Notch pathway, NICD translocates to the nucleus and 
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associates with the DNA-binding protein RBP-J (also known as CSL from the orthologue 
proteins: CBF1, Supressor of Hairless and Lag1) and with the co-activator Mastermind-
like (MAML), activating the transcription of the Notch target genes by displacement of 
co-repressors (Figure 1) [5-7]. Notch effectors include members of Hairy and Enhancer 
of split (Hes) and Hes-related (Hesr, also known as Hrt and Hey) gene families which 
encode basic helix-loop-helix (bHLH) proteins and mediate great part of the Notch 
pathway effects, such as cell proliferation, differentiation, apoptosis and binary cell-
fate decisions. In fact, regulation by Hes and Hesr proteins has been associated to the 
most important effects of the Notch pathway. Usually acting as transcriptional 
repressors, these factors antagonize the effects of bHLH activators, thereby regulating 
the timing of cell differentiation and cell-fate decision that will result in correct organ 
formation [8]. Yet, the expression of Hes/Hesr genes, although being often induced 
following NICD nuclear translocation, it is not exclusively driven by Notch signaling 
activation, as for example Shh pathway has been also shown to activate Hes1 
expression [9, 10].  
 
Figure 1. Canonical Notch pathway. Mammals express four Notch receptors (Notch1-4) and five ligands 
belonging to two families (Delta-like 1, 3 and 4 and Jagged 1 and 2). As ligand and receptor are 
transmembranar proteins Notch signaling is transmitted between neighboring cells. Binding of a ligand 
activates a sequence of proteolytic cleavages of the receptor that culminates in the release of the Notch 
intracellular domain (NICD) mediated by the γ-secretase complex containing presenilin (PSEN) catalytic 
subunit. Cleaved NICD translocates to the nucleus where it forms an active transcriptional complex with 
the DNA-binding protein RBP-J and with co-activators (CoA), including MAML. In the absence of 
activated Notch, RBP-J binds Notch target genes and recruits co-repressors (CoR) acting as a 
transcriptional repressor. In the presence of NICD the co-repressor complex is displaced and RBP-J is 
switched to a transcriptional activator of Notch target genes. Notch targets include members of Hes and 
Hes-related (Hrt) family genes which encode bHLH transcriptional regulators that mediate a great part of 
the downstream events of Notch signaling. Reproduced from [11]. 
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An intrinsic aspect of the Notch pathway, and also associated to Hes/Hesr proteins 
activity, relates to its context-specific nature, in which the cellular-context, timing, 
duration and dose of the signal will determine different outcomes. These features 
often reverberate in contradictory findings, in which a dual effect on a particular 
biological process or pathology is reported. In consequence, the Notch signaling is 
often associated to controversy in the most varied fields of research. 
Notch signaling in cardiac specification and differentiation 
Cardiac fate is specified during gastrulation (E7) in mesodermal progenitors emerging 
from a distal part of the primitive streak [12]. Cardiac progenitors undergo then 
epithelial-to-mesenchymal transition (EMT) and migrate bilaterally from the primitive 
streak to form the left and right heart fields (primary heart field) that will fuse to form 
the cardiac crescent. EMT and migration from the primitive streak depends on the 
expression of Mesp1 transcription factor [13]. Importantly, Mesp1 has also been 
demonstrated to regulate cardiac cell fate and EMT in differentiating ESCs [14]. Also in 
differentiating ESCs, Mesp1 has been shown to transiently upregulate directly 
components of the Notch pathway, while Notch blockade by treatment with a γ-
secretase inhibitor from D2-D4 of in vitro differentiation compromised cardiovascular 
differentiation in Mesp1-induced cells. These observations suggested that Notch acts 
at the specification or early in cardiac lineage commitment [15]. The demonstration 
that transient Notch activation specifies mesodermal progenitors towards a cardiac 
fate using the ESCs differentiation system was soon to appear. Interestingly, in the 
same study, Notch induction in hematopoietic/vascular progenitors, the so-called 
hemangioblasts, redirected the cell fate towards cardiac commitment in detriment of 
the expected hematopoietic lineages [16]. In correlation with these observations, in 
the mouse embryo, Notch1 expression is found in nascent mesodermal cells at 
primitive streak stage (E7), what may indicate the participation in mesodermal 
specification towards its derivatives [17]. However, these findings apparently 
contradict the previous knowledge that Notch exerts a suppressive role on cardiac 
differentiation. Indeed, in mouse embryo enforced NICD1 activation in Mesp1-
expressing cells, although not affecting myocardial and endocardial cell-fate decisions 
from Mesp1+ cells, induced heart abnormalities by impairing myocardial differentiation 
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[18]. Likewise, Notch activation in Xenopus embryos after formation of the early heart 
field suppressed the expression of genes encoding contractile proteins, indicating 
impairment of myocardial differentiation [19]. Interestingly a similar regulation was 
documented in Drosophila [20], suggesting a conservative mechanism throughout the 
animal kingdom evolution. Supporting an inhibitory role in cardiogenesis, mESCs 
deficient in RBP-J [21] or in Notch1 receptor [22] showed enhanced cardiogenic 
potential, while Notch activation favored neuroectodermal fate [22, 23]. Yet, there is a 
possibility that cardiac induction is promoted by a non-canonical Notch pathway which 
is always independent of RBP-J and may occur either dependent or independently of 
ligand interaction and/or cleavage by γ-secretase [24]. This hypothesis would reconcile 
with the demonstration that mice lacking RBP-J show lethality at E8.5, and thus 
presumably have normal cardiac development up to primitive heart tube stage [25]. 
These evidences demonstrate that Notch signaling can interfere with cardiac lineage 
differentiation distinctly, depending on the specific time of induction and duration of 
the signal. 
At later stages in heart development, loss-of-function mutations in Notch pathway 
members result in visible cardiac abnormalities, e.g. random heart looping (double 
Notch1 and Notch2 mutant; Delta-like1 (Dll1); RBP-J) [26, 27], septal and valve defects 
(Hey1, Hey2, double Hey1 and HeyL mutant, Notch2, Jagged1, Hes1) [28-34], and 
impaired trabeculation (Notch1, RBP-J) [35] are some of the described phenotypes. 
The effects of defective Notch signaling have revealed a function for several Notch 
pathway components in the initiation of EMT, required for formation of the cardiac 
septum and valve structures [31]; and in the regulation of myocyte proliferation and 
differentiation, essential for trabeculation and myocardial development [35] (Table 1). 
Thus, Notch signaling plays a crucial role in cardiogenesis and in cardiac repair, 
previously explored in this dissertation [36]. The time and context-specific intervention 
of different components of the Notch pathway will determine the effect in cardiac 
lineage determination and further progression in the differentiation program. This 
tight regulation by Notch signaling will contribute, within a complex crosstalk with 
other pathways, for making the heart of the correct size, organization, shape and cell 
composition.  
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Table 1. Expression of Notch pathway members during heart development  
Pathway member Expression pattern 
Notch1 
Expressed in the cardiac crescent (E7.5). From E8.0 to E11.5 detection is limited to 
the endocardium and highly expressed in the AV canal and outflow tract 
endocardium [17, 37, 38]. 
Notch2 
Expressed in the AV canal (E12.5) and the outflow tract endocardium (E11.5 and 
E14.5). Expressed in atrial and ventricular myocardium (E13.5) [39-41]. 
Notch3 
Expressed in the cardiac crescent (E7.5) but not detected after linear heart tube 
formation (E8) [37].  
Notch4 Expressed in the endocardium (E10.5) [42]. 
Jagged1 
Expressed in the atrium (E10.5) and in the AV canal endocardium and outflow 
tract (E12.5) [43]. 
Delta-like1 Expressed in the endocardium at the base of ventricular trabeculae (E9.5) [35]. 
Delta-like4 
Expressed in the cardiac crescent (E8.0) and restricted to endocardial cells and 
endothelial cells onward [44]. 
Hey1 
Expressed in the endocardium (E8.5-E9.0). Restricted to atrial myocardium at 
E10.5. [38, 45]. 
Hey2 
Expressed in the primitive ventricle of the primordial heart tube (E8.5). Restricted 
to ventricular myocardium at E10.5 [45, 46]. 
HeyL Expressed in the AV canal endocardium (E9.5-E12.5) [31].  
Hes1 Expressed in the second heart field (E8.5 and E10.5) [34]. 
AV, atrioventricular; E, embryonic day; OFT, outflow tract; EMT, epithelial-to-mesenchymal transition. 
Adapted from [47]. 
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Aims and structure of the Thesis 
In the last decade cardiovascular research has developed great efforts to implement 
cell-based strategies to restore myocardial tissue and improve cardiac function. 
Therapies based on the transplantation of cells of different origins have shown variable 
rates of success and, importantly, have revealed the importance of selecting the ideal 
cell source for heart repair/regeneration. The ideal cell-based therapy would involve 
the use of cells whose differentiation program is restrained to the generation of the 
cardiac lineages. Thus, the original discovery of cells displaying stemness features 
within the myocardium, so-called cardiac progenitor cells (CPCs), ignited enthusiasm in 
the field. However, advances have mostly been driven by a clinical urge for heart 
repair, and thus emerged from more applied studies on cell culture and cell 
transplantation. Consequently, a considerable number of clinical trials, very early 
initiated, have not yet gathered a support that can only be granted by robust data on 
the basic biological aspects concerning endogenous CPCs. In good truth, there are, 
undoubtedly, particular challenges to the ex vivo analysis of these cells, e.g. the 
scarcity within the myocardium, rapid senescence and phenotypic alterations due to 
long-term culture. There is also a propensity for variability, related to the 
heterogeneity of the distinct populations under study in different laboratories. This is, 
by large, a result of the distinct methodologies in use, and among others to mention, 
the choice of a single marker for isolation [1]. In a few words, this field of study is 
diseased of a lack of standardization. 
It is currently recognized, that pathways that control embryogenesis are functional or 
reactivated in situations of stress, resulting in either beneficial or deleterious effects. 
Therefore, the comprehension of the regulatory networks orchestrating cardiac 
specification and differentiation will open a window to oversee new possibilities for 
therapeutic strategies; as it would be, for example, the specific modulation of the 
signaling environment to promote pro-cardiogenic processes. The knowledge gathered 
from the embryonic heart development and differentiating ESCs have contributed 
valuable candidates with a central role in cardiogenesis. As examples, master 
transcription factors and miRNAs have been used to reprogram cardiac fibroblasts into 
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cardiomyocytes in vivo [2, 3, 4]. Likewise, it is legitimate to anticipate candidates 
withdrawn from studies in ESCs and in the embryo might show as key factors to 
enhance cardiogenic potential of adult heart-resident CPCs. 
In the framework of this Thesis collaborative work between Pinto-do-Ó & Di Nardo and 
Pinto-do-Ó & Lemischka laboratories was established to come forth with potential 
tools and answers for some of these questions. 
The first objective of this work aimed at the production of a source of unlimited 
replicates of Lin-Sca-1+ progenitors endowed with a stable function and phenotype in 
long-term culture. The experimental design consisted in the isolation and clonal 
selection of heart-resident Lin-Sca-1+ cells immortalized by overexpression of mTERT. 
An extensive in vitro and in vivo characterization of an immortalized Lin-Sca-1+ clone 
was carried out in order to validate the newly generated line as a model system 
representative of the native cellular counterparts. The detailed experimental work and 
results are reported in the Chapter III. 
Next, in recognition that knowledge on the early determination of cardiac fate during 
embryonic development might provide information on how to elicit/enhance 
cardiomyogenic potential in adult CPCs; a screen to identify early regulators in 
cardiogenesis was performed using the ESCs differentiation system. This in vitro model 
system offers the unique advantage of allowing mechanistic studies intended to 
dissect early lineage specification, and overcome technical constraints inherent to 
studies with embryos in very early developmental stages [5]. Chen et al, have 
demonstrated, using the mESCs differentiation system, that transient NICD activation 
directs mesoderm, and remarkably, respecifies the hemangioblast (a 
hematopoietic/vascular progenitor) towards a cardiac fate [6]. Thus, we proposed to 
identify effectors downstream of Notch playing a role in the onset of cardiogenesis. 
Our experimental design consisted in employing a mES cell line that expresses NICD1 
under the control of a Doxycycline (Dox)-inducible promoter to identify the members 
of Hes/Hesr families playing a role in cardiac specification. The detailed experimental 
work and results are reported in the Chapter IV. 
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The final aim of the herein Thesis was to investigate whether the identified 
developmental factor(s) could also play a key role in the modulation/regulation of a 
cardiac molecular program in adult CPCs. A preliminary study was performed aiming at 
the examination of the role of Hes5 (the candidate identified in the Chapter IV) in the 
regulation of proliferation and differentiation in adult CPCs, using the iCPCSca-1 cell line 
(established in the Chapter III) as a model of endogenous adult CPCs. The experimental 
work and preliminary results are reported in the Chapter V. 
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Abstract 
Putative cardiac progenitor cells (CPCs) have been identified in the myocardium and 
are regarded as promising candidates for cardiac cell-based therapies. Although two 
distinct populations of CPCs reached the clinical setting, more detailed studies are 
required to portray the optimal cell type and therapeutic setting to drive robust cell 
engraftment and cardiomyogenesis after injury. Owing to the scarcity of the CPCs and 
the need for reproducibility, the generation of faithful cellular models would facilitate 
this scrutiny. Here, we evaluate whether immortalized Lin-Sca-1+ CPCs (iCPCSca-1) 
represent their native-cell counterpart, thereby constituting a robust in vitro model 
system for standardized investigation in the cardiac field. iCPCSca-1 were established in 
vitro as plastic adherent cells endowed with robust self-renewal capacity while 
preserving a stable phenotype in long-term culture. iCPCSca-1 differentiated into 
cardiomyocytic-, endothelial-, and smooth muscle-like cells when subjected to 
appropriate stimuli. The cell line consistently displayed features of Lin-Sca-1+ CPCs in 
vitro, as well as in vivo after intramyocardial delivery in the onset of myocardial 
infarction (MI). Transplanted iCPCSca-1 significantly attenuated the functional and 
anatomical alterations caused by MI while promoting neovascularization. iCPCSca-1 are 
further shown to engraft, establish functional connections, and differentiate in loco 
into cardiomyocyte- and vasculature-like cells. These data validate iCPCSca-1 as an in 
vitro model system for Lin-Sca-1+ progenitors and for systematic dissection of 
mechanisms underlying CPC subsets engraftment/differentiation in vivo. Moreover, 
iCPCSca-1 can be regarded as a ready-to-use CPCs source for pre-clinical bioengineering 
studies toward the development of novel strategies for restoration of the damaged 
myocardium. 
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Introduction 
Cardiac cell therapy was shown to be a very complex endeavor for which a completely 
innovative vision and novel technologies are necessary. Indeed, in spite of intensive 
scientific and economic efforts, the technological exploitation of the stem cell 
potential has generated frustrating results owing to the unsystematic and simplistic 
approaches considered so far. Myocardial cell delivery in experimental animals and 
patients results in a very low number (~ 3-10%) of cell persistence in the myocardium 
due to significant cell death and/or loss to the bloodstream with subsequent 
entrapment into the lungs [1, 2]. Although some beneficial effects have been reported, 
the improvement of cardiac function has been greatly ascribed to the release of 
paracrine factors rather than to an increased presence of functional cardiomyocytes 
(CMs) in the injured myocardium [3-5]. Regardless, in the last decade, adult cardiac 
progenitor cells (CPCs) have gathered abundant attention [6-18], paving the way to a 
quick transition from the bench to the bedside [19, 20]. In fact, two independent 
clinical trials, each addressing a different subset of progenitor cells (c-Kit-expressing 
cells for SCIPIO [19] and cardiosphere-derived cells for CADUCEUS [20]), were carried 
out to assess their therapeutic potential in the myocardial infarction (MI) setting. 
Although the short-term results on a reduced patient number have shown a partial 
amelioration of the heart condition, most aspects of the CPCs biology are still 
undefined. Hence, only an indisputable demonstration of the beneficial effects of 
these strategies can suppress the innumerable doubts regarding protocols based on 
harsh manipulations of stem/progenitor cells [21]. Among many others, the factors 
governing the admirable equilibrium of the myocardial in vivo complexity, such as the 
interactions between progenitor cells and environmental components, remain largely 
undefined. Therefore, the only possibility to mimic the dynamics of myocardial 
homeostasis in order to establish safe and reliable repair procedures is a stringent 
‘‘standardization’’ of the different aspects of myocardial complexity [22]. 
A clear understanding on CPCs biology is impaired by the scarcity of progenitors 
present within the myocardium as well as by time-consuming isolation procedures, 
and, importantly, by their phenotypic variability when isolated and expanded in 
different laboratories [23]. Consistently, progenitor cells that apparently partake in the 
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same population can display non-comparable features. To circumvent these 
limitations, the aim of this study was to create a benchmark to be used as a reference 
for progenitor cell populations isolated from the myocardium in different laboratories 
on the basis of a plethora of non-specific cell-surface markers [6-15, 17, 18]. For this 
purpose, lineage negative/Sca-1+ (Lin-Sca-1+) CPCs have been isolated from murine 
hearts and immortalized via murine telomerase catalytic subunit (mTERT) 
overexpression. Recently, the role of telomerase activity in maintaining CPCs viability 
and regenerative potential was demonstrated [24]. Aging leads to telomeric shortening 
in CPCs, thus leading to a senescent phenotype, as shown by the expression of 
p16INK4a. Such events have been correlated to cardiac function impairment, 
suggesting that CPCs loss could be a main determinant in heart failure. Moreover, the 
overexpression of the human telomerase reverse transcriptase (TERT) catalytic subunit 
in various cell lines resulted in extended cellular lifespan [25-27] without detectable 
changes characteristic of malignant transformation [28]. 
In the present study, a cell line of immortalized Sca-1+ cardiac progenitor cells (iCPCSca-
1) has been specifically generated for the first time. iCPCSca-1 were extensively 
characterized to assess whether after immortalization these cells had preserved the 
hallmarks of their native-cell counterpart and the recognized capability to engraft and 
differentiate when transplanted in an MI murine model. Cells grew in vitro as adherent 
cells with a typical spindle-shape morphology and displayed robust self-renewal 
capacity, while preserving a CPC tri-lineage potential (i.e., differentiated in CMs-, 
endothelial- and smooth muscle like-cells). iCPCSca-1 transplanted into the MI border 
zone significantly reduced the MI-induced left ventricle (LV) anatomical and functional 
alterations. Importantly, the cells engrafted, established functional connections, and 
differentiated in loco into cardiomyocyte- and vasculature-like cells, as previously 
shown for their native counterparts. Thus, the iCPCSca-1 line constitutes an unlimited 
source of Sca-1+ CPCs replicates and can be used as a model system for in vitro high-
throughput studies and for the dissection of the in vivo role of adult heart-resident 
progenitors. 
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Methods  
Animals 
C57BL/6 mice aged 6-12 weeks were used. Procedures were approved by Instituto de 
Biologia Molecular e Celular – Instituto de Engenharia Biomédica Animal Ethics 
Committee and National Direção Geral de Veterinária (permit no: 022793), and are in 
conformity with the European Parliament Directive 2010/63/EU. Humane endpoints 
were followed according to the Organization for Economic Co-operation and 
Development Guidance Document on the Recognition, Assessment, and Use of Clinical 
Signs as Humane Endpoints for Experimental Animals Used in Safety Evaluation (2000). 
Mice were anesthetized by an intraperitoneal injection (ip) of medetomidine (1 mg/kg; 
Sededorm) and ketamine (75 mg/kg; Clorketam), and its adequacy was monitored by 
the pedal withdrawal reflex.  
Isolation and culture of Sca-1+ CPCs 
CPCs were isolated as previously described [29]: 6 week male C57BL/6 mice hearts 
were minced and digested using 0.25% Trypsin/ethylenediaminetetraacetic acid 
(EDTA) and collagenase II (1500 U; Worthington) in phosphate buffered saline (PBS). 
Tissue fragments were cultured in Dulbecco's Modified Eagle Medium (DMEM; Lonza) 
that was supplemented with 10% fetal calf serum (Lonza), 100 IU/mL penicillin and 100 
µg/mL streptomycin, insulin-transferrin-selenium 1X, 300 ng/mL retinoic acid, 0.8 
µg/mL linoleic acid, 2 mM L-glutamine, 0.1 ng/mL insulin-like growth factor 1, and 0.1 
ng/mL endothelial growth factor (complete medium). After 12-15 days, adherent cells 
migrating out from fragments were harvested and magnetically sorted using anti-
hematopoietic lineages antibody cocktail (Miltenyi Biotec). Sca-1+ cells were enriched 
from the Lin- fraction by two sets of magnetic cell sorting protocols (Miltenyi Biotec) 
and expanded in culture in complete medium before transfection. 
Establishment of iCPCSca-1 
Murine TERT coding sequence, obtained from pGRN190 (kind gift from Geron 
Corporation), was inserted into EcoRI restriction site in pCINeo plasmid (Promega). Lin-
Sca-1+ cells were transfected with pCINeo-TERT or control vector using the Calcium 
Phosphate Method (Promega), according to the manufacturer's instructions and 
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incubated in G418-containing medium (Sigma-Aldrich) for at least 3 weeks. For clonal 
selection, immortalized cells were plated at single-cell density by limiting dilution and 
cultured in Sca-1+-conditioned medium. Clones derived from a single cell were 
expanded under G418 selection and characterized for Sca-1 expression by flow-
cytometry. Proliferative capacity of the established line was calculated using the 
formula log10 (total no./start no.)/log2. 
In vivo tumorigenicity assay 
The tumorigenicity of iCPCSca-1 was assayed by heterotopic injection into syngeneic 
animals [30, 31]. Eight-week-old C57BL/6 female mice were subjected to a 
subcutaneous injection of 1x106 iCPCSca-1 [in 0.2 mL of 2% fetal bovine serum (FBS) in α-
minimal essential medium (α-MEM)] at each shoulder pad. Animals were monitored 
daily for the appearance of palpable tumors. Mice were necropsied after a 5-month 
surveillance and the injection region as well as the heart, spleen, lung, and liver were 
harvested, fixed in 10% formalin neutral buffer (VWR BDH and Prolabo), and paraffin 
embedded.  
Flow cytometry  
Before flow-cytometry analysis, single-cell suspensions were labeled with the following 
antibodies: APC–anti-Pdgfrα (Biolegend), c-Kit and Flk-1 (eBiosciences); PE–anti-CD105 
(Biolegend), CD106 (Biolegend), CD44 (Immunotools), CD45 (Immunotools), CD34 
(Biolegend), CD31 (BD Pharmingen), CD62L (Immunotools), CD40L (BD Pharmingen), 
CD90.2 (BD Pharmingen), and Stro-1 (Santa Cruz Biotech); and FITC–anti-Sca-1 
(eBiosciences) and CD40 (BD Pharmingen). Samples were acquired on an FACS Canto II 
and analyzed using FlowJo software.  
Gene expression 
For the reverse transcription polymerase chain reaction (RT-PCR), total RNA was 
extracted using Trizol Reagent (Sigma-Aldrich), reverse transcribed according to the 
manufacturer's instructions (Bioline) and PCR was performed using BIOTAQ DNA 
polymerase (Bioline) and gene-specific primers. For quantitative RT-PCR (qRT-PCR) 
analysis, cDNAs were synthesized using PrimeScriptTM RT reagent kit following 
manufacturer's instructions (Takara Bio, Inc.). qRT-PCR was performed using iQTM 
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Sybr® Green Supermix (Bio-Rad) and gene specific primers. Reactions were carried out 
in triplicate on the iCycler iQ5 Real-Time PCR system (Bio-Rad). Values were 
normalized to glyceraldehyde-3-phosphate dehydrogenase housekeeping gene. Primer 
sequences are available on request. 
Immunocytochemistry (ICC) 
iCPCSca-1 were fixed with 4% paraformaldehyde (PFA) or cold methanol for Gata4 
detection, permeabilized with 0.2% (cytoplasmic) or 1% Triton X-100/PBS (nuclear 
epitopes), and blocked for 1 h with 1% goat serum, 1% bovine serum albumine (BSA), 
or M.O.M.™ Immunodetection Kit (Vector Lab). Incubation with anti-Nestin (Abcam), 
anti-Gata4 (Santa Cruz Biotech.), anti-Sarcomeric α-actinin (α-actinin, Sigma-Aldrich), 
anti-α-Smooth Muscle Actin (α-SMA, Sigma-Aldrich) or anti-von Willebrand Factor 
(vWF, Sigma-Aldrich) was carried out for 1-2 h at room temperature (RT). Incubation 
with secondary antibodies was for 1 h at RT, with the exception of M.O.M.™ 
Biotinylated Anti-Mouse IgG Reagent (Vector Lab) by which the manufacturer's 
instructions were followed. Slides were mounted in Vectashield with 4,6‐diamidino 
‐2‐phenylindole (DAPI; Vector Lab) and observed on the inverted fluorescence 
microscope Axiovert 200 (Zeiss). 
iCPCSca-1 differentiation 
For cardiomyogenic differentiation, cells were (i) co-cultured with neonatal CMs for 7 
days, (ii) cultured in the presence of transforming growth factor-β (TGF-β) for 21 days 
[32], or (iii) maintained using a commercial cardiomyocyte differentiation medium 
(Millipore) for 21 days. For the co-culture set-up, CMs were isolated from neonatal 
(postnatal day 1-3) C57BL/6 as previously described [33]. iCPCSca-1 were pre-stained 
with viable red fluorescent dye VybrantTM DiI (Molecular Probes) before seeding onto 
CMs for 7 days. For endothelial differentiation, iCPCSca-1 were pre-conditioned for 10 
days in Endothelial Growth Medium with EGM BulletKit (EGM; Lonza) or in α-MEM 
(Gibco) with 10% FBS as control. After this period, cells were plated for 
immunocytochemistry (ICC), processed for CD31 flow cytometry staining, or seeded 
onto Matrigel Growth Factor Reduced Matrix (BD Biosciences). After overnight culture, 
cells were fixed and stained for vWF (PBS/0.05% Tween-20/1% BSA for 4 h at RT) or for 
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calcein AM (BD Biosciences). Briefly, cells were incubated for 30 min at 37ºC in 
calcein/PBS and imaged using the inverted fluorescence microscope Axiovert 200 
(Zeiss). To evaluate tube formation, number of branch points and tube length were 
assessed using ImageJ1.42. For smooth muscle cell differentiation, iCPCSca-1 were 
cultured in DMEM high glucose containing 2% FBS and 50 ng/ml of platelet derived 
growth factor BB (PDGF-BB; R&D Systems) for 10 days, as described earlier [7].  
MI, iCPCSca-1 delivery, and echocardiography 
MI was induced by permanent ligation of left anterior descending (LAD) coronary 
artery as described elsewhere [34] with minor alterations. After anesthesia, female 
C57BL/6 were intubated and ventilated using a small-animal respirator (Minivent 845; 
Harvard Apparatus). The heart was exposed (Ø 5-7 mm) via left thoracotomy on the 
third intercostal space, and the pericardial sac was gently disrupted. A non-absorbable 
7-0 suture (Silkam®; B. Braun) was used for ligation. Immediately afterward, 5x105 
iCPCSca-1 (n=8) or vehicle (0.5% BSA/PBS) only (n=9) were delivered by four 
intramyocardial injections (5 µL each) with a 30-gauge syringe (Hamilton company). 
Thoracic incision was closed using an absorbable 6-0 suture (Safil®; B. Braun), and 
surgical staples were used for skin closure. Anesthesia was reverted by atipamezole 
(ip, 5 mg/kg; Revertor). Analgesia and fluid therapy were performed by ip delivery of 
butorphanol (1 mg/kg; Butador) and a subcutaneous injection of 5% glucose 
physiological saline, respectively. This procedure was repeated every 12 h for 
approximately 72 h post-surgery or until full recovery.  
Echocardiographic assessment 
Transthoracic echocardiography was performed at 2 weeks after LAD coronary artery 
ligation using a portable ultrasound apparatus (GE Vivid I; General Electric) that was 
equipped with a 12 MHz linear probe (GE 12L-RS Linear Array Transducer; General 
Electric). To evaluate LV structural changes, several parameters from M-mode were 
measured, that is, the LV internal diameter at diastole (LVIDd) and at systole (LVIDs), 
the interventricular septum at diastole and at systole, the LV posterior wall at diastole 
(LVPWd) and at systole (LVPWs), and heart rate. Left ventricular ejection fraction (EF) 
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and fraction shortening (FS) were calculated as an index of systolic function: FS (%) = 
[(LVIDd - LVIDs)/LVIDd] x 100 and EF (%) = [(LVIDd3 – LVIDs3)/LVIDd3] x 100. 
Histological procedures 
Hearts were harvested at 2 weeks post-surgery after an injection with potassium 
chloride and fixed in 10% Formalin neutral buffer (VWR BDH & Prolabo) for 
approximately 24 h before paraffin embedding. Representative LV sampling (~ 12 
sections at 3 μm) was obtained by transverse sectioning from apex to base with 300 
μm intervals. Masson's Trichrome (MT) staining was performed using the Trichrome 
(Masson) Stain kit (Sigma-Aldrich) with the following modifications: Nuclei were pre-
stained with Celestine Blue solution following Gill's Hematoxylin staining, and tissue 
was incubated for 1 h in Bouin's solution before muscle staining with Biebrich Scarlet-
Acid Fuchsin. Sections were photographed with a stereomicroscope (Leica) before 
morphometric analysis. 
MI size calculation and morphometric analysis 
Infarct size measurement was based on collagen deposition in the ischemic LV wall 2 
weeks post-infarction and calculated by the area method using the semi-automated 
program MIQuant [35]. The thickness of LV free wall was measured on the infarction 
region using ImageJ1.42 on MT-stained sections.  
Fluorescence in situ hybridization  
Sections were subjected to antigen retrieval using 10 mM sodium citrate buffer (pH 6; 
Sigma-Aldrich) at 98ºC for 10 min followed by 0.01% acid pepsin (Sigma-Aldrich) at 
37ºC for 10 min. For fluorescence in situ hybridization (FISH), samples were 
dehydrated and incubated with a specific probe to whole mouse Y-chromosome (Y-
Chr; Cambio) for 5 min at 82ºC and overnight at 37ºC. Samples were incubated with 
Streptavidin (Invitrogen) for 30 min, mounted in Vectashield with DAPI (Vector Lab), 
and observed on the inverted fluorescence microscope Axiovert 200 (Zeiss). For α-
actinin (Sigma-Aldrich) and CD31 (Santa Cruz Biotech.) immunostaining combined with 
FISH (immuno-FISH), antigen retrieval was achieved by pronase treatment for 30 min 
at 37ºC or with 10 mM Tris/1 mM EDTA (pH 9.0) at 98ºC for 30 min. Samples were 
permeabilized with 0.2% Triton X-100 and blocked using 4% FBS and 1% BSA or 
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M.O.M™ Immunodetection Kit (Vector Lab). Incubation with anti-Connexin43 (Cx43; 
Abcam), anti-α-SMA (Sigma-Aldrich) and anti-CD31 was performed at RT for 1-2 h and 
overnight at 4ºC for anti-α-actinin. After a 1 h incubation with the secondary antibody 
(Invitrogen), slides were rinsed in 50 mM MgCl2/PBS for 5 min and post-fixed with 4% 
PFA and 50 mM MgCl2/PBS for 10 min. Samples were dehydrated and incubated with 
Y-Chr probe as described earlier. 
Blood vessel density quantification 
After antigen retrieval using 10 mM Tris/1 mM EDTA (pH 9.0) at 98ºC for 30 min, 
samples were permeabilized with 0.2% Triton X-100 and blocked for 1 h with 4% FBS 
and 1% BSA. Slides were incubated with anti-CD31 for 1-2 hours at RT, 1 h incubated 
with secondary antibody and mounted in Vectashield with DAPI. Images were captured 
using MosaiX (AxioVision modules; Carl Zeiss). CD31+ cells were counted in 30 fields 
per heart over 3-5 sections at infarcted and border zone regions along the heart's long 
axis (n=9 control group, n=8 iCPCSca-1) using ImageJ1.42. Density was calculated as 
CD31-positive cells per square millimeter (mm2). 
Data and statistical analysis 
Statistical significance was evaluated with SPSS v.19.0 using Mann-Whitney or one-way 
analysis of variance (ANOVA) with post hoc Tukey's test. Values are presented as mean 
± standard error of the mean (SEM). p<0.05 was considered statistically significant. 
*p<0.05, **p<0.01, and ***p<0.001. 
RESULTS 
Generation of an immortalized line representative of Lin-Sca-1+ adult CPCs  
To immortalize Lin-Sca-1+ CPCs by inducing ectopic expression of mTERT, cells 
expressing Sca-1 were isolated from murine hearts and transfected with pCINeo vector 
encoding the mTERT. 
Further analysis was restricted to one transfected clone of myocardium-resident Sca-1+ 
progenitors, that is, the iCPCSca-1. The remaining G418-resistant isolated clones were 
subjected to transcriptional profiling (Supplementary Table S1) and cryopreserved for 
future investigation. 
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iCPCSca-1 grew to confluence as a monolayer of spindle-shape adherent cells similarly to 
their native counterparts (Figure 1A) and presented a doubling time of ~21.6 h. iCPCSca-
1 were continuously sub-cultured for more than 24 months with no signs of 
differentiation and maintaining high levels of Sca-1 expression. Conversely, primary 
(non-transfected) Lin-Sca-1+ CPCs decreased Sca-1 expression after 1 month in culture 
and senesced after 15-20 passages (Supplementary Figure S1).  
Genome integration of mTERT was confirmed by Southern blotting using a specific 
probe for the neomycin phosphotransferase gene (Figure 1B). Chromosome number 
per metaphase plate of iCPCSca-1 was compared with Sca-1+ primary cells; the majority 
of the cells were diploid and displayed a median chromosome number of 44 and 40 in 
iCPCSca-1 and primary culture, respectively (Figure 1C). In addition, tetraploid cells were 
present in both conditions. The tumorigenic potential of iCPCSca-1 was evaluated by 
means of a classical tumorigenesis assay in which syngeneic animals are used as 
recipients for heterotopic delivery of the cell inocula [30]. Hence, iCPCSca-1 were 
subcutaneously delivered to the shoulder pads of syngeneic animals that were daily 
monitored for tumor progression. No local mass formation was observed after a 5-
month inspection period and normal histological appearance was verified for the 
heart, spleen, lungs, and liver (Supplementary Figure S2). 
iCPCSca-1 display a typical tri-lineage potential and a stable phenotype after long-term 
in vitro culture 
Prospective identification of bona fide CPCs based on the unique expression of surface 
markers is at the present not possible. Hence, it is generally accepted that an 
accredited cardiac progenitor cell will meet the following criteria: (i) derive from the 
adult heart; (ii) display either Sca-1 or c-Kit at their surface and lack markers of 
hematopoietic and endothelial commitment/differentiation; (iii) express cardiac-
affiliated transcription factors while lacking mature proteins; and (iv) differentiate both 
in vitro and in vivo into CMs, endothelial cells, and smooth muscle cells. iCPCSca-1 were, 
thus, characterized with regard to the cell surface phenotype, transcriptional profile, 
and functional properties in order to verify whether this cell line meets the premises 
mentioned earlier. 
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Flow cytometry analysis indicated a phenotype consistent with adult Lin-Sca-1+ CPCs, 
that is, a population constituted of cells with high Sca-1 levels (99.8% ± 0.21%), lacking 
hematopoietic (Stro-1, CD45, CD34) and endothelial (Flk-1, CD31 and CD34) markers, 
and expressing mesenchymal-associated proteins (e.g. CD29, CD44, CD105, CD106 and 
Pdgfrα), several of which are critical to cell migration, adhesion, and communication 
(Figure 1D). Furthermore, the characterized clone (Clone No. 3, Supplementary Table 
S1) did not express c-Kit, a protein that singly or together with Sca-1 has been used to 
isolate CPCs. A detailed transcriptional profile was carried out in parallel with primary 
Sca-1+ CPCs (CPCSca-1), embryonic stem cells, bone marrow, and heart as controls. The 
side-by-side transcriptional analysis demonstrated that iCPCSca-1 and primary Sca-1+ 
cells consistently expressed stemness-related genes (Bcrp1, Bmi1, and Nestin) and 
early cardiac transcription factors (Gata4, Isl1, Mef2c, and Tef1) while lacking 
transcripts for mature contractile myofilaments (α- and β-Mhc), fibroblasts (Tcf21) and 
regulators of pluripotency (Sox2, Nanog, Oct4), thus corroborating that iCPCSca-1 
preserves the phenotype of cardiac-affiliated Sca-1+ multipotent progenitors (Figure 
1E). It should be noted that both primary and immortalized CPCSca-1 expressed c-Myc, a 
transcription factor known to block differentiation in distinct model-systems [36] and 
particularly shown to synergize with Pim-1 to induce the proliferation and survival of 
CPCs [37]. Overall, the data demonstrated that the immortalization of the cells did not 
alter the transcriptional profile of Sca-1+ CPCs. The only obvious difference between 
the established line and the native counterparts is the lack of c-Kit in the immortalized 
cells, as a result of clone selection. Flow cytometry analysis clearly exposed the 
enrichment for the Sca-1-expressing fraction in CPCSca-1 (91.8%) and iCPCSca-1 (99.8%). 
Moreover, likely as a result of clonal selection, the iCPCSca-1 displayed a stronger and 
less disperse pattern of Sca-1 expression as compared with primary cells. Proper sub-
cellular allocation of stemness-associated proteins Gata4 and Nestin was further 
confirmed by ICC for both primary and immortalized cells (Figure 1F). To test iCPCSca-1 
multipotency, distinct sub-passages were cultured under cell differentiation 
conditions. Cardiomyocytic differentiation potential was evaluated by co-culture with 
mouse neonatal CMs. iCPCSca-1 were pre-stained with viable red fluorescent dye 
Vybrant DiI to enable detection in the co-culture system. 
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Figure 1. Generation and characterization of immortalized Lin-Sca-1+ cardiac progenitors (iCPCSca-1) cell 
line. (A) Representative image of primary (CPCSca-1) and immortalized (iCPCSca-1) Sca-1+ CPCs. (B) 
Successful integration of pCINeo-murine telomerase catalytic subunit into iCPCSca-1 genome was 
confirmed by Southern blotting for Neomycin. The empty plasmid was used as positive control. (C) 
Chromosome counts on ( ) iCPCSca-1 metaphase spreads show aneuploidy (n=42) when compared with 
( ) Sca-1+ counterparts (n=23). (D) Flow cytometry analysis of iCPCSca-1 displays high expression of Sca-1 
and mesenchymal-associated antigens (Pdgfrα, CD29, CD44, CD105, and CD106). iCPCSca-1 lack 
hematopoietic- (CD45, c-Kit) and endothelial-affiliated (Flk-1, CD31, CD34) markers. Bars are 
represented as mean ± standard error of the mean (SEM). 
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After a week, iCPCSca-1 upregulated Gata4, displayed a functional pattern of Cx43 and a 
typical myofibrillar assembly of sarcomeric α-actinin (α-actinin) (Figure 2A). Although 
the gold-standard protocol to trigger CPCs differentiation is the direct co-culture with 
neonatal CMs [33], this assay is prone to misleading interpretations due to 
spontaneous cell fusion events [38, 39]. Hence, we further addressed iCPCSca-1 
differentiation in CMs by culturing the cell line for 21 days in cardiomyocytic 
differentiation medium (Millipore) or in the presence of TGF-β. In this conditions, 
iCPCSca-1 were also able to upregulate α-actinin expression when compared with cells 
subjected to basal, that is, cell-maintenance, conditions for the same time period 
(Figure 2B). Furthermore, when iCPCSca-1 were transduced with a green fluorescent 
protein (GFP) reporter under the cardiac troponin T (cTnT) promoter and subjected to 
TGF-β [32] for 45 days, approximately 97% of cells displayed GFP expression 
(Supplementary Figure S3). Since cTnT and α-actinin are also expressed in the 
developing skeletal muscle, we evaluated the possibility of iCPCSca-1 having a skeletal 
origin. The latter was clearly excluded by demonstrating the upregulation of β-Mhc 
expression after differentiation, while no detectable expression of myogenic 
differentiation 1 (MyoD), a marker of skeletal commitment, was found (Figure 2B). 
Endothelial differentiation potential was assessed by priming iCPCSca-1 with EGM 
medium for 10 days followed by a classical Matrigel assay to evaluate the capacity of 
the cells to form tubular-like structures. Primed iCPCSca-1 seeded onto Matrigel 
exhibited tube-like interconnected structures, similar to the capillary assembly of 
human umbilical vein endothelial cells (HUVECs) (Figure 2C, n=6), whereas unprimed 
iCPCSca-1 (iCPCSca-1 pre-cultured in α-MEM) were unable to assemble a fully organized 
capillary network (n=6). In fact, the tubular complex formed by unprimed cells 
presented  a significantly  smaller number of  branch points (p<0.001) and tube length 
(p<0.05 and p<0.01)  as compared  with that  assembled  by  EGM-primed  iCPCSca-1 and  
(E) Reverse transcription polymerase chain reaction (RT-PCR) profile of primary CPCSca-1 and iCPCSca-1 
reveals the expression of stemness-related genes (Bcrp1, Bmi1, and Nestin) and early cardiac 
transcriptional regulators (Gata4, Isl1, Mef2c, and Tef1). Mature contractile myofilaments [α- and β-
cardiac myosin heavy chain (Mhc)] and pluripotency (Sox2, Nanog, and Oct4) transcripts were not 
detected. Embryonic stem cells (ESC); bone marrow (BM), and heart (Hrt) were used as controls. (F) 
Flow cytometry displays the profile of Sca-1 expression in primary CPCSca-1 and iCPCSca-1 and 
immunocytochemistry (ICC) corroborates the expected sub-cellular location of progenitor-associated 
proteins Gata4 and Nestin. Scale bar: 10 µm. 
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HUVECs (Figure 2C). An endothelial phenotype was further addressed by analyzing 
vWF and CD31 protein expression. vWF was only detected in iCPCSca-1 cells after EGM-
priming (Figure 2C). Accordingly, CD31 was increased by 1.75% on primed cells when 
compared with iCPCSca-1 maintained in α-MEM for the same period (Figure 2C). 
The capacity to differentiate into smooth muscle cells was evaluated by subjecting 
iCPCSca-1 to PDGF-BB for 10 days. After this period, iCPCSca-1 became elongated and 
displayed α-SMA protein expression, as demonstrated by ICC and flow cytometry 
(27%) (Figure 2D). In addition, the expression levels of the smooth muscle-affiliated 
genes, α-SMA, Myocardin (Myocd), Transgelin (SM22), Calponin 1 (Cnn1), and Desmin 
were also assessed by qRT-PCR (Figure 2D). After 10 days of PDGF-BB treatment, 
iCPCSca-1 upregulated α-SMA, SM22, and Cnn1; while no clear alteration was observed 
for Desmin mRNA levels. In addition, no detectable expression of Myocd was found, 
even on PDGF-BB stimulation. Since some of the genes mentioned earlier are also 
displayed by fibroblasts/myofibroblats, expression of the fibroblast marker Tcf21 was 
evaluated in order to discard a fibroblastic origin of the iCPCSca-1. Detectable expression 
of Tcf21 was not found, neither in basal conditions nor after PDGF-BB treatment 
(Figures 1E and 2D). Overall, these results demonstrate that iCPCSca-1 were not derived 
Figure 2. iCPCSca-1 in vitro differentiation potential. (A) Immunostaining demonstrating increase in Gata4 
expression and presence of Cx43 and α-actinin in Vybrant-stained iCPCSca-1 after 1 week co-culture with 
neonatal cardiomyocytes. Scale bar: 20 µm. (B) iCPCSca-1 α-actinin expression is increased after 21 days of 
culture in cardiomyocytic differentiation conditions: transforming growth factor-β or commercial medium 
(Millipore). Scale bar: 20 µm. RT-PCR representing the upregulation of β-Mhc in iCPCSca-1 cultured in 
Millipore medium, while no MyoD transcript was observed in basal conditions or after differentiation. (C) 
Calcein staining evidencing the tubular structures formed by human umbilical vein endothelial cells 
(HUVECs) and iCPCSca-1 [pre-conditioned in either α-minimum essential medium (α-MEM) or endothelial 
growth medium (EGM)] on Matrigel. Scale bar: 200 µm. The tube length and the number of branch points 
formed in each culture condition were assessed. Data are represented as mean ± SEM [n=6, ***p<0.001; 
**p<0.01; *p<0.05 and not significant (ns) by one-way ANOVA with post hoc Tukey's test]. EGM-
preconditioned iCPCSca-1 grown on Matrigel exhibit increased von Willebrand Factor (vWF) and CD31 
expression as assessed by ICC and flow cytometry, respectively. Scale bars: 20 µm and 5 µm. Data are 
represented as mean ± standard deviation (SD). (D) α-Smooth muscle actin (α-SMA) expression in control 
iCPCSca-1 and after 10 days of culture in differentiation medium containing PDGF-BB. Scale bar: 20 µm. 
Histogram plots show control in white and specific staining in black. Data are represented as mean ± SD. 
Quantitative RT-PCR revealed an upregulation in α-SMA, SM22, and Cnn1 mRNA levels; while no dramatic 
alteration in Desmin expression levels was found. No detectable levels of expression were observed for 
Myocd and Tcf21 (n.d.).Data are represented as a fold increase relative to basal condition (n=3). 
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from cardiac fibroblasts and that, after PDGF-BB stimulation, cells undergo an 
incomplete smooth-muscle differentiation program as the levels of Myocd and Desmin 
have not changed after PDGF-BB treatment. 
Taken together, the data demonstrate that iCPCSca-1 preserved the in vitro phenotype 
and functional ability to moderately differentiate as described by our team [29, 33] 
and others [5, 12, 13, 16] for the native Lin-Sca-1+ counterparts. 
iCPCSca-1-transplanted hearts show improved systolic function and lessened LV 
remodeling after MI 
The beneficial effect of Lin-Sca-1+ CPCs administration into the MI heart has been 
clearly established. Notably, CPCs are able to improve cardiac function and attenuate 
LV remodeling after MI. However, the in vivo differentiation of the CPCs in CMs and 
endothelial cells is minimal, and the amelioration observed on MI is primarily 
attributed to paracrine effects [5]. Aiming at demonstrating that iCPCSca-1 display the 
hallmarks of CPCs in the myocardium in the onset of injury, a proof-of-principle 
experiment was performed using a commonly reported experimental injury setting 
[16, 40]. Female C57BL/6 mice subjected to MI via LAD coronary artery ligation were 
immediately injected on the peri-infarct region with either vehicle medium (n=9) or 
male-derived iCPCSca-1 (n=8). MI size measurement (based on collagen deposition) at 14 
days post-infarction showed that MI extent was comparable between both 
experimental groups with 52% of the LV wall being affected (Figure 3A). 
Notwithstanding, echocardiography at 14 days post-surgery in animals injected with 
iCPCSca-1 showed improved LV function when compared with vehicle controls, as 
demonstrated by significantly increased (p<0.05) EF and FS in iCPCSca-1-transplanted 
hearts (Figure 3B). 
Altered cardiac loading after MI due to extensive loss of myocardial cells induces 
changes in the heart shape, size, and function that are commonly designated as 
cardiac remodeling. A stereoscopic view of representative cross-sections of infarcted 
hearts showed that iCPCSca-1 transplantation prevented the major LV wall thinning and 
LV chamber expansion observed in the vehicle control group (Figure 3C). This was 
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corroborated by a morphometric analysis of MT stains, evidencing an increase (p<0.01) 
in LV wall thickness of iCPCSca-1-transplanted hearts (Figure 3D) to a value not 
statistically different from the non-manipulated animals (Figure 3D). However and 
despite this increase, the LV contractile function of iCPCSca-1-injected animals was not 
comparable with that of non-manipulated animals (p<0.01, Figure 3B). 
Figure 3. Functional and histological assessment of ischemic hearts transplanted with either iCPCSca-1 or 
vehicle. (A) Both iCPCSca-1 and vehicle-injected groups display similar myocardial infarction (MI) size. (B) 
Ejection fraction and fractional shortening measured in non-manipulated animals, vehicle-control and 
iCPCSca-1-injected hearts at 2 weeks post-intervention show a significant improvement in left ventricle (LV) 
contractile capacity in iCPCSca-1-transplanted hearts. (C) Increased LV wall thickness and decreased LV 
dilation in iCPCSca-1-injected animals, demonstrated by Masson's Trichrome staining of LV sections. Broken 
and continuous lines highlight the thickness of the infarcted LV wall in vehicle and iCPCSca-1 transplanted 
animals, respectively. (D) Measurements of LV wall thickness in non-manipulated hearts and in the 
ischemic region corroborate a significant difference between both experimental groups. Scale bar: 100 
µm. Data are represented as mean ± SEM (***p<0.001; **p<0.01, and *p<0.05 by Mann-Whitney test). 
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Overall, the data suggest that iCPCSca-1 exerted a cardioprotective effect, translated on 
a reduction of the deleterious consequences of ischemia and a partial recovery of 
cardiac functional parameters at 2 weeks post-MI. 
Transplanted iCPCSca-1 improve neovascularization of the infarcted myocardium, 
engraft, and differentiate into CMs-, endothelial-, and smooth muscle-like cells 
To address whether cardiac performance amelioration after iCPCSca-1 administration 
occurred at least partly via stimulation of the de novo vessel formation by paracrine 
mechanisms, the density of small blood vessels in the infarcted myocardium and in the 
border zone was quantified at 2 weeks post-surgery (Figure 4A). Overall, iCPCSca-1 
transplantation resulted in a significant increase in CD31+ cells per mm2 when 
compared with the vehicle control (709±19 vs. 555±24, respectively, p<0.001, Figure 
4B). iCPCSca-1, identified by Y-chromosome (Y-Chr) staining were consistently observed 
in close proximity to vessels, suggesting contribution to either endothelial precursors 
mobilization/proliferation and/or differentiation into endothelial cells. The latter 
possibility was evaluated by FISH combined with immunostaining for CD31, and, 
indeed, double positive events were observed in all analyzed animals although at very 
low frequencies (4.1±0.7 cells per transverse heart section) (Figure 4C and 5I). In fact, 
the majority of small vessels were not formed by donor cells, hinting that iCPCSca-1 
contribution to neovascularization is more likely to occur by stimulating the 
mobilization and/or proliferation of host endothelial precursors/cells (paracrine 
action).  
We next investigated iCPCSca-1 functional engraftment and contribution to the de novo 
cardiac cells formation. In vehicle-injected female mice, no Y-Chr+ cells were detected 
in the heart (Figure 5A); whereas in transplanted animals, numerous iCPCSca-1 were 
observed throughout ischemic myocardium and MI border zone at 2 weeks post- 
infarction. This demonstrates that cells were able to survive and engraft the LV 
ischemic region (Figure 5B). Moreover, iCPCSca-1 or their progeny were not found in 
healthy remote areas of the injury site. Ki67 staining was frequently associated with Y-
Chr evidencing iCPCSca-1 proliferation within the host myocardium (data not shown). 
Assembly of the gap junction protein Cx43 at the cellular membrane confirmed that 
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donor cells established functional communication to both donor and to host cells 
(Figures 5C and 5D), substantiating successful iCPCSca-1 engraftment within the host 
tissue. 
Although the majority of grafted cells retained an undifferentiated morphology and 
Sca-1 expression (Supplementary Figure S4), discrete differentiation events were 
observed. Co-localization of Y-Chr with α-SMA was observed in all analyzed animals 
(41.2±5.6 cells per transverse heart section) (Figure 5I), either integrating small vessels 
(Figure 5E) or displaying a fibroblast-like morphology (Figure 5F). In fact, in addition to 
smooth muscle cells, α-SMA is also expressed by myofibroblasts, cells capable of 
Figure 4. Contribution of iCPCSca-1 to neovascularization post-MI. (A) Immunolocalization of CD31 in the 
ischemic region of control and iCPCSca-1-transplanted animals. Scale bar: 100 µm. (B) Quantification of 
CD31+ cells demonstrates a significant increase in small vessels number in iCPCSca-1-injected animals. (C) 
Immunostaining combined with fluorescence in situ hybridization (immuno-FISH) demonstrating iCPCSca-1 
differentiation into CD31+ cells (arrowheads). Scale bar: 10 µm. Data are represented as mean ± SEM (*** 
p<0.001 by Mann-Whitney test). 
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establishing cell connections through gap junctions, and relevant players in formation 
of the contractile granulation tissue [41]. However, considering that Tcf21 is a marker 
of fibroblasts [42] and is also involved in the activation of myofibroblasts [43], and that 
iCPCSca-1 failed to express this marker even when specifically stimulated (Figures 1E and 
Figure 2D), there is little support for considering a myofibroblast fate. Furthermore, 
Figure 5. In vivo characterization of iCPCSca-1 
on transplantation into MI hearts. (A, B) Y-
Chromosome detection (FISH) in vehicle (A) 
and male-derived iCPCSca-1-injected hearts 
(B) demonstrates the immortalized cell line 
successful engraftment. (C-H) Functional 
communication between donor-donor [*, 
(C)] and donor-host [#, (D)] were revealed by 
the assembly of Cx43 at the cellular 
membrane. iCPCSca-1 expressing α-SMA 
(arrowheads) were found integrating small 
vessels [*, (E)] and scattered throughout the 
myocardium displaying a fibroblast-like 
morphology (F). α-actinin+ iCPCSca-1 
(arrowheads) in the infarcted tissue 
displayed an immature phenotype (G) and, 
less-frequently, well-defined cross-striations 
(H). Scale bar: 10 µm. (I) Graph displaying 
the number of cells, per transverse 
histological section, bearing the Y-Chr and 
expressing α-SMA, α-actinin or CD31. Data 
are represented as mean ± SEM (*** 
p<0.001 by one-way ANOVA with post hoc 
Tukey's test). 
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iCPCSca-1 contributed to the cardiomyocytic compartment as evidenced by α-actinin 
expression. The majority of α-actinin+ iCPCSca-1 presented an immature phenotype in 
three out of six analyzed animals (9.0±0.6 cells per transverse heart section) (Figure 5I), 
suggesting an incomplete differentiation. Moreover, α-actinin+ iCPCSca-1 were found in 
close proximity with α-actinin+ host cells displaying a similar immature phenotype, 
suggesting an eventual iCPCSca-1-mediated recruitment/activation of endogenous 
precursors (Figure 5G). Donor cells presenting well-defined cross-striations, 
characteristic of a more mature phenotype, were found in one animal (Figure 5H; 
Supplementary Figure S5). While we do not rule out the possibility that these scarce 
events resulted from cell fusion, differentiation into more mature CMs seems a more 
consistent scenario (Supplementary Figure S5). 
Overall, these results are in agreement with the previous observations, that Lin-Sca-1+-
mediated beneficial effects after MI are partially mediated by paracrine mechanisms 
[5, 44] in detriment to a major contribution to cardiac cell types after transplantation. 
Discussion  
Different progenitor cell subsets have been so far suggested as candidates for the 
optimal cell population to be implanted in infarcted and/or failing hearts (Figure 6), 
but a relationship among these populations remains undetermined. The absence of a 
specific molecular signature as well as the multiplicity of the isolation and 
characterization protocols do not enable an understanding of whether the described 
CPCs populations constitute different subsets of a common progenitor or independent 
cell lineages of distinct ontogeny. Indeed, it has been suggested that the various 
identified CPCs partake in the same cell lineage, and the different phenotypes are a 
consequence of the particular culturing protocols used in different laboratories [21]. 
Importantly, other aspects account for an increased difficulty in the identification of 
CPCs and to understand their real efficiency. Namely, primary cells can easily change 
along time in culture as a consequence of genotypic and phenotypic drift and/or 
senescence [45-47] and, thus, lead to a lack of reproducibility across studies. 
Taken together, the experience accumulated in the last decade indicates that only two 
strategies are used to implement a reliable cell therapy: to try and fail, that is, to 
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implant whatever progenitor cell phenotype in the patient trusting to identify the 
perfect treatment, or to systematically dig the complexity of the stem/progenitor cell 
behavior and, based on novel data and concepts, to formulate a logically stringent 
procedure to transfer experimental observations to the clinical setting.  
  
Novel tools must be developed to help understanding and, thus, governing the CPCs 
complexity and phenotype variability and to enable the standardization of the 
experimental sets and the inter-laboratory comparison. Consistently, the present study 
has been carried out to create an immortalized cardiac progenitors cell line retaining a 
constant phenotype corresponding to native features. CPCs immortalization has been 
achieved by inducing TERT overexpression, in order to circumvent the limitations 
determined by the diminished mitotic capacity of somatic cells [48-52]. The use of 
Figure 6. Illustrative scheme of described multipotent progenitor cell populations isolated from the 
adult heart. Several isolation methods have been applied to separate CPCs based on the expression of 
specific cell-surface markers (e.g. c-Kit+ and Sca-1+), in vitro functional assays (e.g. cardiospheres, side 
population), or the expression of a specific genetic marker (Wt-1 epicardial progenitors). Regardless of 
the increasing number of putative CPCs reported, the functional, hierarchical, and anatomical 
relationship of the illustrated cell progenitor subsets is still elusive. 
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immortalized lines that retain the in vivo features of primary cells, by combining the 
advantages of a high proliferative cell source with a stable phenotype in long-term 
culture, is a major breakthrough in cell biology. Indeed, we have previously shown that 
bone marrow-derived mesenchymal stromal/stem cell (MSC) immortalized lines 
preserve multipotency in standard and three-dimensional conditions in vitro [49, 53]. 
Although telomerase overexpression does not induce oncogenesis, it may provide cells 
with a greater opportunity to accumulate mutations, predisposing to later malignant 
transformation [54, 55]. The iCPCSca-1 karyotype analysis showed aneuploidy, 
characteristic of malignant cells. However, an in vivo tumorigenicity assay [30, 31], 
monitored for 5 months, did not reveal tumor formation either locally 
(subcutaneously) or in any of the analyzed organs (heart, spleen, lungs, and liver). 
Consistently with adult Lin-Sca-1+ CPCs, the iCPCSca-1 phenotype was characterized by 
the expression of high levels of Sca-1, stemness-related genes (Bcrp1, Bmi1, and 
Nestin), mesenchymal-associated proteins (e.g. CD29, CD44, CD105, CD106, and 
Pdgfrα), and early cardiac transcription factors (Gata4, Isl1, Mef2c, and Tef1). 
Conversely, immortalized cells did not express c-Kit while also lacking hematopoietic, 
endothelial, fibroblasts, mature contractile myofilaments (α-Mhc and β-Mhc), and 
pluripotency (Sox2, Nanog, and Oct4) markers. 
iCPCSca-1 displayed the capability to generate in vitro cardiomyocyte-, smooth muscle-, 
and endothelial-like cells, with the differentiation toward smooth muscle-like cells 
being the most efficient. This differential in vitro potential of Sca-1+ cells has been 
previously demonstrated by others [16]. Whether this indicates a higher commitment 
of CPCSca-1 to smooth muscle-like cells or to the fact that the in vitro differentiation 
conditions are less favorable to activate endothelial and cardiomyocytic pathways, 
and, thus, not suitable to demonstrate the full potential of these cells, still needs to be 
determined. 
iCPCSca-1 is a phenotypically stable cell line that provides investigators with the same 
unique cell model to dissect CPCs behavior and differentiation mechanisms. 
Furthermore, iCPCSca-1 could represent a benchmark to compare with other cells 
posited to bear stemness characteristics. In fact, the immortalized CPCs retain the 
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features of their ex vivo counterparts, that is, moderate differentiation into 
cardiomyocyte-, endothelial-, and smooth-muscle-like cells, when subjected to 
appropriate stimuli in vitro as well as in vivo, in a myocardial injury setting. 
Furthermore, the cell line combines the advantages of a high proliferative cell source 
with a stable phenotype in long-term culture. Indeed, murine cells are prone to 
undergo spontaneous immortalization after prolonged in vitro culture [46, 56, 57], 
which may result in accumulation of unpredictable cytogenetic modifications and 
malignant transformations [47]. The use of uncharacterized spontaneously 
immortalized cell clones as in vitro models for their native cell counterparts should be 
circumvented due to the dissimilar phenotypes generated by unpredictable 
cytogenetic alterations in overextended sub-culture in vitro. 
The iCPCSca-1 capability to mimic their native non-immortalized corresponding cells has 
also been apparent in in vivo experiments. In fact, iCPCSca-1 were able to contribute 
toward repairing the myocardial injuries experimentally provoked by coronary ligation 
in vivo, as shown by minor LV chamber expansion and increased thickness of the LV-
free wall. Importantly, echocardiography follow-up revealed improved systolic function 
after iCPCSca-1 transplantation into MI animals. iCPCSca-1 abundance in the host infarcted 
and peri-infarcted myocardium was particularly surprising, and cells were able not only 
to survive but also to engraft. Moreover, engrafted cells established donor-donor and 
donor-host Cx43-mediated connections. Indeed, Cx43 promotes MSC survival in the 
ischemic heart [58], and it is critical for protection against ventricular tachycardia, 
which is a resultant from the transplantation of embryonic CMs in MI [59]. Accordingly, 
it can be conjectured that Cx43 is involved in iCPCSca-1 resistance to the adverse 
scenario of myocardial ischemia. 
The implantation of immortalized cells into infarcted mouse hearts also induced a 
significant improvement in the vascularization of the damaged region, very likely, 
through a paracrine action. Since an improved vascularization is associated with a 
“pro-regenerative” response, the formation of new vessels in the infarcted tissue was 
carefully assessed. iCPCSca-1 transplanted hearts exhibited a denser capillary network, 
when compared with the vehicle control group. In addition, iCPCSca-1 contributed 
directly to de novo vessel formation, as demonstrated by CD31 and α-SMA expression 
Chapter III 
89 
 
on Y-Chr bearing cells. However, endothelial differentiation was modest; hence, direct 
contribution of engrafted cells to new vessel formation is minimal, suggesting that 
paracrine mechanisms are involved in the recruitment and/or proliferation of 
endothelial cells and/or precursors. 
CPCs differentiation into CMs has been frequently demonstrated by the expression of 
proteins of the contractile machinery [5, 6, 12, 15]. Indeed, although CPCs appear to 
grasp a lot of expectations with regard to cardiac cell therapies, most studies still 
report an immature phenotype for the differentiated cells, to a great extent 
resembling fetal-neonatal CMs [5, 6, 12, 15]. In our in vivo setting, iCPCSca-1 
differentiated into cardiomyocyte-like cells, though the majority displayed a 
disorganized structure with no detectable sarcomeres, characteristic of an immature 
phenotype. It should be noted that both primary CPCSca-1 and iCPCSca-1 express the 
transcription factor c-Myc, which has been previously shown to play a role in the 
blockage of cell differentiation [36] and in the survival and proliferation of CPCs [37]. 
Whether the levels of c-Myc are regulating CPCs cell-fate decision to differentiate at 
the expenses of cell proliferation remains to be determined and should be subject to 
further investigation. Since iCPCSca-1 showed an in vitro and in vivo differentiation 
potential similar to their native counterparts, it is our conviction that iCPCSca-1 
constitutes a reliable easy-to-use model to dissect the key molecular mechanisms 
governing cardiomyocytic differentiation from adult CPCs.  
In this work, an immortalized cell line for modeling mouse Lin-Sca-1+ CPCs was 
specifically generated by means of TERT overexpression. The immortalization did not 
appear to impair any important cellular property, as iCPCSca-1 were phenotypically and 
functionally similar to their primary cell counterparts. Overall, the results indicate that 
iCPCSca-1 are representative of the native Sca-1+ cardiac population, thus constituting a 
suitable tool for functional and mechanistic studies in need in the field. Hence, with 
regard to the heterogeneity and low frequency in the adult heart of described CPCs 
populations (Figure 6), iCPCSca-1 comes forth as a uniquely validated off-the-shelf line 
for in vitro high-throughput and bioengineering studies. The latter combined with the 
remarkable capacity of iCPCSca-1 to engraft and differentiate in loco makes this cell line 
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a valuable model system to investigate in vivo the role of the Sca-1+ stem/progenitor 
cells resident in the adult heart. 
Last but not the least, the widespread use of this and other similarly generated cardiac 
progenitor-subset cell lines will enable the reduction of animal usage and will 
contribute in a properly standardized manner to the definition of benchmark(s) for 
stem/progenitor cells from distinct organ systems and from different laboratories. 
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Supplementary Figure S1. iCPCSca-1 display a stable phenotype in long-term in vitro culture. (A) 
Lin-Sca-1+ primary (non-transfected) CPCs undergo a dramatic decrease in Sca-1 expression 
following 1 month in culture (P6, 36%) as compared with the high Sca-1 levels after isolation 
(P0, 82%). (B) iCPCSca-1 maintain their undifferentiated phenotype even after long-term 
culture, as evidenced by high Sca-1 expression (P38, 99%) and proliferation rate (P38, Ki67 
staining). Scale bar: 20 µm. P, passage number. 
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Supplementary Figure S2. iCPCSca-1 tumorigenic behavior was evaluated in vivo by injecting 
subcutaneously 1.0 x 106 cells in each flank of the shoulder blades of three C57BL/6 mice. 
Animals were monitored for 5 months for observation of tumor mass formation in the 
injected area. After this period, no abnormal tissue was found locally, surrounding the 
transplanted region, or in the analyzed organs (liver, heart, lung, and spleen). 
Representative images of hematoxylin and eosin-stained cross-sections of the collected 
organs demonstrate normal histology. Scale bars: 100 µm. 
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Supplementary Figure S3. Real-time imaging of GFP under cardiac Troponin promoter indicates that 
iCPCSca-1 differentiated into cardiomyocyte-like cells when subjected to the appropriate stimulus. (A) The 
pGreenZeo lenti-reporter containing the mouse cardiac Troponin (pGreenZeo-cTnT) promoter driving 
GFP and Zeocin selection (Cambrigde Bioscience) enables the identification and real-time imaging of 
differentiating cells. (B) iCPCSca-1 cells transduced with the reporter (iCPCSca-1 cTnT GFP) were cultured in 
cardiomyocytic differentiation medium containing TGF-β, and GFP levels were assessed overtime. After 
45 days in culture, the expression of cTnT was greatly upregulated, as indicated by the high GFP levels 
(63%) when compared with the initial culture (9%). Zeocin-selected cTnT-GFP yielded approximately  
97% purity. Scale bar: 100 µm. 
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Supplementary Figure S4. Representative sections of iCPCSca-1 transplanted hearts at 2 
weeks after MI were consecutively processed for either FISH for Y-Chr or Sca-1 
immunostaining. The majority of grafted cells (Y-Chr+, green) retained an undifferentiated 
morphology and also Sca-1 (red) expression. The analyzed region is adjacent to the 
infarcted area, and, thus, remnants of sutures are observed (*). Scale bar: 10 µm. 
 
Supplementary Figure S5. Detailed view of a representative iCPCSca-1 transplanted cell resembling a 
mature cardiomyocyte at 2 weeks after transplantation. (A) Sarcomeres are highlighted by α-actinin 
staining (red), and Y-Chr (green) demonstrates the donor cell origin. (B) Three-dimensional rendering of 
z-stack images further supports the origin of the differentiated cells by showing that the Y-Chr is in the 
same plane as the cell nuclei. Scale bar: 10 µm. 
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Supplementary Table S1. 
Transcriptional profiling of 20 selected Lin-Sca-1+ Cardiac Progenitor Cell Clones by RT-PCR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
According to the densitometry analysis of the gel bands, the expression levels were categorized as 
follows: (-) not detected, (+/-) low level of expression, (+) moderate level of expression, (++) high 
level of expression, and (+++) very high level of expression. Clone 3 was selected for a further 
analysis, while the remaining clones were cryopreserved for future investigation. 
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Summary 
Studies in developing embryos and in differentiating mouse embryonic stem cells have 
unveiled the complex signaling environment that leads to heart formation. Within an 
interconnected network with other pathways, Notch signaling plays an essential role in 
specifying cardiac lineages but the exact molecular regulatory mechanisms remain 
elusive. In this study we identified Hes5 as a mediator of Notch1 in the specification of 
cardiac lineages. Loss of Hes5 compromised Notch1 activity in cardiogenesis while 
favoring hematopoietic commitment. Our data demonstrate that Hes5 enhances 
cardiac fate in a transient temporal window while its sustained activity compromises 
cardiac maturation. We identified Isl1 and Scl as putative effectors of Hes5 activity in 
cardiac specification, supporting a tight inter-connection between hematopoietic and 
cardiac regulatory networks. These findings provide mechanistic insights into how the 
Notch pathway controls cardiac specification and identify a novel role for Hes5 as a key 
regulator in the early cardiac molecular program. 
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Introduction 
The heart is the first organ formed in a developing embryo and thus, specification of 
cardiac lineages occurs very early during embryonic development. Although cardiac 
morphogenetic events, such as the contribution of first and second heart field 
progenitors as well as from external sources are well described (Brade et al., 2013), the 
process of cardiac fate specification is still largely undefined. Cardiac precursors derive 
from mesodermal cells at the early primitive streak stage and segregate shortly after 
the migration of prospective hematopoietic progenitors to the yolk sac (Parameswaran 
and Tam, 1995). Given the ontogenic proximity, it is not surprising that the networks 
that control heart and vascular/hematopoietic development are tightly inter-
connected and mutually antagonistic (Caprioli et al., 2011; Schoenebeck et al., 2007; 
Simoes et al., 2011). 
Differentiating mouse embryonic stem cells (mESCs) recapitulate in vitro the molecular 
events from pre-gastrulation up to cardiomyocyte formation and thus, contribute 
mechanistic insights into early lineage specification (Doetschman et al., 1985; Kattman 
et al., 2006; Maltsev et al., 1993; Miller-Hance et al., 1993). Studies in the embryo and 
in differentiating mESCs have unveiled the complex temporal and spatial crosstalk 
between Nodal/Activin, Wnt, BMP and Notch signaling pathways. Detailed knowledge 
of the regulatory signaling network of embryonic heart development will shed light for 
regenerative strategies, especially, considering that pathways governing heart 
formation are functional or reactivated in cardiac disease (Freire et al., 2014). 
Notch is an evolutionarily conserved signaling pathway involved in a multiplicity of 
biological processes (e.g. cell fate specification, cell differentiation, boundary 
formation, progenitor cell maintenance, apoptosis and cell proliferation) (Bray, 2006). 
In mammals, Notch signaling is mediated by the interaction of transmembrane 
receptors (Notch1-4) and ligands (Jagged1 and 2, and Delta-like1, 3 and 4) expressed 
on the surface of neighboring cells. The activation of a Notch receptor results in further 
cleavage of the intracellular domain (NICD) which translocates to the nucleus and 
binds RBP-J/CSL, resulting in activation of Notch targets, such as members of Hes and 
Hes-related (Hesr) families (Bray, 2006). Hes and Hesr genes encode basic helix-loop-
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helix (bHLH) transcriptional regulators which mediate Notch functions, such as 
maintenance of progenitors and binary cell-fate decisions; thereby, controlling the 
normal timing of differentiation (Kageyama et al., 2007). Notch signaling is crucial for 
heart morphogenesis (Grego-Bessa et al., 2007; Rones et al., 2000; Rutenberg et al., 
2006) and loss-of-function mutations in several Notch members, e.g. Notch1, Hey1 
(also known as Hesr1), Hey2 (also known as Hesr2), Heyl (also known as Hesr3), and 
Hes1 result in severe cardiac phenotypes (Nemir and Pedrazzini, 2008; Rochais et al., 
2009). Importantly, the effects of Notch activity are highly dependent on the cellular 
context. For example, differentiation to cardiomyocytes is enhanced in mESCs deficient 
in RBP-J (Schroeder et al., 2003) or Notch1 receptor (Nemir et al., 2006) whereas the 
activation of NICD in mesodermal and hemangioblast populations induces cardiac fate 
(Chen et al., 2008). Nevertheless, it remains unclear how Notch specifies cardiac fate 
from mesodermal progenitors, although the mechanism involves in part the regulation 
of Wnt and BMP signaling (Chen et al., 2008). 
In this study we aimed to identify downstream players of the Notch1 receptor involved 
at the onset of the cardiogenic molecular program. We show that Hes5, a member of 
the Hes gene family, is a downstream mediator of Notch1 in the specification of 
cardiac lineages while repressing the hematopoietic program. Moreover, we unveil the 
temporal window for cardiac induction in response to Hes5 and identify the putative 
downstream effectors responsible for its cardiogenic activity. Our results provide 
mechanistic insights into how the Notch pathway controls cardiac specification and 
report for the first time a role for Hes5 as a determinant player in the early cardiac 
molecular network. 
Results  
Hes5 is a putative Notch1 mediator in cardiac specification 
To identify downstream effectors of the Notch1 pathway in cardiac specification we 
used the AinV/Bry-GFP/NICD1 mES cell line (Cheng et al., 2008) that expresses the 
Notch1 intracellular domain (NICD1) under the control of a Doxycycline (Dox)-inducible 
promoter. In addition, this cell line contains the GFP targeted to the Brachyury (Bry; 
also known as T) locus, a pan-mesodermal marker (Showell et al., 2004). The mESCs 
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were differentiated towards mesoderm as previously described (Kattman et al., 2011) 
with some modifications (Figure 1A). Within the mesodermal compartment, 
expression of Flk-1 identifies prospective vascular/hematopoietic and cardiovascular 
progenitor subsets (Faloon et al., 2000; Kattman et al., 2006). Bry-GFP+Flk-1+ 
mesodermal cells were isolated at day (D) 3.75 of differentiation and NICD1 expression 
was induced by the addition of Dox. Consistent with the earlier findings (Chen et al., 
2008), we observed enhanced cardiac output, as indicated by an increased frequency 
of cells expressing the contractile filament, cardiac Troponin T (cTnT) (26.9% to 46.3%) 
upon NICD1 induction (Figure 1B). 
Next, as a preliminary screen for Notch effectors involved in cardiac specification, the 
published dataset (Chen et al., 2008) was organized to identify genes upregulated at 12 
hours (h) after NICD4 activation in Bry-GFP+/Flk-1+ cells. Among the top ranked genes, 
Hes5 and Heyl, encoding members of the Hes family were identified (Figure 1C). We 
asked whether these genes would be similarly affected upon Notch1 activation, given 
that NICD1 overexpression was also shown to induce cardiac fate (Chen et al., 2008). 
Assuming that Hes and Hesr genes are generally responsible for Notch functions, we 
evaluated the expression of Hes5, Hes1, Heyl ,Hey1 and Hey2 at 0, 4, 12, 24, 48 and 96 
h after NICD1 induction in D3.75 mesodermal progenitors. As result of NICD1 
activation, Hes5, Heyl and Hey2 were upregulated, Hey1 mRNA levels were moderately 
increased and Hes1 expression was not altered (Figure 1D). As previously reported for 
Notch4 (Chen et al., 2008) our results show particular Hes5 and Heyl upregulation, 
suggesting that Notch1 and Notch4 play similar regulatory functions. However, while 
Heyl showed sustained upregulation after NICD1 induction, Hes5 levels were highly 
increased within 24 h followed by a dramatic decrease (Figure 1D). This gene 
expression pattern suggests a temporal role for Hes5 as a mediator of Notch1 in the 
onset of the cardiac molecular program. 
Hes5 depletion favors the hematopoietic program 
To evaluate whether loss of Hes5 would have an effect on the differentiation of cardiac 
lineages, its mRNA expression was downregulated in AinV/Bry-GFP/NICD1 mESCs using 
2 different short hairpin (sh) RNAs targeting Hes5 coding sequences (sh1_Hes5 and 
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sh2_Hes5). NICD1 was induced at D3.75 to promote Hes5 upregulation and the mRNA 
levels were analyzed after 24 h to determine the knockdown (KD) efficiency for each 
shRNA. Transduction with sh1_Hes5 and sh2_Hes5 resulted in 70% and 80% of Hes5 
downregulation, respectively when compared to cells transduced with control shRNA 
targeting Luciferase (sh_Luc) (Figure 1E). 
Cells infected with sh2_Hes5 were differentiated towards mesoderm-derived lineages 
to evaluate the effect of Hes5 downregulation in the emergence of contracting 
cardiomyocytes. Interestingly, rare contracting areas were observed in Hes5-KD 
cultures at D8 of differentiation. Nevertheless, the emergence of hematopoietic-like 
cells was enhanced, as demonstrated by morphology and the accumulation of brown-
reddish pigmentation indicative of hemoglobinization (Figure 1F and Movie S1). In 
contrast, control cultures were characterized by a mixture of contracting cardiac cells 
and hematopoietic cells (Figure 1F and Movie S2). These results suggest that Hes5 acts 
as a repressor of the hematopoietic program. 
Following these observations, mRNA expression levels of cardiac genes (Tbx5, Gata4, 
Isl1 and Myh6) and hematopoietic regulators (Scl (also known as Tal1) and Gata1) 
were analyzed at D4.75 and at D8 of differentiation (Figure 1G). Tbx5, Gata4 and Isl1 
are transcriptional regulators mainly expressed in cardiac progenitors, while Myh6, 
encodes the alpha heavy chain subunit of cardiac myosin that comprises the 
contractile machinery, indicative of differentiation into cardiomyocytes. Scl is essential 
for specification of the hemogenic program from mesoderm (Endoh et al., 2002; 
Schlaeger et al., 2005) and Gata1 expression is required for embryonic and definitive 
terminal erythroid maturation (Fujiwara et al., 1996). Hes5-KD cells had markedly 
decreased levels (varying from 2.0 up to 12.5-fold differences) of cardiac gene 
expression, especially Gata4 at D4.75 and Isl1 at D8 of differentiation (Figure 1G). In 
addition, Scl mRNA levels were similar to control levels; whereas, Gata1 expression 
was significantly increased at D4.75 (4.8-fold increase) and comparable to control 
levels at D8 (Figure 1G). 
These results show that loss of Hes5 favors commitment to the hematopoietic 
program. Furthermore, the decreased cardiac output, likely the consequence of 
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Figure 1. Hes5 is a mediator of Notch1 in mesoderm specification into cardiac and hematopoietic 
derivatives. (A) Experimental procedure for mesoderm differentiation. Generation of EBs was promoted 
in serum-free medium. After 48 h cells were reaggregated in the presence of Activin A, BMP4 and VEGF. 
At D3.75 mesodermal progenitors were sorted, allowed to form aggregates for 24 h and plated in 
gelatin-coated plates. (B) Flow cytometry analysis shows increase in cTnT+ cell percentage after NICD1 
activation (+Dox). Auto, autofluorescence. 
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perturbing the cardiac and hematopoietic regulatory networks, hints a function for 
Hes5 in cardiogenesis. Taken together, these observations suggest a role for Hes5 as a 
mediator of Notch1 in the specification of mesodermal progenitors into cardiac and 
hematopoietic derivatives. 
Loss of Hes5 compromises Notch1 effects on preferential cardiac commitment 
We next investigated whether loss of Hes5 compromises early events downstream 
Notch1 activation in Bry+Flk-1+ mesodermal cells. Cells transduced with sh1_Hes5 and 
sh2_Hes5 were differentiated towards mesoderm and the percentage of Bry+ and Flk-
1+ cells was analyzed at D3.75 (Figures 1H and 1I). Loss of Hes5 did not affect 
mesodermal commitment, assessed by the appearance of Bry-GFP-expressing cells 
(>90%) (Figure 1H), while generation of Flk-1+ mesoderm was enhanced, as shown by 
the higher frequencies of Bry+Flk-1+ cells (61% to 83-85%) (Figures 1H and 1I).  
NICD1 expression was induced (+Dox) in D3.75 Bry+Flk-1+ cells and mRNA levels of 
Tbx5, Gata4, Isl1 and Gata1 were analyzed after 24 h (D4.75). After NICD1 induction, 
control cells (sh_Luc, +Dox) showed upregulated Tbx5 expression, while no changes 
were observed in Gata4 and Isl1 levels when compared to non-induced (sh_Luc, -Dox) 
cells (Figure 1J). In contrast, as result of NICD1 activation Gata1 was downregulated 
(Figure 1J). When compared to induced control (sh_Luc, +Dox), induced Hes5-KD cells 
(sh1_Hes5 and sh2_Hes5, +Dox) demonstrated significant downregulation of Tbx5 (2.4 
(C) Heat map depicting the top-ranked genes at 12 h after NICD4 activation from the published data set 
(GSE12425). The data was analyzed by Cluster 3.0 and displayed by TreeView. Hes5 and Heyl (highlighted 
in red) are members of the Notch pathway. Red and green colors represent increased and decreased 
expression relatively to -Dox, respectively. (D) Relative mRNA expression of Notch targets (Hes5, Hes1, 
Heyl, Hey1 and Hey2) at 0, 4, 12, 24, 48 and 96 h after NICD1 activation (+Dox). Expression is normalized 
to 0h. (E) Hes5 mRNA levels in cells infected either with sh_Luc, sh1_Hes5 or sh2_Hes5 at 24 h after 
NICD1 activation (n=3). Expression is normalized to sh_Luc. (F) Brightfield images show preponderance 
of hematopoietic-like colonies when Hes5 is depleted (sh2_Hes5) relatively to the control (sh_Luc). Top: 
lower and bottom: higher magnification. Scale bar: 50 µm. (G) qRT-PCR results show downregulation of 
cardiac-related genes (Tbx5, Gata4, Isl1 and Myh6) at D4.75 and D8 and upregulated Gata1 expression 
at D4.75 in Hes5-KD cells (sh2_Hes5), while Scl mRNA levels are similar to control (n=3). Expression is 
normalized to sh_Luc at each time point. (H and I) Flow cytometry profile (H) and quantification (I) of 
D3.75 Bry+Flk-1+ cells demonstrate increased percentage in Hes5-KD cultures (sh1_Hes5 and sh2_Hes5) 
(n=3). (J) qRT-PCR data demonstrate significant Tbx5 and Isl1 downregulation and Gata1 upregulation in 
Hes5-KD cells at 24 h after NICD1 induction (+Dox) (n=3). Expression is normalized to sh_Luc -Dox. Data 
are represented as mean ± SEM. *p<0.05; **p<0.01; ***p<0.001. See also Movies S1 and S2 
(https://www.dropbox.com/sh/9220b3egbpkhkk4/AADNg0mDURnjgVmpy_50qI4Ka?dl=0). 
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and 2.8-fold) and Isl1 (1.7 and 2.7-fold) and a moderate decrease of Gata4 (Figure 1J). 
As predicted, Gata1 expression significantly increased compared to sh_Luc +Dox 
condition (2.7 and 3.6-fold), achieving levels superior to the non-induced control cells 
(sh_Luc, -Dox) (Figure 1J). Taken together, our observations indicate that Hes5 
mediates Notch1 activity by preferentially directing mesodermal cells towards a 
cardiac fate, while repressing the hematopoietic program. 
Temporal mapping discloses a confined transient window for cardiac specification in 
response to Hes5 activation 
To dissect the role of Hes5 in the specification of cardiac lineages over hematopoietic 
fate we specifically induced Hes5 overexpression in mesodermal progenitors using a 
Dox-inducible gain-of-function expression system. A lentiviral cassette containing Flag-
tagged Hes5 cDNA driven by a tetracycline response element (TRE) promoter was 
transduced into reverse tetracycline transactivator (rtTA)-expressing AinV/Bry-GFP 
mESCs (Figure 2A). In this system, exogenous Hes5 is expressed only in the presence of 
Dox. To select Flag-tagged Hes5 overexpressing clones, transduced mESCs were single-
cell sorted and screened for Flag epitope expression (Figure 2B). 
Sorted D3.75 Bry+ mesodermal progenitors were cultured in the presence or absence 
of Dox. Analyses of mRNA levels after 24 h and 48 h demonstrated effective Hes5 
induction by Dox (Figure 2C). Hes5 activation promoted upregulation (4.2-fold) of the 
cardiac gene Isl1 measured 48 h after induction; however, no substantial changes were 
observed in the mRNA levels of Tbx5. Scl and Gata1 hematopoietic regulators were 
downregulated (2.8 and 5.0-fold, respectively) 24 h after Hes5 induction and further 
decreased (4.2 and 6.7-fold, respectively) at 48 h (Figure 2D). These results confirm 
that Hes5 regulates cardiac and hematopoietic outputs from mesodermal progenitors. 
Given the temporal and context-dependent nature of Hes genes (Kageyama et al., 
2007), we conducted a temporal mapping to identify the time-window permissive to 
cardiac induction in response to Hes5 activity. Our Hes5-KD studies suggested an effect 
on the generation of Bry+Flk-1+ progenitors; therefore, we investigated whether early 
induction of Hes5 would impair the onset of Flk-1+ mesoderm. To that end, we induced 
exogenous Hes5 expression at D2 of differentiation, concomitant with the addition of 
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Nodal and BMP signals, and analyzed the effects at D3.75 of differentiation. Hes5 
induction from D2 to D3.75 of differentiation had no effect on the development of Bry+ 
cells but significantly compromised the emergence of Bry+Flk-1+ progenitors (79% to 
6%) (Figures 2E and 2F). Given the role of Mesp1 (Lindsley et al., 2008) and Etv2 (Lee et 
al., 2008) as inducers of Flk-1+ mesoderm, their mRNA levels were analyzed at D3 
following 24 h of Hes5 induction (Dox D2-D3). In addition, Mesp1, although firstly 
described as a master cardiac regulator (Lindsley et al., 2008; Saga et al., 2000), was 
recently demonstrated to define mesodermal patterning into cardiac, hematopoietic 
or skeletal myogenic progenitors in a context-dependent manner (Chan et al., 2013). 
Etv2 promotes commitment towards hemogenic mesoderm (Kataoka et al., 2011; Liu 
et al., 2012). Early Hes5 activation significantly compromised the expression of Mesp1 
(4.5-fold) while Etv2 was slightly decreased (2.0-fold) (Figure 2G); possibly, explaining 
the diminished frequency of Bry+Flk-1+ cells. 
Figure 2. A short-pulse of Hes5 is required for cardiac specification and maturation in a confined 
temporal window. (A) AinV/Bry-GFP mESCs were transduced with a cassette containing a tetracycline 
response element (TRE) promoter driving the expression of exogenous Flag-tagged Hes5 and blasticidin 
(Bsd) via an IRES element in the presence of Dox. (B) Immunofluorescence demonstrating expression of 
Flag in mESCs derived from a blasticidin-resistant clone. Scale bar: 50 µm. (C) Efficient Hes5 
overexpression after addition of Dox to D3.75 Bry+ cells (n=3-4). Expression is normalized to -Dox at each 
time point. (D) qRT-PCR data show Isl1 upregulation and Scl and Gata1 downregulation after Hes5 
activation in D3.75 Bry+ cells, while no substantial changes are detected in Tbx5 mRNA levels (n=3-4). 
Expression is normalized to -Dox at each time point. (E and F) Flow cytometry profile (E) and 
quantification (F) of D3.75 Bry+Flk-1+ cells after Hes5 activation from D2 (Dox D2-D3.75) (n=3). (G) 
Decreased Mesp1 and Etv2 mRNA expression at D3 after Hes5 induction from D2-D3 (n=4). Expression is 
normalized to No Dox. (H and I) Non-induced control (No Dox) and cultures treated with Dox at different 
stages of differentiation (D2-D3, D3-D3.75, D3.75-D4.75 or D4.75-D5.75). Dashed white lines delimiting 
contracting foci (H) and quantification per well (3 wells per biological triplicate) (I) show higher number 
of contracting foci as result of Hes5 activation from D3.75-D4.75. Scale bar: 100 µm. (J) qRT-PCR analysis 
at D3 demonstrates Isl1 downregulation as result of Hes5 induction from D2-D3 (n=4). Expression is 
normalized to No Dox. (K) Relative mRNA quantification shows lower Hes5 levels after a 24 h pulse 
(+Dox, 24 h pulse) compared to sustained addition of Dox (+Dox, sustained) at 96 h after induction. Tbx5 
and, particularly, Isl1 expression levels increase with longer exposure to Dox, while Myh6 levels 
upregulate only in 24 h pulse induced cultures (n=3). Expression is normalized to -Dox. (L) 
Immunofluorescence detecting cTnT protein indicates increased expression in 24 h pulse induced 
cultures (+Dox, 24 h pulse) when compared to cultures that were not induced (-Dox) or continuously 
induced (+Dox, sustained). Scale bar: 50 µm. (M) Quantification of the number of contracting foci per 
well (3 wells per biological triplicate) demonstrates enhanced cardiomyocytic output as result of a 24 h 
pulse (+Dox, 24 h pulse) when compared to sustained (+Dox, sustained) or non-exogenous Hes5 
activation (-Dox). Data are represented as mean ± SEM. *p<0.05; **p<0.01; ***p<0.001. 
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To dissect the temporal effect of Hes5 on cardiac differentiation, pulses of Hes5 
expression were applied over a time-course of embryoid body (EB) differentiation (D2-
D3, D3-D3.75, D3.75-D4.75 and D4.75-D5.75). Interestingly, only an activation pulse 
between D3.75-D4.75 resulted in a significantly higher cardiac output, as reflected by 
the number of contracting foci per well; whereas, in the other stages of differentiation 
this number was comparable amongst groups (Figures 2H and 2I). Given that Isl1 
cooperates with Mesp1 in mESCs to promote cardiac differentiation (Bondue et al., 
2011), its expression was analyzed at D3 of differentiation 24 h after Dox addition (Dox 
D2-D3). Levels of Isl1 which positively responded to Hes5 induction at D3.75 (Figure 
2D), decreased significantly as a consequence of early Hes5 activation (Figure 2J). 
These observations indicate a confined temporal window permissive for efficient 
cardiac induction in response to Hes5. 
Sustained Hes5 induction impairs cardiac maturation 
Our results demonstrate that NICD1 activation at D3.75 promotes transient Hes5 
upregulation (Figure 1D) and that induction of Hes5 at this time results in increased 
cardiac output (Figures 2D, 2H and 2I). These observations indicate a confined 
temporal window for Hes5 activity in cardiac specification. We then asked whether 
cardiac specification mediated by Hes5 requires a short pulse-activation, implying that 
continuous Hes5 induction would impair cardiac maturation. A 24 h pulse or sustained 
expression was induced at D3.75 and the mRNA levels of cardiac progenitor genes 
(Tbx5, Isl1) and cardiomyocytes (Myh6) were analyzed 96 h after induction. We 
observed that when Hes5 was induced (+Dox), either as a 24 h pulse or sustained, Tbx5 
(1.6 and 2.2-fold, respectively) and Isl1 (3.7 and 9.5-fold, respectively) mRNA levels 
increased; whereas, Myh6 was only upregulated when a 24 h pulse was applied (5.1-
fold) (Figure 2K). In addition, expression of cTnT protein was more prominent in cells 
induced for 24 h (+Dox, 24 h pulse) than in sustained (+Dox, sustained) or non-induced 
conditions (-Dox) (Figure 2L). These results were further supported by a significantly 
higher number of contracting foci after a pulse of Hes5 (Figure 2M). Taken together, 
our observations demonstrate that Hes5 activity is required as a transient pulse to 
permit the initiation and further progression of the cardiac program. 
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The genetic program regulated by Hes5 is implicated in cardiogenic and 
hematopoietic processes 
To investigate the underlying mechanism by which Hes5 promotes cardiac fate, 
chromatin immunoprecipitation combined with DNA sequencing (ChIP-Seq) was 
performed at 48 h after Hes5 activation in D3.75 Bry+ cells. Hes5 was recruited to more 
than 6500 sites, the majority of them located within 1 kb from the transcription start 
site (TSS) (Figure 3A and Table S1). Most of the target genes were implicated in 
protein-binding and transcriptional regulation (Figure 3B). 
Functional annotation analyses using the Panther classification system revealed that 
the targets of Hes5 were significantly enriched in cardiovascular and 
vascular/hematopoietic developmental processes (Figure 3C and Table S2). Of interest, 
genes related to the Wnt pathway were also present in the significantly enriched 
categories (Figure 3C and Table S2). The Notch pathway has been demonstrated to 
specify cardiac fate in part by inhibiting canonical Wnt and activating BMP pathways 
(Chen et al., 2008). These results suggest that regulation of the Wnt pathway might be, 
at least partially, mediated by Hes5. We next performed a survey using the Mouse 
Genome Informatics (MGI) online resource to identify mammalian abnormal 
phenotypes caused by mutations in genes regulated by Hes5. These analyses showed 
significant enrichment for genes associated with embryonic (p=3.17x10-49) and 
extraembryonic (p=1.59x10-33) tissue development, as well as, heart morphology and 
cardiovascular development (p=1.57x10-31 and p=1.01x10-29) (Figure 3D and Table S3). 
Furthermore, using the Online Mendelian Inheritance in Man (OMIM) disease 
database we identified genes associated with leukemia at the top of the ranked list 
(p=1.12x10-06) (Figure 3E and Table S4). Examples of Hes5 targets include: Scl (binding 
site at 3.8 kb from the TSS) and Gata2 (binding sites at the promoter-TSS and at 1.8 kb 
from the TSS), both crucial for early hematopoiesis (Pimanda et al., 2007), and Isl1 and 
Gata4 (binding sites at the promoter-TSS), which are essential for cardiac development 
(Dodou et al., 2004) (Figure 3F). 
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Figure 3. The genetic program regulated by Hes5. (A) Frequency of peaks by ChIP-Seq demonstrates 
that Hes5 binds within 1 kb of the TSS in the majority of targets. (B) Gene ontology (GO) molecular 
function analysis of Hes5 target genes using the Enrichr gene list enrichment analysis tool 
(http://amp.pharm.mssm.edu/Enrichr/index.html) (Chen et al., 2013). (C) Gene ontology (GO) biological 
process analysis of Hes5 target genes using the Panther classification system database 
(http://www.geneontology.org/) demonstrates significant enrichment in cardiovascular and 
vascular/hematopoietic developmental processes.  
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Hes5 promotes cardiac specification from mesoderm by regulating Isl1 and Scl 
In primitive-streak stage embryos Flk-1 expression overlaps with Pdgfrα (also known as 
CD140a) expression in some cells from the nascent mesoderm. However, in contrast to 
Flk-1, Pdgfrα is not detected in the blood islands (Kataoka et al., 1997). Similarly, in the 
mESCs differentiation system, subpopulations based on the expression of these 
receptors emerge at different times and hold distinct potentials (Sakurai et al., 2006). 
Presumptive primitive/unpatterned mesodermal progenitors co-express both 
receptors whereas progenitors that downregulate Pdgfrα are putatively committed to 
vascular/hematopoietic lineages (Kataoka et al., 2011; Liu et al., 2012). At D3.75 of 
differentiation the majority of Bry+ cells co-express both receptors (67%) (Figure 4A).  
To understand whether Hes5 plays an instructive role in mesodermal specification, 
progenitors committed to a hemogenic fate were excluded based on the lack of Pdgfrα 
expression within the Flk-1+ compartment. A 24 h pulse of Dox was then given to the 
population enriched for putative unpatterned mesodermal progenitors (Bry+Flk-
1+Pdgfrα+) (Figure 4A). Owing to Hes5 pulse-activation, cardiac commitment was highly 
favored, as shown by enhanced emergence of contracting foci (Figure 4B and Movies 
S3 and S4). To address whether Hes5 could play a selective rather than an instructive 
role, proliferation and apoptosis were assessed after Hes5 induction. The former was 
analyzed 24 h after Dox addition with a 5 h pulse of bromodeoxyuridine (BrdU). 
Apoptosis was measured by combined Annexin V and 7-aminoactinomycin D (7-AAD) 
staining which allows discrimination of apoptotic, dead and living cells. Aggregates 
were allowed to adhere 24 h after Dox addition and apoptosis was assessed after 12 h. 
Non-induced and induced cultures contained similar percentages of BrdU-labeled (9% 
and 7%, respectively) (Figure 4C) and apoptotic cells (16%) (Figure 4D). These data 
suggest that Hes5 does not promote the selection of particular subsets of progenitors, 
but rather acts instructively on unpatterned mesodermal cells. 
(D and E) Canvas created by Network2Canvas (http://maayanlab.net/N2C/) representing gene list 
enrichment analysis using the Mouse Genome Informatics (MGI) (D) and Online Mendelian Inheritance 
in Man (OMIM) disease (E) online resources. White circles highlight enriched categories. Relevant terms 
are indicated. (F) Representation of Hes5 binding sites at Scl, Gata2, Isl1 and Gata4 loci. The blue 
highlighted boxes indicate the statistically significant Hes5 binding peaks. See also Tables S1, S2, S3 and 
S4 (https://www.dropbox.com/sh/9220b3egbpkhkk4/AADNg0mDURnjgVmpy_50qI4Ka?dl=0). 
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Hes and Hesr proteins repress transcription by DNA binding-dependent and 
independent mechanisms, the latter includes prevention of DNA binding by lineage-
specific bHLH activators, such as MyoD or Mash1 (Fischer and Gessler, 2007). 
Therefore, we asked if Hes5 regulates Scl in a similar manner as Hey1 regulates MyoD, 
by counteracting the formation of the MyoD/E47 heterodimer (Sun et al., 2001). Our 
results do not demonstrate protein-protein interactions between Hes5 and Scl (Figure 
4E), indicating that Hes5 and Scl are not likely to form an inactive heterodimeric 
complex with impaired DNA-binding abilities. 
We reasoned that the Hes5 targets Gata4, Isl1, Scl and Gata2 would be good 
candidates to validate in further studies. The quantification of mRNA levels 24 h after 
Hes5 induction in the Bry+Flk-1+Pdgfrα+ population showed a significant increase in Isl1 
expression levels (3.9-fold) and a decrease in Scl levels (4.3-fold); whereas, no 
significant differences were detected in Gata4 and Gata2 levels (Figure 4F). The 
alignment of DNA motifs found in the ChIP-Seq peak binding regions allowed us to 
identify the putative sites at the Isl1 and Scl loci (Figure 4G). Regulation of Isl1 and Scl 
levels was further confirmed at the protein level with an increased percentage of Isl1-
expressing cells (5% to 22%) at 48 h after Dox addition (Figure 4H), while the opposite 
effect was observed for Scl (16% to 4%) (Figure 4I). Taken together, these findings 
indicate that Hes5 directly regulates Isl1 and Scl by a DNA binding-dependent 
mechanism and suggest a role for these genes, as downstream mediators of Hes5 in 
cardiac specification. 
Discussion 
Pluripotent stem cells offer the unique advantage of allowing mechanistic studies 
aimed at the dissection of early lineage specification. Here we identify Hes5 as a novel 
regulator, downstream of the Notch1 pathway, in the specification of cardiac lineages 
from mesodermal progenitors. Hes5 is a member of the Hes gene family, which 
encodes bHLH transcriptional regulators. Hes proteins regulate the maintenance of 
progenitors and binary cell fate decisions; thereby, controlling the normal timing of 
differentiation (Kageyama et al., 2007). 
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Figure 4. Hes5 regulates Isl1 and Scl levels in primitive mesodermal progenitors. (A) Flow cytometry 
profile and quantification of Bry+Flk-1+Pdgfrα+ (Bry+F+P+) cells at D3.75 (n=8). (B) Morphological 
evaluation shows distinct lineage outcomes as result of Hes5 24 h pulse induction. Dashed white lines 
indicate contracting foci. Scale bar: 100 µm.  
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(C) Flow cytometry profile and quantification of BrdU+ cells (5 h BrdU pulse) demonstrate no differences 
in cell proliferation after Hes5 pulse (n=3). Auto, autofluorescence. (D) Flow cytometry profile and 
quantification of Annexin V/7-AAD stained cells show no differences in cell apoptosis after Hes5 pulse 
(n=3). (E) Immunoprecipitation for HA-tagged Hes5 followed by immunoblotting for HA and Myc 
detection in lysates from HEK-293T cells co-transfected with HA-tagged Hes5 and Myc-tagged Scl. Results 
show no protein-protein interaction. (F) Quantification of Gata4, Isl1, Scl and Gata2 mRNA levels shows 
significant Isl1 upregulation and Scl downregulation as result of Hes5 pulse (n=3). Expression is 
normalized to -Dox. (G) Putative Hes5 binding sites at Isl1 and Scl loci identified by alignment of DNA 
motifs found in the ChIP-Seq peak binding regions. Sequences were analyzed and aligned using VectorNTI 
and ClustalW softwares. (H) Flow cytometry profile and quantification of Isl1-expressing cells 
demonstrate increased percentage after Hes5 pulse (n=3). (I) Immunofluorescence and quantification of 
Scl+ cells show decreased percentage after Hes5 pulse (>20 fields per biological triplicate). Scale bar: 10 
µm. Data are represented as mean ± SEM. *p<0.05; **p<0.01. See also Movies S3 and S4 
(https://www.dropbox.com/sh/9220b3egbpkhkk4/AADNg0mDURnjgVmpy_50qI4Ka?dl=0). 
 
Hes5-null mouse embryos; although, with apparently normal morphology, show 
premature neuronal differentiation at E10.5 with a more severe phenotype when 
combined with a Hes1 mutation (Ohtsuka et al., 1999). Hes5 regulates the specification 
of glial cell fate at the expense of neurons in the retina (Hojo et al., 2000) and, in 
combination with Hes1, modulates arterial cell fate of endothelial cells during brain 
vascular development (Kitagawa et al., 2013). Yet, to date, Hes5 participation in 
cardiac development has neither been demonstrated nor suggested. 
Our results indicate that Hes5 is a mediator of the Notch1 pathway in cardiogenesis, as 
its loss compromised the effect of Notch1 on preferential cardiac commitment. Hes5-
null embryos have no apparent cardiovascular phenotype, but to our knowledge, no 
studies specifically aimed to address heart malformations in Hes5-null embryos have 
been performed. Nevertheless, is also possible that another bHLH protein(s) 
compensates for the cardiogenic activity of Hes5. Given the Hes1 expression profile 
upon NICD1 induction we suggest that Hes5 function in cardiogenesis is likely not 
compensated by Hes1, as often demonstrated in other organ systems (Kitagawa et al., 
2013; Ohtsuka et al., 1999). However, future investigation is needed to confirm this 
hypothesis. 
We demonstrate that Hes5-KD favored hematopoietic commitment while cardiac 
genes were downregulated, supporting previous findings that the onset of 
cardiogenesis is concomitant with the repression of the hemogenic program. Our 
results also corroborate published reports demonstrating that inhibition of the Notch 
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pathway is required for primitive erythropoietic specification (Cheng et al., 2008). 
Interestingly, when Hes5 levels were downregulated, the emergence of Flk-1+ 
progenitors was enhanced. We cannot precisely determine whether this increase 
represents a higher contribution to the hematopoietic reservoir or a disruption in the 
normal timing of differentiation. However, given the role of Hes proteins in repressing 
premature differentiation, we hypothesize that Hes5-KD cells engaged in premature 
hematopoietic commitment. 
We further show that Hes5 enhances cardiac output in a confined transient temporal 
window. Activation of the gene at early stages; although, not having an impact in Bry 
expression greatly compromised the emergence of Flk-1+ mesodermal derivatives. 
Likewise, expression of Mesp1 and Etv2, inducers of Flk-1+ mesodermal development 
(Lee et al., 2008; Lindsley et al., 2008), was also compromised as result of early Hes5 
activation. This is in accordance with previous reports that Notch activation in mESCs 
inhibits the generation of Flk-1+ mesodermal progenitors (Schroeder et al., 2006). 
Interestingly, a specific temporal window (D3.75-D4.75) was permissive for enhanced 
cardiac induction, implying an instructive role for Hes5 in primitive mesoderm.  
Our data show that Hes5 regulates pivotal target genes for normal 
vascular/hematopoietic and heart development. In addition, the enrichment for genes 
related to the Wnt signaling suggests that Hes5 might mediate part of the crosstalk 
between Notch and Wnt pathways, previously shown to control cardiac and primitive 
erythropoietic specification (Chen et al., 2008; Cheng et al., 2008). 
Furthermore, our observations strongly implicate Isl1 and Scl as the potential 
downstream mediators of Hes5 action. The crucial roles for these genes in cardiac and 
hematopoietic development have been demonstrated. Homozygous Isl1-null mice 
have several abnormalities in heart development with lethality at E10.5 (Cai et al., 
2003), while Scl deficient embryos die at E9.5 with a complete absence of yolk sac 
hematopoiesis (Robb et al., 1995; Shivdasani et al., 1995). Moreover, Scl-null embryos 
show ectopic cardiogenesis in the yolk sac (Van Handel et al., 2012). Hes proteins 
repress transcription by DNA binding-dependent and independent mechanisms. DNA 
binding-dependent mechanisms usually involve recruitment of co-factors, such as 
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Groucho/TLE co-repressors, and independent mechanisms include prevention of DNA 
binding by lineage-specific bHLH activators, such as MyoD or Mash1 (Fischer and 
Gessler, 2007). Hes5 does not seem to form an inactive heterodimer complex with Scl 
but is rather likely to directly regulate its expression. Although Hes proteins usually act 
as transcriptional repressors, there is evidence for a switch in the function of Hes1, 
from a repressor to an activator, by dismissal of the Groucho/TLE complex and 
occupancy by co-activators at Mash1 promoter during neuronal differentiation (Ju et 
al., 2004). Normal organ development relies on the precise switching between gene 
repression and activation. We show that Hes5 tightly regulates Isl1 in a temporal 
manner, as Hes5 activation in early stage of differentiation (D2-D3) downregulated Isl1 
expression whereas induction at D3.75 had a positive effect on Isl1 levels. Whether 
this temporal regulation requires recruitment and further dismissal of the 
Groucho/TLE complex from Isl1 promoter needs further investigation. 
In addition, our results show that cardiac maturation requires Hes5 withdrawal. These 
observations are in agreement with reports demonstrating that Hes1-Hes5 maintain 
neural stem cells in the embryo telencephalon in an undifferentiated state (Ohtsuka et 
al., 2001) while in cardiac development, Notch activation in a specific cellular-context 
impairs normal cardiomyocytic maturation (Chau et al., 2006; Chen et al., 2008; 
Rutenberg et al., 2006; Watanabe et al., 2006). Our results point that one possible 
explanation for the blockage of maturation is the continuous promotion of high Isl1 
levels by Hes5. Isl1 is expressed transiently by cardiogenic precursors, suggesting that 
its function might be detrimental for cardiomyocytic differentiation (Cai et al., 2003). 
Collectively, the data we present unveil Hes5 as a novel player in the determination of 
cardiac lineages. Importantly, the onset of cardiogenesis depends on temporal Hes5 
regulation in order to trigger the cardiac program and proceed in maturation. 
Moreover, our data support the existing knowledge of a tight inter-correlation 
between hematopoietic and cardiac regulatory networks, where Hes5 balances Isl1 
and Scl levels to determine cardiac fate (Figure 5). Our results provide mechanistic 
insights into how the Notch pathway controls cardiac specification and report for the 
first time a role for Hes5 as a determinant player in the early cardiac molecular 
network. 
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Experimental Procedures 
Detailed experimental procedures can be found in the Supplemental Experimental 
Procedures section. 
mESC lines 
The AinV/Bry-GFP/NICD1 and AinV/Bry-GFP mESC lines (Cheng et al., 2008) were a 
kind gift from Dr Gordon M. Keller and Dr Valerie Gouon-Evans. 
Cell differentiation 
mESCs were differentiated as previously described (Kattman et al., 2011) with some 
modifications. 
shRNA design 
shRNA sequences were obtained from the TRC library database 
(http://www.broadinstitute.org/genome_bio/trc/publicSearchForHairpinsForm.php) 
and are listed in Table S5. 
Generation of Hes5 overexpressing clones 
AinV/Bry-GFP mESCs were infected with a lentiviral pTRE-IRES-BsdR vector containing 
Flag-tagged Hes5 cDNA driven by a tetracycline response element (TRE) promoter. 
Figure 5. Model portraying the role of Hes5 in cardiac specification. Proposed model for the 
mechanism underlying cardiac induction mediated by Hes5. At D3.75 of in vitro differentiation Hes5 
regulates Isl1 and Scl levels in primitive mesodermal progenitors determining cardiac versus 
hematopoietic outcomes. Cardiac induction occurs in a confined temporal window that requires a short 
pulse activation of Hes5 to allow cardiac maturation after commitment to the cardiac program. 
Meso, Mesodermal progenitor; CP, Cardiac progenitor; HP, Hematopoietic progenitor; CM, 
Cardiomyocyte; → Activation;  Repression. 
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Cells were cultured under blasticidin selection, single-cell sorted and screened for Flag 
expression. 
Gene expression analysis 
RNA was isolated using Trizol reagent and reverse transcribed using PrimeScript RT 
reagent kit (Takara Bio, Inc.). Gene-specific primers are listed in Table S6. 
ChIP-Seq 
ChIP-Seq was performed as previously described (Ang et al., 2011) with few 
modifications. 
Data and statistical analysis 
Data are represented as mean ± SEM. Statistical significance was determined by 
unpaired t test and ANOVA as appropriate. p<0.05 was considered statistically 
significant. 
ACCESSION NUMBERS 
ChIP-Seq data are deposited in NCBI-GEO database under accession number 
GSE64540. 
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Supplemental Movies and Tables  
Movie S1, related to Figure 1. Hes5-KD cultures at D8 of differentiation 
Absence of contracting foci in Hes5-KD (sh2_Hes5) cultures at D8 of in vitro 
differentiation. 
Movie S2, related to Figure 1. Control cultures at D8 of differentiation 
Presence of contracting foci in control (sh_Luc) cultures at D8 of in vitro differentiation. 
Movie S3, related to Figure 4. Cultures derived from D3.75 Bry+Flk-1+Pdgfrα+ 
mesodermal progenitors  
Presence of rare contracting foci in cultures derived from sorted D3.75 Bry+Flk-
1+Pdgfrα+ cells that were cultured in the absence of Dox for 1 week. 
Movie S4, related to Figure 4. Cultures derived from D3.75 Bry+Flk-1+Pdgfrα+ 
mesodermal progenitors after Hes5 pulse  
Presence of a high number of contracting foci in 24 h pulse induced cultures at 1 week 
after sorting of D3.75 Bry+Flk-1+Pdgfrα+ cells. 
 
 
 
 
Table S5, related to Experimental Procedures. shRNA sequences used for knockdown 
studies 
shRNA shRNA sequence 
sh_Luc CTTACGCTGAGTACTTCGA 
sh1_Hes5 CCGTCAGCTACCTGAAACACA 
sh2_Hes5 GATGCTCAGTCCCAAGGAGAA 
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Table S6, related to Experimental Procedures. Primers used for qRT-PCR 
Gene Forward Reverse 
Etv2  AGGACTGGGAGCGGAATTTG TCTTCGTGAGGTAAAGCGGG 
Gapdh CGTCCCGTAGACAAAATGGT TTGATGGCAACAATCTCCAC 
Gata1 TGGGGACCTCAGAACCCTTG GGCTGCATTTGGGGAAGTG 
Gata2 CAGACGACAACCACCACCTTA CAGTGGCCTGTTAACATTGTGC 
Gata4 CCCTACCCAGCCTACATGG ACATATCGAGATTGGGGTGTCT 
Hes1 TCATGGAGAAGAGGCGAAGGGCA   GAGCGCGGCGGTCATCTGC   
Hes5 GGAGAAAAACCGACTGCGGA TGTTTCAGGTAGCTGACGGC 
Hey1 GAGAAGCGCCGACGAGACCG   GGCGTGCGCGTCAAAATAACCTTT   
Hey2 TGCGTTCCGCTAGGCGACAG   TGAGCTTGTAGCGTGCCCAGG   
Heyl CAGCCCTTCGCAGATGCAA CCAATCGTCGCAATTCAGAAAG 
Isl1 ATGATGGTGGTTTACAGGCTAAC TCGATGCTACTTCACTGCCAG 
Mesp1 GCAGTCGCAGTCGCTCGGTC   CGCTGCTGAAGAGCGGAGATGA   
Myh6 GCCCAGTACCTCCGAAAGTC GCCTTAACATACTCCTCCTTGTC 
Scl  CACTAGGCAGTGGGTTCTTTG GGTGTGAGGACCATCAGAAATCT 
Tbx5 GGAGCCTGATTCCAAAGACA TTCAGCCACAGTTCACGTTC 
 
Supplemental Experimental Procedures 
Cell culture and cell differentiation 
mESCs were maintained in the absence of feeders on 0.1% gelatin (Sigma) coated-
plates in high glucose Dulbecco's Modified Eagle Medium (DMEM) (Gibco, Life 
Technologies) supplemented with 15% Fetal Bovine Serum (FBS) (BenchMark, Cat Lot 
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No: A00D05C), 100 mM MEM non-essential amino acids, 100 U/mL 
penicillin/streptomycin (Gibco, Life Technologies), 1 mM sodium pyruvate, 2 mM L-
glutamine (Gibco, Life Technologies), 0.1 mM β-mercaptoethanol and 1000 U/ml 
Leukemia inhibitory factor (LIF) (Esgro, Millipore). Mesoderm differentiation was 
induced as previously described (Gadue et al., 2006; Kattman et al.,2011) with few 
modifications. Briefly, at day (D) 0 of differentiation mESCs were dissociated with 
TrypLE Express (Gibco, Life Technologies) and cultured at 1-2x105 cell/ml in serum-free 
differentiation medium that consisted of 75% Iscove's Modified Dulbecco's Medium 
(IMDM) and 25% Ham's F12 medium (HyClone) supplemented with 0.5x of both N-2 
and B-27 (Gibco, Life Technologies), 0.05% bovine serum albumin (BSA), 
penicillin/streptomycin, 2 mM L-glutamine, 4.5×10-4 M 1-thioglycerol (Sigma) and 50 
µg/mL ascorbic acid in ultra-low attachment 6-well plates (Corning) for 48 h to allow 
formation of embryoid bodies (EBs). After this period EBs were collected by 
centrifugation, dissociated by TrypLE Express and plated at 1.5-4x105 cells/ml in the 
previous medium supplemented with 5 ng/mL human VEGF (R&D Systems), 25 ng/mL 
human Activin A (R&D Systems) and 1 ng/mL human BMP4 (R&D Systems). At D3.75 of 
differentiation cells were reaggregated in StemPro-34+StemPro®-Nutrient Supplement 
(Gibco, Life Technologies) containing 2 mM L-glutamine, penicillin/streptomycin, 200 
µg/ml human transferrin (Sigma), 4.5x10-4 M 1-thioglycerol and 0.5 mM ascorbic acid, 
at 2x105 cells/ml in ultra-low-attachment 24-well plates (Corning), as previously 
described (Kattman et al., 2006). After 24 h, aggregates were collected and replated in 
gelatin-coated 24-well plates in StemPro34+StemPro-Nutrient Supplement with 2 mM 
L-glutamine and penicillin/streptomycin. Doxycycline (Dox) (1 µg/mL; Sigma) was 
added to the medium at indicated time points. Cultures were monitored for cell 
contraction under the light microscope and photographs and movies were acquired 
using Leica DMI4000 (Leica) or Axiovert 200 (Zeiss) microscopes.  
Flow activated cell sorting 
D3.75 cells were dissociated with TrypLE Express and directly sorted based on the 
expression of GFP-Bry, or incubated with phycoerythrin (PE)-conjugated anti-Flk-1 
(Avas 12α1, BD Pharmingen) alone or in combination with allophycocyanin (APC)-
conjugated Pdgfrα/CD140a (APA5, BioLegend) at 1:100 dilution for 20 minutes (min) 
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on ice. Cells were washed twice and resuspended in phosphate buffered saline (PBS) 
containing 2% FBS, 25 mM Hepes, 1 mM EDTA and sorted using Mo-Flo 
(DakoCytomation) or FACS Aria (BD Biosciences) cell sorters. 
shRNA design 
shRNA sequences were obtained from the TRC library database 
(http://www.broadinstitute.org/genome_bio/trc/publicSearchForHairpinsForm.php). 
shRNA oligos were synthesized by Integrated DNA Technologies, annealed, and cloned 
into AgeI/EcoRI sites of the lentiviral-based shRNA expression vector pLKO.1 Blasticidin 
(BsdR) (Addgene) (Moffat et al., 2006) according to the supplier's protocol. All shRNA 
constructs were confirmed by sequencing. Sequences are listed in Table S5. 
Lentivirus production and mESCs transduction 
Lentiviral-based shRNA vectors and pCMV-dR8.2 (packaging) and pCMV-VSVG 
(envelope) plasmids were co-transfected into HEK-293T cells using the calcium 
phosphate method (Chen and Okayama, 1987). In summary, HEK-293T cells were 
grown to 70-80% confluency in DMEM with 10% FBS. DNA was mixed with CaCl2 and 
slowly added dropwise to 2x BES buffered saline (Sigma), while subjected to bubble air 
caused by continuous pipetting, and incubated for 15 min. The calcium phosphate-
DNA complexes were added dropwise onto cells that were kept at 37ºC overnight and 
then transferred into a 32.5ºC incubator. Viral supernatants were harvested after 36, 
48 and 72 h, filtered (0.45 µm) and concentrated with Amicon ultra centrifugal filter 
units (Millipore). mESCs were incubated overnight with virus in medium supplemented 
with polybrene (8 µg/ml, Sigma) and cultured in fresh medium for 4 days. After this 
period, cells were cultured in medium supplemented with 5 μg/mL blasticidin for 
additional 4 days. 
Gene expression analysis 
RNA was extracted using Trizol reagent and reverse transcribed using PrimeScript RT 
reagent kit (Takara Bio, Inc.) according to the manufacturer's instructions. Quantitative 
RT-PCR was performed using iQ Sybr Green Supermix (Bio-Rad) and gene-specific 
primers. Reactions were carried out in triplicate on the iCycler iQ5 Real-Time PCR 
system (Bio-Rad). Relative gene expression was normalized according to 
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glyceraldehyde-3-phosphate dehydrogenase (Gapdh) expression. Gene-specific 
primers are listed in Table S6. 
Flow cytometry 
For cardiac Troponin T (cTnT) staining, cells were dissociated with TrypLE Express and 
fixed with 4% paraformaldehyde (PFA) for 30 min and then permeabilized with PBS 
with 10% fetal calf serum and 0.1% saponin for 10 min. After two washes, cells were 
incubated with unconjugated mouse anti-cardiac Troponin T (13-11, 
NeoMarkers/Thermo Scientific) at 1:100 dilution for 30 min at room temperature (RT). 
Cells were then washed and stained with PE-conjugated goat anti-mouse secondary 
antibody (Invitrogen) at 1:200 dilution for 30 min at RT. Lastly, cells were washed twice 
with saponin containing buffer and once in PBS with 3% FBS. For Isl1 detection, cells 
were dissociated with TrypLE Express and stained using the Foxp3/Transcription Factor 
Staining Buffer Set (eBioscience). Briefly, cells were fixed and permeabilized in the 
Fixation/Permeabilization solution, prepared according to manufacturer's instructions, 
for 45 min at RT in the dark. Cells were then washed in permeabilization buffer and 
incubated with PE-conjugated anti-Isl1 (Q11-465, BD Pharmingen) at 1:100 dilution at 
RT for 60 min. Cells were washed once in permeabilization buffer and then once in PBS 
with 3% FBS. Flow cytometry acquisition was performed on a 5-laser LSRII or FACS 
Canto II (BD Biosciences) and analyzed using FlowJo software. 
Immunofluorescence 
For Flag and cTnT detection, cells were fixed with 4% PFA for 20 min and permeabilized 
with 0.2% Triton X-100 in PBS for 5 min. Blocking for unspecific staining was achieved 
using PBS containing 4% FBS and 1% BSA for 60 min and followed by incubation with 
mouse anti-Flag (M2, Sigma) at 1:100 dilution or mouse anti-cardiac Troponin T (13-11, 
NeoMarkers/Thermo Scientific) at 1:500 dilution for 120 min. Cells were then 
incubated with anti-mouse 488 for 60 min. For Scl staining, cells were dissociated, 
cytospun into slides and fixed with cold methanol for 2 min. After permeabilization 
with 1% Triton X-100 in PBS for 5 min, cells were blocked for 60 min with PBS buffer 
containing 4% FBS and 1% BSA. Incubation with goat anti-Scl (C21, Santa Cruz (sc-
12984X)) at 1:10000 dilution was carried out for 90 min and followed by incubation 
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with secondary antibody donkey anti-goat 568 for 45 min. For nuclei staining, samples 
were incubated with 4,6-diamidino-2-phenylindole (DAPI) at 0.5 µg/ml or mounted in 
Vectashield with DAPI (Vector Lab). Images were acquired using a Leica DMI4000 
(Leica) or a Axiovert 200 (Zeiss) microscope. 
ChIP-Seq sample preparation and analysis 
Sample preparation for ChIP-Seq was performed as previously described (Ang et al., 
2011) with few modifications. Briefly, 48 h after Dox treatment 10x106 cells were 
dissociated with TrypLE Express and fixed with 11% formaldehyde in medium for 20 
min with rotation. The fixation reaction was stopped by adding 125 mM glycine 
solution and rotating the mixture for 5 min at RT. Cells were then quick frozen and 
stored at -80°C. Samples were thawed and lysed first in lysis buffer I and then in lysis 
buffer II. The resulting nuclear pellets were resuspended in lysis buffer III. Sonication 
was performed using the Covaris sonication instrument using the following settings: 
Time: 10 min, Duty cycle: 5%, Intensity: 4, Cycles per burst: 200, Temperature: 4°C. 
ChIP pull down was performed using Protein G Dynabeads conjugated to anti-Flag 
antibody (M2, Sigma) overnight at 4°C. Cells without Dox were used as negative 
control. DNA library preparation was done using the NEB ChIP-Seq sample preparation 
kit. The libraries were run on HiSeq 2000 machines at the genomics shared resource 
facility at Icahn School of Medicine at Mount Sinai. ChIP-Seq analysis was done using 
the raw fastq files. The raw reads were mapped using bowtie software (v1.0). To 
determine significant binding peaks MACS (v1.4) analysis software was used. The gene 
annotation information was derived from the peaks files using the Homer software. 
The visualization of the ChIP-Seq data was done using UCSC genome browser. 
Cell proliferation and cell apoptosis analyses 
Cell proliferation was assessed by bromodeoxyuridine (BrdU) incorporation. Cells were 
incubated with 10 µM BrdU for 5 h and then dissociated with TrypLE Express and fixed 
with 1% PFA for 20 min at 4ºC. Next, samples were permeabilized with 0.2% Triton X-
100 in PBS for 10 min at 4ºC. Washes were carried out in PBS buffer with 2% FBS and 
0.1% saponin and followed by incubation in 2M HCl for 20 min. After washing, 
unspecific staining was blocked with PBS containing 5% normal goat serum (NGS) and 
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0.1% saponin for 20 min. V450-conjugated BrdU antibody (BD Biosciences) was added 
for 30 min at RT diluted 1:25 in PBS containing 1% NGS and 0.1% saponin. Apoptosis 
was assessed using the Annexin V detection kit (eBioscience) according to the 
manufacturer's protocol. In summary, cells were gently dissociated with StemPro 
Accutase Cell Dissociation Reagent (Gibco) for 5 min, washed in PBS and then in 
Binding Buffer provided by the kit. V450-conjugated Annexin V was incubated at 1:20 
dilution for 15 min at RT. After washes in Binding Buffer, samples were incubated with 
7-Aminoactinomycin D (7-AAD) viability staining solution and acquired in the FACS 
Canto II (BD Biosciences). Analyses were performed using FlowJo software. 
Immunoprecipitation and immunoblotting 
HEK-293T cells were cultured in DMEM supplemented with 10% FBS. Cells were 
transfected with pSIN-EF2-Myc-Scl and pSIN-EF2-HA-Hes5 vectors using the 
Lipofectamine 2000 transfection reagent (Invitrogen). Immunoprecipitation and 
immunoblotting were performed as described (Hu et al., 2004; Lee et al., 2007; Lee et 
al., 2009). Briefly, cells were lysed 48 h after transfection in RIPA-B buffer (20 mM 
Na2HPO4 [pH 7.4], 150 mM NaCl, 1% Triton X-100) in the presence of protease 
inhibitors (3 μg/ml aprotinin, 750 μg/ml benzamidine, 1 mM phenylmethylsulfonyl 
fluoride, 5 mM NaF and 2 mM sodium orthovanadate) and incubated on ice for 1 h 
followed by centrifugation to remove cell debris. Samples were incubated with anti-HA 
antibody (12CA5, Roche) overnight at 4ºC followed by incubation with protein G 
agarose (Roche) for 2-3 h at 4ºC. After five-time washes in ice-cold RIPA-B buffer with 
protease inhibitors, the immunoprecipitated complexes were resolved by SDS-PAGE 
and transferred to PVDF membranes (Bio-Rad) for immunoblotting. Membranes were 
blocked with TBST buffer (10 mM Tris-HCl (pH 7.9), 150 mM NaCl, and 0.05% Tween 
20) containing 5% skim milk for 1 h and incubated with anti-Myc (9E10, Roche) or anti-
HA (12CA5, Roche) antibodies at 1:3000 dilution overnight at 4ºC. After 3 washes with 
TBST, samples were incubated with horseradish peroxidase (HRP)-conjugated 
secondary antibodies, washed three times and detected either by ECL or ECL Plus (GE 
Healthcare). 
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Abstract 
Adult cardiac progenitor cells (CPCs) hold promise as candidates for cell-based 
therapies aiming at improvement of heart function. However, to date, the mechanisms 
that trigger the activation of these cells in cardiac homeostasis and disease are still 
elusive. Knowledge gathered from the embryonic development provides valuable 
information on the regulators that determine early cell-fate decision. These factors 
may constitute key candidates for the modulation of cardiogenic processes in 
endogenous CPCs. We have recently demonstrated a function for Hes5 in promoting 
cardiac fate from embryonic stem cells (ESCs)-derived mesodermal progenitors in a 
discrete time window. However a role in the regulation of cardiogenic processes in 
adult CPCs remains unexplored. In the herein work we show that Hes5 overexpression 
in the iCPCSca-1 cell-line, a representative model system of endogenous CPCs, promoted 
the upregulation of cardiomyocytic structural genes, likely by inducing transient Isl1 
downregulation. Our data supports a role for Hes5 as a key candidate to enhance 
cardiomyocytic differentiation in endogenous adult CPCs. 
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Introduction  
In the last years cardiovascular research has been stricken by the identification of a 
number of heart resident adult CPCs reported to give rise to cardiomyocytes (CMs) and 
vasculature forming-cells [1-12]. However, the molecular signature and developmental 
origin of CPCs as well as the role in aging and response to injury are still largely elusive. 
We have recently been able to generate a cell line of heart-derived Lin-Sca-1+ 
progenitors specifically immortalized by overexpression of the murine telomerase 
catalytic subunit (mTERT), and therefore named iCPCSca-1 [13]. iCPCSca-1 cell line 
preserves the hallmarks of the primary cell counterparts while maintaining a stable 
phenotype in long-term culture, thus representing a unique in vitro tool to study 
biological relevant features related to Lin-Sca-1+ adult CPCs. In resemblance to its 
freshly isolated counterparts this cell line demonstrates limited ability to differentiate 
into cardiomyocyte-like cells both in vitro and in vivo. Thus, the identification of 
cardiogenic master regulators that can enhance cardiomyogenic differentiation from 
these cells is of great interest.  
We have identified a novel function for Hes5 in the specification of cardiac fate from 
embryonic stem cells (ESCs)-derived mesodermal progenitors (Freire, AG et al, under 
peer review). Yet, the role of Hes5 in the regulation of cardiogenic processes in the 
adult heart, and namely in adult CPCs, has not been unveiled. Hes genes encode basic 
helix-loop-helix (bHLH) transcriptional regulators which are commonly effectors of the 
Notch signaling [14]. The expression of several Notch pathway members is crucial for 
heart morphogenesis [15-17] and decreases during postnatal life [18]. Interestingly, 
Notch pathway reactivation has been demonstrated in response to cardiac stress in 
association to pro-survival and repair processes [19], including prevention of apoptosis 
in cardiomyocytes and promotion of neovascularization [18, 20, 21]. Importantly, 
activated Notch promotes expansion of Sca-1+ CPCs [22] and induces myocytic 
differentiation from c-Kit+ CPCs [23]. Given Hes5 participation in cardiogenesis and the 
need to drive efficient cardiomyocytic differentiation in adult CPCs, we proposed to 
validate Hes5 as a factor to enhance cardiomyocytic differentiation using the iCPCSca-1 
cell line as a model. Data on the role of Hes5 in the regulation of proliferation and 
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differentiation in iCPCSca-1 is shortly reported thereby opening the way towards 
elucidation of the role of Hes5 in the adult CPCs context. 
Results and Discussion 
To examine the role of Hes5 in adult cardiac progenitors, Hes5 overexpression was 
promoted in the cell line we have previously validated as a model of Lin-Sca-1+ heart-
resident progenitors (iCPCSca-1). Hes5 upregulation was observed as early as 24 hours 
(h) after transfection (Figure 1Ai). After 10 days Hes5 expression was maintained in 
stable transfected cells following blasticidin selection (Figure 1Aii). Conversely, control 
iCPCSca-1 cells transfected with the empty vector (Mock) did not express Hes5 (Figure 
1Ai and 1Aii).  
Activation of Notch induces proliferation in immature cardiomyocytes [24] and cell 
cycle reentry of quiescent cardiomyocytes [25]. Moreover, Hes5 and Hes1 were shown 
to maintain proliferating neural stem cells in the embryo telencephalon [26]. 
Therefore, we evaluated whether Hes5 overexpression induces proliferation in CPCs by 
assessing the percentage of Ki67-expressing cells at 48 h after transient transfection. 
The percentage of Ki67+ cells was similar in Mock and Hes5-transfected cells (72.2% 
and 68.6%, respectively) (Figure 1B), suggesting that Hes5 overexpression has no effect 
in adult CPCs proliferation. 
To assess if Hes5 overexpression promotes cardiomyocytic differentiation in adult 
CPCs, the mRNA levels of Gata4, Isl1, Myh6 and Myh7 were analyzed at 10 days after 
transfection in blasticidin-resistant cells growing in basal conditions. Isl1 and Gata4 are 
early transcriptional regulators in the cardiac program, whereas the mature contractile 
myofilaments Myh6 (also known as α-Mhc) and Myh7 (also known as β-Mhc) associate 
with the differentiation into cardiomyocytes. We had previously shown that although 
in basal conditions iCPCSca-1 expressed Isl1 and Gata4 and lacked transcripts for the 
contractile myofilaments, the cells were capable to upregulate Myh7 when stimulated 
in cardiomyocytic differentiation medium [13]. Remarkably, in this work we observed 
that while Gata4 and Isl1 mRNA levels were comparable to control levels at 10 days 
after transfection, Myh6 (2-fold) and, significantly, Myh7 (12-fold) were upregulated 
following Hes5 overexpression (Figure 1C). These data indicate that Hes5 is capable of  
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Figure 1. Hes5-transfected iCPCSca-1 engage cardiomyocytic differentiation likely in response to 
transient Isl1 downregulation. (A) Quantitative RT-PCR results show efficient Hes5 overexpression at 24 
hours (h) after transfection. Gene expression is normalized to Mock (i). After selection for 4 days in 
blasticidin-supplemented medium, stable Hes5-transfected cells were obtained. Cells transfected with 
empty vector (Mock) do not express Hes5 (ii). (B) Flow cytometry analysis demonstrates similar 
percentage of Ki67-expressing cells at 48 h after transfection, indicating no alteration in iCPCSca-1 
proliferation following Hes5 overexpression (n=2). (C) Relative mRNA expression demonstrates modest 
and significant upregulation of Myh6 and Myh7, respectively, in blasticidin-resistant cells expressing 
Hes5, while Gata4 and Isl1 levels are similar to control levels (Mock) at 10 days (d) after transfection 
(n=3). Gene expression is normalized to Mock. (D) Quantitative RT-PCR data demonstrate Gata4 and Isl1 
mRNA levels at 24 and 48 h after transfection. Results show decreased Isl1 mRNA levels at 48 h after 
transfection with exogenous Hes5 (n=3-6). Gene expression is normalized to Mock. (E) Flow cytometry 
analysis at 72 h (n=3) and 10 d (n=2) after transfection shows similar Isl1+ cell percentage in Mock and 
Hes5-transfected iCPCSca-1 populations. Data are represented as mean ± SEM. *p<0.05. 
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triggering the cardiomyocytic program in iCPCSca-1, and importantly, in the absence of 
additional stimulation from culture medium components. 
Next, we aimed to understand the early events after Hes5 overexpression that could 
account for the effect on iCPCSca-1 differentiation. Our previous work identified Isl1 and 
Gata4 as genes bound and putatively regulated by Hes5 in ESCs-derived mesodermal 
progenitors. Moreover, the results indicated that Hes5 tightly regulates Isl1 expression, 
promoting its significant downregulation or upregulation in a time-dependent manner, 
suggesting Isl1 as a downstream effector of Hes5 during specification of cardiac fate 
(Freire, AG et al, under peer review). In light of these results, we questioned whether 
Hes5 regulates the same genes also in the adult CPCs context. Isl1 and Gata4 mRNA 
expression was evaluated 24 and 48 h after transfection. No considerable differences 
were observed for both genes after 24 h. Interestingly, Isl1 mRNA levels were 
decreased 48 h upon Hes5 overexpression (2-fold), while Gata4 levels were similar to 
control levels (Figure 1D). It is worth noting these results represent gene expression 
alterations early after transient transfection and prior to blasticidin selection. More 
dramatic differences would be expected if only transfected cells were analyzed. These 
data suggest that Hes5 may also bind and regulate Isl1 in the context of adult CPCs. 
Although we have previously verified Isl1 expression at the transcript level in iCPCSca-1 
[13], the frequency of cells expressing the protein among iCPCSca-1 population had not 
been evaluated. Therefore, we evaluated Isl1 protein expression in iCPCSca-1 by flow 
cytometry, and assessed whether Hes5 expression has an impact on the frequency of 
cells expressing Isl1 in the iCPCSca-1 population. At 72 h after transfection similar cell 
percentages were observed for Mock and Hes5-transfected iCPCSca-1 (21.5% and 24.8%, 
respectively) (Figure 1E). This observation was also verified at 10 days after 
transfection following blasticidin selection for transfected cells, where Mock and Hes5-
transfected iCPCSca-1 presented similar cell percentages of Isl1-expressing cells (30.0% 
and 27.6%, respectively) (Figure 1E). In summary, these results show ls1 
downregulation at 48 h but not at 10 days after transfection, and no alterations in the 
frequency of cells expressing Isl1 among iCPCSca-1 population after Hes5 
overexpression. These observations suggest that an Isl1+ cell-subset within the iCPCSca-1 
population transiently downregulates Isl1 in response to Hes5 expression.  
Hes5, a candidate to enhance CPCs differentiation  
154 
 
During embryonic development, Isl1 is expressed in cardiac progenitors and 
downregulates as they differentiate into cardiomyocytes [27], suggesting that Isl1 may 
be detrimental for the progression of cardiac differentiation. Moreover, this indicates 
Isl1 may maintain an undifferentiated state. Isl1+ cells have been isolated from 
postnatal [28, 29] and adult hearts [29, 30], and although postnatal Isl1+ cardioblasts 
did not show Sca-1 expression [28], adult Sca-1+ CPCs isolated by us and others [13, 31, 
32] express Isl1, suggesting that the Sca-1+ CPCs reservoir includes a subset of Isl1+ 
progenitor cells in the adult heart.  
The evidence that Isl1 dowregulation is required for cardiomyocyte differentiation [27, 
28, 33] supports our previous findings indicating that, after cardiac induction, 
sustained Hes5 expression impairs cardiac maturation, likely due to continuous 
promotion of high Isl1 levels (Freire, AG et al, under peer review). Thus, in light of 
these observations, we hypothesize that Isl1 levels in iCPCSca-1 are downregulated early 
after Hes5 overexpression triggering the expression of cardiomyocytic markers. 
Further investigation is warranted to dissect the mechanism of Isl1 regulation 
mediated by Hes5 and to elucidate whether Hes5 will drive more robust 
cardiomyocytic differentiation from endogenous CPCs.  
Materials and Methods 
iCPCSca-1 cell culture 
iCPCSca-1 were maintained in 70% high glucose Dulbecco's Modified Eagle Medium 
(DMEM) (Gibco, Life Technologies) and 30% Claycomb medium (Sigma-Aldrich), 
supplemented with 10% Fetal Bovine Serum (FBS) (Lonza), 100 U/mL 
penicillin/streptomycin (Gibco, Life Technologies) and 2 mM L-glutamine (Gibco, Life 
Technologies). 
iCPCSca-1 transfection 
For transient transfection Lipofectamine 2000 reagent was used according to the 
manufacturer's protocol. Briefly, iCPCSca-1 were plated at 1x105 cells/24-well at the day 
before transfection to achieve 90% confluency at the time of transfection. 0.8 µg of 
DNA per 24-well were complexed with lipofectamine for 30 minutes (min) at room 
Chapter V 
155 
 
temperature (RT). Complexes were added to cells and medium was changed 24 h after 
transfection. For stable transfection, the calcium phosphate method was followed as 
previously described [34]. In summary, cells were grown to 70-80% confluency in 
DMEM with 10% FBS. 10 µg of DNA per 6-well was mixed with CaCl2 and slowly added 
dropwise to 2x BES buffered saline (Sigma), while subjected to bubble air caused by 
continuous pipetting, and incubated for 15 min. The calcium phosphate-DNA 
complexes were added dropwise onto cells that were kept at 37ºC overnight. Medium 
was replaced after 24 h. Four days after transfection cells were cultured in medium 
supplemented with 5 μg/mL blasticidin and medium was maintained for additional 
four days. 
Gene expression analysis 
RNA was extracted using Trizol reagent and reverse transcribed using PrimeScript RT 
reagent kit (Takara Bio, Inc.) according to the manufacturer's instructions. RT-PCR and 
quantitative RT-PCR (qRT-PCR) were performed using BIOTAQ DNA polymerase 
(Bioline) and iQ Sybr Green Supermix (Bio-Rad), respectively, and gene-specific 
primers. qRT-PCR reactions were carried out in triplicate on the iCycler iQ5 Real-Time 
PCR system (Bio-Rad). Relative gene expression was normalized according to 
glyceraldehyde-3-phosphate dehydrogenase (Gapdh) expression. 
Flow cytometry 
For Isl1 and Ki67 detection, cells were dissociated with trypsin and stained using the 
Foxp3/Transcription Factor Staining Buffer Set (eBioscience). Briefly, cells were fixed 
and permeabilized using the Fixation/Permeabilization solution, prepared according to 
manufacturer's instructions, for 45 min at RT in the dark. Cells were then washed in 
permeabilization buffer and incubated with PE-conjugated anti-Isl1 (Q11-465, BD 
Pharmingen) at 1:100 dilution or FITC-conjugated anti-Ki67 (556026, BD Pharmingen) 
at 1:20 dilution for 30 min on ice. Cells were washed once in permeabilization buffer 
and then once in phosphate buffer saline (PBS) with 3% FBS. Flow cytometry 
acquisition was performed on a FACS Canto II (BD Biosciences) and analyzed using 
FlowJo software. 
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Data and statistical analysis 
Data are represented as mean ± SEM. Statistical significance was determined by 
unpaired t test. p<0.05 was considered statistically significant. *p<0.05. 
References 
1. Beltrami, A.P., et al., Adult cardiac stem cells are multipotent and support 
myocardial regeneration. Cell, 2003. 114(6): p. 763-776. 
2. Messina, E., et al., Isolation and expansion of adult cardiac stem cells from 
human and murine heart. Circulation Research, 2004. 95(9): p. 911-921. 
3. Urbanek, K., et al., Stem cell niches in the adult mouse heart. Proceedings of the 
National Academy of Sciences of the United States of America, 2006. 103(24): 
p. 9226-9231. 
4. Linke, A., et al., Stem cells in the dog heart are self-renewing, clonogenic, and 
multipotent and regenerate infarcted myocardium, improving cardiac function. 
Proc Natl Acad Sci U S A, 2005. 102(25): p. 8966-71. 
5. Johnston, P.V., et al., Engraftment, differentiation, and functional benefits of 
autologous cardiosphere-derived cells in porcine ischemic cardiomyopathy. 
Circulation, 2009. 120(12): p. 1075-83, 7 p following 1083. 
6. Urbanek, K., et al., Myocardial regeneration by activation of multipotent 
cardiac stem cells in ischemic heart failure. Proc Natl Acad Sci U S A, 2005. 
102(24): p. 8692-7. 
7. Bearzi, C., et al., Human cardiac stem cells. Proc Natl Acad Sci U S A, 2007. 
104(35): p. 14068-73. 
8. Oh, H., et al., Cardiac progenitor cells from adult myocardium: homing, 
differentiation, and fusion after infarction. Proc Natl Acad Sci U S A, 2003. 
100(21): p. 12313-8. 
9. Matsuura, K., et al., Adult cardiac Sca-1-positive cells differentiate into beating 
cardiomyocytes. J Biol Chem, 2004. 279(12): p. 11384-91. 
10. Wang, X.H., et al., The role of the Sca-1(+)/CD31(-) cardiac progenitor cell 
population in postinfarction left ventricular remodeling. Stem Cells, 2006. 24(7): 
p. 1779-1788. 
11. Pfister, O., et al., CD31- but Not CD31+ Cardiac Side Population Cells Exhibit 
Functional Cardiomyogenic Differentiation. Circ Res, 2005. 97(1): p. 52-61. 
12. Oyama, T., et al., Cardiac side population cells have a potential to migrate and 
differentiate into cardiomyocytes in vitro and in vivo. J Cell Biol, 2007. 176(3): p. 
329-41. 
Chapter V 
157 
 
13. Freire, A.G., et al., Stable phenotype and function of immortalized Lin-Sca-1+ 
cardiac progenitor cells in long-term culture: a step closer to standardization. 
Stem Cells Dev, 2014. 23(9): p. 1012-26. 
14. Kageyama, R., T. Ohtsuka, and T. Kobayashi, The Hes gene family: repressors 
and oscillators that orchestrate embryogenesis. Development, 2007. 134(7): p. 
1243-51. 
15. Grego-Bessa, J., et al., Notch signaling is essential for ventricular chamber 
development. Dev Cell, 2007. 12(3): p. 415-29. 
16. Rones, M.S., et al., Serrate and Notch specify cell fates in the heart field by 
suppressing cardiomyogenesis. Development, 2000. 127(17): p. 3865-76. 
17. Rutenberg, J.B., et al., Developmental patterning of the cardiac atrioventricular 
canal by Notch and Hairy-related transcription factors. Development, 2006. 
133(21): p. 4381-90. 
18. Gude, N.A., et al., Activation of Notch-mediated protective signaling in the 
myocardium. Circ Res, 2008. 102(9): p. 1025-35. 
19. Freire, A.G., T.P. Resende, and O.P. Pinto-do, Building and repairing the heart: 
what can we learn from embryonic development? Biomed Res Int, 2014. 2014: 
p. 679168. 
20. Kratsios, P., et al., Distinct roles for cell-autonomous Notch signaling in 
cardiomyocytes of the embryonic and adult heart. Circ Res, 2010. 106(3): p. 
559-72. 
21. Oie, E., et al., Activation of Notch signaling in cardiomyocytes during post-
infarction remodeling. Scand Cardiovasc J, 2010. 44(6): p. 359-66. 
22. Nemir, M., et al., The Notch pathway controls fibrotic and regenerative repair in 
the adult heart. Eur Heart J, 2014. 35(32): p. 2174-85. 
23. Boni, A., et al., Notch1 regulates the fate of cardiac progenitor cells. Proc Natl 
Acad Sci U S A, 2008. 105(40): p. 15529-34. 
24. Collesi, C., et al., Notch1 signaling stimulates proliferation of immature 
cardiomyocytes. J Cell Biol, 2008. 183(1): p. 117-28. 
25. Campa, V.M., et al., Notch activates cell cycle reentry and progression in 
quiescent cardiomyocytes. J Cell Biol, 2008. 183(1): p. 129-41. 
26. Ohtsuka, T., et al., Roles of the basic helix-loop-helix genes Hes1 and Hes5 in 
expansion of neural stem cells of the developing brain. J Biol Chem, 2001. 
276(32): p. 30467-74. 
27. Cai, C.L., et al., Isl1 identifies a cardiac progenitor population that proliferates 
prior to differentiation and contributes a majority of cells to the heart. Dev Cell, 
2003. 5(6): p. 877-89. 
Hes5, a candidate to enhance CPCs differentiation  
158 
 
28. Laugwitz, K.L., et al., Postnatal isl1+ cardioblasts enter fully differentiated 
cardiomyocyte lineages. Nature, 2005. 433(7026): p. 647-53. 
29. Genead, R., et al., Islet-1 cells are cardiac progenitors present during the entire 
lifespan: from the embryonic stage to adulthood. Stem Cells Dev, 2010. 19(10): 
p. 1601-15. 
30. Khattar, P., et al., Distinction between two populations of islet-1-positive cells in 
hearts of different murine strains. Stem Cells Dev, 2011. 20(6): p. 1043-52. 
31. Takamiya, M., K.H. Haider, and M. Ashraf, Identification and characterization of 
a novel multipotent sub-population of Sca-1(+) cardiac progenitor cells for 
myocardial regeneration. PLoS One, 2011. 6(9): p. e25265. 
32. Ye, J., et al., Sca-1+ cardiosphere-derived cells are enriched for Isl1-expressing 
cardiac precursors and improve cardiac function after myocardial injury. PLoS 
One, 2012. 7(1): p. e30329. 
33. Sun, Y., et al., Islet 1 is expressed in distinct cardiovascular lineages, including 
pacemaker and coronary vascular cells. Dev Biol, 2007. 304(1): p. 286-96. 
34. Chen, C. and H. Okayama, High-efficiency transformation of mammalian cells by 
plasmid DNA. Mol Cell Biol, 1987. 7(8): p. 2745-52. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Chapter VI 
Concluding remarks and future perspectives 
 
 
 
 
 
 
 
 
 
 
 
Chapter VI 
161 
 
Concluding remarks and future perspectives 
Originally, the proposal for the herein Doctoral dissertation had as driving forces the 
scarcity of fundamental knowledge on the biology and on the role in heart 
homeostasis and disease of putative adult cardiac progenitors. In this context we were 
further challenged by a general lack of standardization on the methods applied in what 
was an emerging area. Hence, we aimed at engendering in vitro systems in which the 
initiation and further progression of the cardiac molecular program could be robustly 
investigated. Our objectives have been delineated in order (i) to create and validate a 
benchmark to be used as a reference for Lin-Sca-1+ adult CPCs, (ii) to identify effectors 
downstream of Notch in the onset of cardiogenesis using the well-established ESCs in 
vitro model system for cardiac differentiation and, (iii) to validate these factors as key 
regulators for cardiogenic processes in adult CPCs. 
Within this conceptual framework, our work has materialized into tools and knowledge 
that fulfill some of the needs in the cardiovascular field. A cell line of Sca-1+ CPCs 
specifically immortalized by overexpression of mTERT (iCPCSca-1) has been established 
for the first time. An extensive in vitro and in vivo characterization has validated the 
newly generated line as a model system representative of the native cellular 
counterparts, while preserving a high mitotic capacity and a stable phenotype in long-
term culture. Importantly, after immortalization, cells preserved the phenotypic 
features described for endogenous CPCs expressing Sca-1. iCPCSca-1 cell line display 
early cardiac transcription factors and features typical of mesenchymal affiliation, 
while lacking transcripts for cardiac structural genes and markers associated to 
hematopoietic/endothelial cells, pluripotent cells and fibroblasts. Importantly, these 
cells survived and engrafted the injured myocardium while contributing to repair 
processes, as demonstrated by a decreased LV remodeling and improved cardiac 
function. Moreover, an increase in neovascularization was observed and has been 
attributed mostly to the secretion of paracrine factors inducers of mobilization and/or 
activation of resident progenitors and/or other relevant cells. Indeed, secretion of 
paracrine factors appear to account for the beneficial effects observed upon cell 
transplantation in a manner rather independent of the cellular source [1]. iCPCSca-1, 
similarly to what is recognized for their native counterparts, exhibited modest 
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differentiation into cardiomyocyte-, smooth muscle- and endothelial-like cells in vitro 
and after transplanted into infarcted murine hearts, although differentiation into the 
smooth muscle lineage appeared preponderant. In fact, the multipotency of CPCs has 
been questioned, as lineage tracing studies tracking Sca-1-derived cells have suggested 
a restricted lineage potential [2]. Moreover, protocols for in vitro differentiation of 
these cells involve DNA demethylation by 5-aza [3] and/or co-culture with 
cardiomyocytes [3, 4], rather unusual requirements for bona fide stem cells. However, 
the prospect that CPCs are innately endowed to originate all cardiac lineages cannot 
be excluded, as the appropriate signals for the unfolding of the full differentiation 
potential could be absent. Hence, although this particular study did not contribute new 
knowledge on the biology of CPCs and on their role in cardiac homeostasis and repair, 
it made available to the scientific community a reliable in vitro tool which will ease 
functional and mechanistic studies on the fundamental biological aspects regarding 
endogenous Sca-1+ CPCs. In light of this, parallel studies from our laboratory and 
collaborators have been addressing biological features of adult CPCs using this cell line 
as a model system. As examples, the role of mechano-transduced signals in the 
regulation of CPCs differentiation [5] and the ability of CPCs to colonize ontogenic 
stage-specific decellularized ECM (Silva, AC et al.; unpublished data) have been 
investigated using the iCPCSca-1 cell line. 
Also in the frame of this Thesis we proposed to identify early regulators at the onset of 
cardiogenesis. The rational for this derived from the recognition that developmental 
factors are putative regulators in the adult molecular regulatory circuitry and 
candidates for in situ activation of adult CPCs. In this sense, pluripotent stem cells have 
been proficuous as a model system for “eyeglassing” the molecular events at the onset 
of lineage determination. Hence, ESCs constitute a unique platform for the 
identification of master regulators of cardiogenic processes, presently a rather more 
reliable application than their clinical use, due to the reasons discussed earlier in this 
dissertation, e.g. of immunological, oncological or safety nature. 
Apparently at odds with previous studies in embryos and differentiating ESCs, 
demonstrating an inhibitory role for Notch in cardiac differentiation [6-9], Chen et al, 
have demonstrated that transient NICD activation directs ESCs-derived mesodermal 
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progenitors and hemangioblasts towards a cardiac fate [10]. These findings highlight 
the context-dependent nature of Notch pathway and suggest that the dual effects as 
repressor or inducer of cardiogenic differentiation are much likely associated to the 
stage during differentiation the signal is being activated. 
Thus, we proposed to identify the downstream mediators of Notch in the 
determination of cardiac fate using the robustness of the ESCs system for cardiac 
differentiation. This work demonstrates for the first time a role for Hes5 as an early 
regulator at the onset of cardiogenesis. In fact, to the best of our knowledge, this is the 
first collection of experimental data reporting Hes5 participation in cardiogenic 
processes whatsoever. Hes5 is a member of the Hes gene family of well-known Notch 
targets and has been described as a mediator of Notch effects in non-cardiac systems 
[11, 12]. Hes genes encode bHLH transcriptional regulators which mediate the 
maintenance of progenitors and binary cell fate decisions, thereby controlling the 
normal timing of differentiation [13]. We were able to show that Hes5 mediates, at 
least in part, the effects of NICD1 in the determination of cardiac fate, contributing 
mechanistic insights into how Notch pathway determines cardiac fate from 
mesodermal progenitors. Moreover, the results strongly indicate that Hes5 specifies 
cardiac over hematopoietic cell-fate choice in mesodermal progenitors, and fit into the 
current understanding that networks controlling heart and vascular/hematopoietic 
development are tightly inter-connected and mutually antagonistic [14-16]. In 
resemblance to what has been documented for activated Notch a time-dependent 
function and a dual effect on cardiogenic differentiation was observed for Hes5. Loss 
and gain-of-function of Hes5 early during in vitro differentiation affected the Flk-1+ 
mesodermal reservoir, resulting in increased and decreased cell percentage, 
respectively. Due to these observations and the described role for Hes factors in 
controlling the normal timing of cell differentiation [13], we speculate Hes5 regulates 
the timing of determination of Flk-1+ hematopoietic and cardiac mesodermal 
derivatives.  
Furthermore, in ESCs-derived mesodermal progenitors Hes5 binds and putatively 
regulates pivotal target genes for normal vascular/hematopoietic, e.g. Scl, and heart 
development, e.g. Isl1. Isl1 is indispensable for heart development [21], while Scl 
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prevents ectopic cardiogenesis in prospective hemogenic tissue [22] by occupying 
primed enhancers used by cardiac regulators for gene activation [23]. Thus, our results 
suggest that, in mesodermal progenitors, Hes5 directs cell-fate decision towards 
cardiac over hematopoietic lineages through Isl1 and Scl effectors. Moreover, a dual 
role for Hes5 as a repressor or an activator of Isl1 at specific stages of ESCs 
differentiation is hinted. This switch of function, from a repressor to an activator, has 
been described for Hes1 at Mash1 promoter during neuronal differentiation [24]. 
Indeed, normal organ development relies on the precise switching between gene 
repression and activation. This work contributes a preliminary insight in the 
mechanism of action downstream of Hes5 in cardiogenesis, and demands the 
confirmation of effective regulation and sequence-specific binding at Isl1 and Scl loci 
by endogenous Hes5. Moreover, those studies should contemplate whether tight 
temporal regulation of Isl1 expression involves the recruitment and further dismissal of 
the Groucho/TLE co-repressor complex from Isl1 promoter. 
Notably, we were able to identify the appropriate temporal window for cardiac 
induction in vitro mediated by transient high levels of Hes5. Evidence piles up, 
including our own, reporting an inhibitory effect for Notch pathway in cardiac 
maturation, which appears to correlate to an activation at later-stages in cardiac 
differentiation, after cardiac induction have already occurred [8-10, 18-20]. It is our 
conviction these data fit like a glove within the prior knowledge, at first glance 
contradictory, documenting a dual role for the Notch signaling as an inducer or 
suppressor of cardiogenesis. Moreover, our work highlights the context-specific and 
time-dependent nature of Hes proteins. Importantly, not only the timing of induction, 
but also the duration of the signal has impact on cell-fate determination and lineage 
differentiation. Thus, the inhibitory effect on cardiogenesis seems to be at the level of 
development and maturation rather than at the time of cardiac specification, as long 
as inducted at the exact timing. 
Worth noting, the use of a genetically-modified ES cell line enabled us to capture a 
flash-moment which is technically challenging to visualize in the developing embryo. 
Moreover, a transient temporal window for Hes5 function in cardiogenesis has been 
identified that otherwise would stay unnoticed. 
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Although these findings are novel and of great importance, they represent nonetheless 
effects of loss and gain-of-function mutations. Thus, the validation of the role of Hes5 
in specifying cardiac fate in the most close to physiological conditions is undoubtedly 
required. In our laboratory investigation has been started to address whether 
endogenous Hes5 is expressed in prospective cardiomyogenic precursors in a cell-
autonomous fashion during normal ESCs differentiation and in early/mid-streak stage 
embryos (prior to E7.0). Notch1 expression is documented in nascent mesodermal cells 
in the developing embryo [25], correlating with the stage we have identified Hes5 as a 
downstream effector of NICD1 in vitro. Thus, it will be worthwhile to investigate in the 
embryo whether Hes5 is expressed as a downstream target of Notch1 in nascent 
mesodermal cells primed to become cardiac progenitors. Hes5-null embryos have no 
apparent cardiac phenotype though, to the best of our knowledge, no studies were 
conducted to specifically address cardiac malformations. However, the possibility that 
another bHLH protein could compensate for Hes5 function in cardiogenesis is high. 
Indeed, compensation between Hes/Hesr factors is suggested in non-cardiac systems 
[11, 12] and in later stages in cardiac development, as for example Hey1 and HeyL are 
important in heart morphogenesis but only the double mutant display cardiac 
abnormalities [26]. Thus, it will be interesting to assess the compensatory function of 
other Hes/Hesr factors after Hes5 depletion, and whether these proteins share binding 
site specificity at the same target genes. 
Determinant players in the onset of cardiogenesis during development are putative 
regulators of the cardiac molecular circuitry in adult CPCs and candidates for in situ 
activation of these cells. Our premise was inspired by the key role developmental 
transcription factors display in triggering a cardiogenic program in non-cardiac cells, 
such as cardiac fibroblasts [27-29] or hemangioblasts [10], or favoring cardiac cell-fate 
determination from mesoderm [30]. In fact, boosted by Yamanaka's findings, the 
seeking for key factor combinations to reprogram to a given lineage has widespread in 
multiple fields of research. Complementarily, in vivo reprogramming and gene delivery, 
in many ways still in their infancy, may hold the key for multiple therapeutic 
applications. The discovery of key factors that can be delivered to particular cell-types, 
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in which a biological process will be specifically triggered, is a major goal for translation 
to the clinic. 
Hence, in a proof-of-concept approach the role of Hes5 in the regulation of 
proliferation and differentiation in adult CPCs was evaluated using the iCPCSca-1 cell line 
as a model of endogenous CPCs. Hes5 expression in iCPCSca-1 had no effect in cell 
proliferation while remarkably promoting Myh6 and, particularly, Myh7 upregulation 
in basal culture conditions. Interestingly, Hes5-transfected iCPCSca-1 showed Isl1 
downregulation, similarly to the regulation we observed when Hes5 was activated 
during mesodermal induction from ESCs. Considering that Isl1 expression 
downregulates once cardiac progenitors differentiate [21, 31, 32], we hypothesize that 
after Hes5 transfection the transiently decreased levels of Isl1 in iCPCSca-1 trigger the 
progression in the cardiomyocytic program, visible by the upregulation of transcripts 
for contractile myofilaments. Although a very preliminary assumption, these 
observations constitute a first glance at the potential Hes5 may hold as a key regulator 
for enhancing cardiomyogenic differentiation in adult CPCs. Future work is required to 
demonstrate binding and regulation of Isl1 promoter by Hes5, although it is tempting 
to speculate the consistent timely-dependent regulation of Isl1 at different stages of 
cardiac differentiation may in part explain the effect of Hes5 in cardiac maturation. 
Yet, several questions arise from these findings, as for instance, what is the role of 
Hes5 in adult heart homeostasis and cardiac repair, and in particular, in the regulation 
of endogenous CPCs? To the best of our knowledge there are no studies specifically 
targeted to investigate the role of this gene in the regulation of adult CPCs, not even 
roughly addressing a participation in cardiac repair processes. Notch signaling 
however, has been demonstrated to play a cardioprotective role in the damaged 
myocardium [33, 34]. Importantly, activated Notch promotes expansion of Sca-1+ CPCs 
[35] and induces myocytic differentiation from c-Kit+ CPCs [34]. In light of our original 
findings, Hes5 participation as a mediator in some of the described effects for the 
Notch pathway, and particularly in the regulation of CPCs differentiation, should be 
investigated. 
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Thus, the present Thesis introduces another piece in the complex puzzle that is the 
interconnected network of combinatorial codes to be perceived by the cells. The 
decision to engage a determined lineage is far to be a single variable process. Indeed, 
the particular molecular milieu will define how that specific signal will be decoded by 
the cell in a given time and space. That said, the context-specific effects of Hes5 in 
cardiogenesis result from the interactions played by itself, as well as by its targets, with 
a plethora of transcriptional regulators and co-factors within a particular epigenetic 
status. Likewise, the genes bound and regulated by Hes5 in a different cellular context 
are not necessarily the same. Therefore, it is highly unlikely that Hes5 could drive 
cardiac fate in cells that are not primed to originate that lineage. It would be like 
planting in an infertile soil. In this sense, Hes5 does not determine cardiac fate or 
differentiation by itself, but instead through the particular environment it encounters. 
In this work we gave the first steps in the translation of Hes5 function to the adult CPCs 
regulatory network. It will be very interesting to validate whether Hes5 is a key factor 
to enhance cardiogenic differentiation potential in endogenous CPCs. Importantly, this 
work hints that the mechanisms of regulation in embryonic and adult systems may 
overlap, reinforcing the importance of understanding the embryonic development 
while seeking for novel therapeutic targets. 
Ideal regenerative procedures may involve the in situ activation of cardiogenic 
processes. Speculating that Hes5 plays a role in CPCs, one can foresee the design of 
strategies for targeted Hes5 delivery into CPCs, as for instance by particles 
functionalized with specific antibodies for the recognition of a particular surface 
marker. However, given the lack of a specific marker for CPCs, the choice of c-Kit or 
Sca-1 will not be ideal given the overlap with other cell types. Another issue is the 
control of the timing and duration of activation. The effects of Hes5 are highly time-
dependent, therefore the designed strategy must contemplate the inducible 
expression of the gene. As alternative, cardiomyogenic differentiation from CPCs can 
be driven ex vivo followed by the transplantation of the differentiated cells. However, 
one can wonder whether Hes5 plays a different role in CPCs partaking distinct cell-
subsets. Assuming that the different subsets correspond to distinct developmental 
stages from the same progenitor, it will be interesting to address if the effects of Hes5 
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in different CPCs will recapitulate the set of events occurring along the progression of 
the embryonic cardiomyocytic program. 
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